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PREFACE 
 
This dissertation was a sequence of six investigations conducted in two phases, as 
a collaboration between the Department of Kinesiology at Louisiana State University, 
Baton Rouge, Louisiana, and the Department(s) of Biology and Exercise and Sports 
Science, Brigham Young University – Hawaii, Laie, Hawaii.  The first phase was a series 
of three pilot studies, while the second phase was three experiments.  The presentation 
style is based on that adopted by Acta Physiologica Scandinavica for publication of 
medical dissertations (New Series No. 641 ISSN 0346-6612 ISBN 91-7191-748-9, Acta 
Physiologica Scandinavica Volume 168 Supplementum 646, January 2000).  Chapter 1 
provides a critical review of the literature, presentation of the problem, and discussion of 
the rationale for experimentation.  Chapter(s) 2, 3, and 4, present each experiment, 
respectively.  Chapter 5 presents overall discussion and conclusions, and suggestions for 
future work. 
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ABSTRACT 
 
PURPOSE: To examine the effect of L-Aspartic Acid (L-Asp) supplementation 
on short-term arm-crank power (i.e. W·min-1) and exercise-induced hyperammonemia in 
two gender-specific investigations.  METHODS: The male investigation (MALE) used 
nine highly-trained intercollegiate water polo players (WP) and nine moderately-trained 
college students (MOD); the female investigation (FEM) used 18 recreationally-trained 
college students.  All exercised to exhaustion on two occasions following 
counterbalanced double-blind ingestion of 12.5g x 2 of L-Asp or placebo (P).  The warm-
up phase began at 25 W·min-1 and increased in 25 W·min-1 stages every 30 seconds 
(constant 100 rpm).  Performance began (i.e. the subjects turned the crank ‘as fast as 
possible for as long as possible’) with stage completion of rating of perceived exertion of 
17 (6-20 scale) in MOD and FEM and at the 4-minute mark (200 W·min-1) for WP.  
Individual warm-up time in session 1 for MOD and FEM was used as warm-up time for 
session 2, respectively.  Venous blood samples were drawn at 3 minutes post-exercise 
and assayed for blood NH3 [µM/L].  A 2 x 2 ANOVA with repeated measures was used 
for MALE, and a one-way ANOVA with repeated measures for FEM, with Tukey’s t-test 
for post hoc differences.  RESULTS:  Blood NH3 [µM/L] decreased with L-Asp (vs. P) in 
WP (241.0 ± 18.4 vs. 200.6 ± 20.5, p < 0.01) and MOD (219.7 ± 20.8 vs. 185.6 ± 27.5, p 
< 0.05).  Performance power (W·min-1) with L-Asp improved (p < 0.01) in WP (270.2 ± 
19.7 vs. 227.6 ± 14.3) but not (p > 0.05) in MOD (220.1 ± 9.1 vs. 204.4 ± 8.3).  There 
was no treatment effect in FEM.  CONCLUSION:  These results suggest that 12.5 g x 2 
QD of L-Asp reduces hyperammonemia and enhances short-term power in intercollegiate 
water polo players.  Conversely, in MOD and FEM, 12.5 g x 2 QD of L-Asp does not 
attenuate exercise-induced hyperammonemia sufficiently to improve power. 
 x 
  
 
CHAPTER 1.  REVIEW OF LITERATURE 
 
1.1 Introduction 
Ammonia (NH3) is a normal metabolic product.  At high physiological levels, 
however, NH3 is adverse to clinical status, metabolic function, and exercise performance.  
Blood ammonia concentrations are normally < 50 µM/L at rest (Fischbach, 1988).  
However, as reviewed by Batshaw (1984), prolonged symptomatic blood concentrations 
exceeding 100 µM/L comprise the medical condition known as clinical hyperammonemia 
(CH).  The symptomatic etiology of CH is encephalopathy preceded by hepatic dysfunction 
(Allen and Conn, 1960; Bessman and Bradley, 1955).  Strenuous physical activity elevates 
blood ammonia concentrations to the criteria for mild to moderate CH (100 µM/L – 500 
µM/L).  Interestingly, the symptoms and blood ammonia values of mild to moderate CH 
are similar to those observed during physical exhaustion with ‘exercise-induced 
hyperammonemia’ (EIH).  These include confusion, hyperventilation, and muscular 
dysfunction.  If prolonged, CH symptoms may exacerbate to convulsions, coma, and death.  
With EIH, maintenance of high power is difficult, and exhaustion is imminent (Allen and 
Conn, 1960; Banister et al., 1983; Hermansen and Stensvold, 1972; Wilkerson et al., 1977).  
Treatments for lowering CH and EIH are similar, and include: 1) restriction of dietary 
protein, 2) increasing carbohydrate (%) intake, 3) administration of amino acids (AA’s) 
that enhance ammonia clearance into (the less toxic) urea, and 4) correction of the 
underlying metabolic etiology.  A major focus of sports nutrition physiology is 
performance improvement by enhancing ATP production, glycogen storage, and sports-
specific training.  As reviewed by Graham et al. (1997), Yuan and Chan (2000), and noted 
by Brooks et al. (1996), "amino acids and proteins are, in fact, integrally involved in the 
metabolic adjustment to exercise".  Although understood that lower blood ammonia levels 
are desirable for optimal performance, few report the impact of acutely reducing EIH by 
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supplementation with ammonia-reducing amino acids (e.g. L-arginine, L-ornithine, L-
aspartate).  Further, the impact of lowering blood ammonia in this manner to improve 
short-term high-intensity performance is unknown.  Therefore, the primary focus of this 
dissertation is to critically address the importance of metabolic ammonia and the impact of 
reducing ammonia on exercise performance. 
As reviewed by Graham et al. (1997), there is an apparent beneficial association 
between exercise performance, reduced blood ammonia concentration, and improved 
training status.  For instance, Lo and Dudley (1987) reported that endurance trained 
subjects had lower plasma ammonia levels than untrained subjects at the same absolute 
power output during a short-term incremental protocol.  Data from Snow et al. (1992) 
demonstrated the benefits of seven weeks of sprint training include absolute increases in 
power and reduced blood ammonia at a given relative exercise intensity.  As suggested by 
Holloszy and Coyle (1984) and demonstrated by Denis et al. (1989) and Green et al. 
(1991), short-term endurance training lowers blood ammonia at a submaximal intensity.  
However, as cited by Graham et al. (1997), it is doubtful that two weeks of endurance 
training (Denis et al., 1989) is sufficient to increase mitochondrial density, plus, sprint 
training should not tax the mitochondria.  Therefore, there must be some other 
mechanism(s) (in an overall or combined fashion) for the reduction of blood ammonia with 
training.  To date, it is unclear whether the blood ammonia response to training reflects 
reduced muscular production, greater removal from the blood, enhanced buffering in either 
muscle or blood, or increased conversion into amino acid(s) (i.e. branched chain amino 
acids).   
As described by Mutch and Banister (1983), fatigue is the decreased ability of an 
organism or one of its parts to respond or function because of prolonged exertion or 
repeated stimulation.  Although muscular fatigue is a well-known phenomenon and 
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"exercised until exhaustion" is understood, a myriad of factors contribute to fatigue.  These 
include: 
1) Substrate depletion of adenosine triphosphate (ATP), phosphocreatine (PC), 
and carbohydrate (CHO), 
2) Accumulation of waste products (e.g. CO2, H
+
, NH3, hypoxia), 
3) Inhibition of metabolic function, and/or 
4) Central factors (e.g. tryptophan uptake by the brain, leading to seratonin 
accumulation). 
 
  For example, Frumerie (1913) pointed out that the onset of physical fatigue is experienced 
initially at the joints and tendons, while Mosso (1915) suggested that fatigue was a 
consequence of "a kind of poisoning resulting from products derived from chemical 
changes in cells".  The hydrogen ion hypothesis (i.e. muscular fatigue as a result of tissue 
acidosis) was first proposed by Hill et al. (1924), who noticed a consistent relationship 
between the rate of recovery from a tetanic contraction and the rate of disappearance of 
lactic acid from muscle.   
At rest, circulating ammonia exists in minute quantities [10 - 40 µM/L] and is 
tolerated without symptoms.  However, prolonged clinical hyperammonemia ([100 - 2000 
µM/L]) interferes with respiration, cell and mitochondrial permeability, and central nervous 
system (CNS) function (Batshaw, 1984).  Deterioration of brain function in response to 
hyperammonemia is progressive, and if exacerbated, is often fatal.  As reviewed by Mutch 
and Banister (1983), ammonia is produced both centrally and peripherally, and depletes 
reserves of glutamate, aspartate, and GABA, essential neurotransmitters.  Further, Mutch 
and Banister (1983), and Banister et al. (1985) have suggested that the accumulation of 
ammonia is a contributing factor to muscular exhaustion.  It is well known that strenuous 
muscular activity elevates blood ammonia to the symptomatic levels observed in clinical 
hyperammonemia (> [100 µM/L]) (Allen and Conn, 1960; Banister et al., 1983; Hermansen 
and Stensvold, 1972; Wilkerson et al., 1977).  Data from Eriksson et al. (1985) and Graham 
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et al. (1990) suggest that the blood ammonia rise with exercise reflects production rate 
exceeding removal.  Further, Washio and Mahima (1963) and Heald et al. (1975) 
demonstrated progressively inhibited in situ contractile responses of skeletal muscle in 
concentrated extracellular ammonium ion solutions.  Washio and Mashima (1963) 
demonstrated that the majority of muscle fibers (e.g., 22 of 25) become electrically 
inexcitable following progressive exposure to ammonium ions.  These observations suggest 
that 1) muscular performance and ammonia levels are inversely related, and 2) excessive 
ammonia accumulation is a regulator of performance. 
Fortunately, acute and chronic reductions of hyperammonemia generally improve 
clinical prognosis and muscular performance (Batshaw, 1984).  In apparently healthy 
populations, the magnitude of EIH reduction to improve performance is not established, 
nor are target population(s) and methods (e.g. exercise modalities, intensities, and 
duration).  In the clinical setting, the amino acids L-Aspartate, L-Ornithine, L-Arginine, 
and/or L-Glutamate reduce CH and increase desirable prognosis (Balesteiri et al., 1967; 
DuRuisseau et al., 1956; Najarian et al., 1958; Winitz et al., 1956).  However, exercise 
studies using similar supplementation (Denis et al., 1991; Edwards and Day, 2000; and Eto 
et al., 1994) indicate that L-Ornithine, L-Arginine, and/or L-Glutamate are ineffective as an 
ergogenic aid for the acute reduction of EIH and/or improvement in exercise performance.   
Alternatively, data from animal and human studies suggests that in certain 
situations administration of L-Aspartic Acid, (or one of the magnesium-potassium salts of 
L-Aspartate) lowers blood ammonia concentration (Kendrick, 1976; Keul, 1971; Laborit et 
al., 1958; Wesson et al., 1988) and enhances performance (Ahlborg et al., 1968; Franz and 
Chintanaseri, 1977; Gupta and Srivastava, 1973).  Application of the results is 
controversial, possibly due to the variability in training status of testing populations, dosage 
regimes, and modalities.  Although data from Derave et al. (1997) demonstrate gender 
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differences in ammonia response, the effect of aspartate supplementation on exercise 
performance in women is unknown.  The impact of aspartate ingestion to reduce transient 
EIH and enhance short-term high-intensity (> 90% VO2max) power when blood ammonia 
levels peak, has not been reported.  Therefore, this critical review and dissertation will 
focus on the bioenergetics and impact of L-Aspartic Acid supplementation to reduce EIH 
and improve high-intensity exercise performance in men and women. 
1.2 Bioenergetics: ATP Production, NH3 Production, NH3 Removal 
1.2.1 Introduction 
The high-energy compound ATP (Adenosine Triphosphate), derived from 
foodstuffs, provides essentially all of the energy required for physiological functions.  
However, due to a low amount of ATP readily available in cells, specific metabolic 
pathways for digested components (ATP-PC, carbohydrate, amino acids, triacylglycerol 
derivatives) produce ATP for energy.  As discussed by Astrand and Rodahl (1986), 
recruitment of substrate for ATP production is mediated by: 
1) Exercise intensity, duration, modality, type (continuous or intermittent) 
2) State of training 
3) Diet 
4) State of health 
5) Availability and source of substrate. 
 
Table 1.1 lists the various biochemical pathways, energy sources, production 
characteristics, and waste products of ATP metabolism, assuming 10 kcal/mole ATP 
(Brooks et al., 1996).  Muscular activity increases ATP utilization rate, demand for 
replenishment, and waste product formation (e.g. NH3, H+, CO2).  The waste products 
generated depend on the source, speed, and amount of substrate consumed.  Ammonia, for 
instance, accumulates rapidly with 1) accelerated ATP hydrolysis (i.e. during short bursts 
of high-intensity activity) and/or 2) inhibited removal (e.g., limitation(s) in urea cycle 
enzyme efficiency, urea cycle substrate availability, and hepatic blood flow).  As 
 5 
  
 
Table 1.1. ATP sources, production characteristics, and waste products.  
 
Metabolic 
Pathway(s) 
Energy 
Source 
Estimated Rate 
(moles/min) 
Estimated 
Capacity 
(moles) 
Waste 
Products 
ATP-PC Intramuscular 
ATP 
Phosphocre-
atine 
 
Very Fast 
(> 3.6 ATP/min) 
Very Low (0.5 
ATP) 
Pi 
NH3 
Glycolysis 
(exclusively) 
Glucose  
Glycogen 
Fast  
(1.5 ATP/min) 
Low  
(500g CHO – 
9 ATP) 
H+ 
Glycolysis + TCA 
+ ETC 
Glucose  
Glycogen 
Somewhat 
Fast  
(1 ATP/min) 
Med 
(500g CHO -
114 ATP)  
 
CO2 
Gluconeogenesis; 
Transamination/ 
Oxidation – 
TCA Cycle, ETC 
BCAA’s  
Glycerol  
Lactate  
Alanine 
Variable  High (2500g 
PRO-175 
ATP) 
NH3 
CO2 
β-Oxidation -TCA 
Cycle, ETC  
Fatty acids  
Glycerol 
Ketones 
Very Slow Very High  
(>15,000g Fat 
– 8,000 ATP) 
CO2  
 
 
depicted in Table 1.1, maximal ammonia production occurs in short term high-intensity 
athletic events (e.g. 400 – 800 meter run, water polo sprints), which accelerate ATPase, 
adenylate kinase, and adenosine monophosphate (AMP) deaminase activity (Astrand and 
Rodahl, 1986).  During intense exercise, a 50% reduction in muscular [ATP] yields up to a 
20-fold change in adenosine diphosphate [ADP], and 700-fold increase in [AMP] (Astrand 
and Rodahl, 1986).  Elevated blood NH3 occurs also with long duration exercise, but to a 
smaller degree, from the metabolism of branched chain amino acids (BCAA’s) used for 
gluconeogenesis.  The amount of ammonia produced with endurance exercise is far greater 
 6 
  
 
(and more tolerable) versus short-term high-intensity exercise, due to a lower rate of 
production (Graham et al., 1995a; Wagenmakers et al., 1990).  The demand for ATP, 
availability of substrate, and status of training are principal factors in ammonia metabolism.  
The bioenergetic sources, fates, and impact of ATP, ammonia, and aspartate are discussed 
in the following sections of this chapter. 
1.2.2 ATP - PC System 
ATP is a readily available energy source in active muscle, consisting of a base 
(adenine), a sugar (ribose), and a chain of three phosphates.  During short-term intense 
exercise, ATP depletion (i.e. demand exceeding supply) occurs rapidly (i.e. < 1 minute).  In 
response, additional pathways are activated to 1) reproduce ATP quickly (i.e. glycolysis, 
gluconeogenesis), and 2) transport and remove waste products (i.e. NH3) efficiently (e.g. 
transamination, Cori Cycle activity, urea cycle activity,).  Ammonia is a deamination by-
product of the very fast phosphagen (ATP-PC) pathway for ATP production, utilization, 
and regeneration (Sabina et al., 1984).  ATP hydrolysis elevates ADP, AMP, inosine 
monophosphate (IMP), and ammonia via coupling of ATPase, AMP deaminase, and the 
purine nucleotide cycle (PNC) (Hellsten et al., 1999).  The impact of ATP hydrolysis, the 
PNC, and ammonia production on bioenergetics are presented and discussed in this 
chapter. 
Schmidt (1928) first reported that AMP deamination, in response to accelerated 
ATP hydrolysis, is a major source of ammonia production in active muscle.  As presented 
below in reactions (1) and (2), the ATP-PC pathway is a 2-reaction cycle.  Accelerated in 
response to high-intensity exercise, the products of the ATPase (1) (ADP, Pi) become 
reactants for ATP regeneration either by either a reversal of reaction (1) (utilizing energy 
released); or by myokinase in reaction (2) (ADP + ADP <=> ATP + AMP).  The 
production of NH3 by AMP deaminase (AMP + H2O => IMP + NH3), is the primary source 
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of the NH3 (reaction (3)) rise with short-term intense activity (Sabina et al., 1984; Schmidt, 
1928; Wajzer et al., 1956).  Studies by Meyer and Terjung (1979; 1980) have shown a 50% 
conversion rate of ATP into IMP and ammonia during short-term intermittent stimulation 
(5 min) of rat gastrocnemius muscle. 
ATP + H2O <=> ADP + Pi        (ATPase)  (1) 
ADP + ADP <=> AMP + ATP             (myokinase) (2) 
AMP + H2O => IMP + NH3  (AMP deaminase) (3) 
 
1.2.3 Purine Nucleotide Cycle 
Ammonia production via AMP deaminase is proportional to the rate of ATP 
hydrolysis.  Although AMP deaminase (AMP + H2O => IMP + NH3) is irreversible, AMP 
may be regenerated (reactions 4,5) by a process termed the purine nucleotide cycle (PNC) 
(Goodman and Lowenstein, 1977; Lowenstein, 1972; Wheeler and Lowenstein, 1979).  
According to Banister et al. (1983), maintenance of the total amount (TAN) of adenine 
nucleotides (ATP + ADP + AMP) during exercise is desirable.  Further, the PNC requires 
aspartate as a substrate (reaction 4).  Thus, aspartate administration stimulates the 
regeneration of AMP assisting the maintenance of TAN’s.  In addition, the TCA cycle 
intermediate fumarate (reaction 5) is a product of the PNC.  The PNC steps are: 
AMP + H2O => IMP + NH3                                (AMP deaminase)   (3) 
IMP + Aspartate + GTP => Adenylosuccinate + GDP + Pi   (adenylosuccinate 
synthetase)   (4) 
Adenylosuccinate <= > AMP + Fumarate    (adenylosuccinase)         (5) 
 
The overall summary is: 
Aspartate + GTP + H2O => Fumarate + NH3 + GDP + Pi   (6) 
The bioenergetic results of the PNC are: 
1) Regeneration of AMP 
2) Deamination of aspartate to fumarate, and  
3) Liberation of ammonia.  
Data from several studies (Gerez and Kirsten, 1965, Meyer and Terjung, 1979; 
Raggi et al., 1969; Winder et al. 1974) indicates that recruitment of fast-twitch muscle 
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fibers (vs. slow twitch) increases AMP deaminase activity and ammonia production.  AMP 
deaminase is activated also by high intramuscular [ADP], [AMP], and a fall in pH -- and 
inhibited by high [ATP], [GTP], and [Pi] (Wheeler and Lowenstein, 1979).  On the other 
hand, slow-twitch muscle fibers contain low amounts of AMP deaminase (Gerez and 
Kirsten, 1965; Meyer and Terjung, 1979; Raggi et al., 1969; Winder et al. 1974), and 
therefore produce less ammonia.  Thus, mitochondria-rich muscle (slow oxidative) 
produces less ammonia with high-intensity exercise than mitochondria-poor (fast 
glycolytic) muscle.  Washio and Mashima (1963), and Heald (1975) demonstrated inhibited 
in situ skeletal muscle contractile responses in a concentrated extracellular ammonium ion 
solution.  Therefore, recruitment of fast-twitch muscle fibers accelerates ATP hydrolysis, 
AMP deamination, PNC activity, and intramuscular [NH3]. 
Summarizing, the resynthesis of AMP by the PNC requires aspartate for the 
maintenance of total adenine nucleotides.  Secondly, the PNC and aspartate provide 
carbons for fumarate for TCA cycle bioenergetics (Lowenstein, 1972).  The impact of 
removing (or buffering) the toxic ammonia product is a priority, and will be discussed in 
detail in the section on ammonia removal.   
1.2.4 Glycolysis and Pyruvate Oxidation 
Second in speed to the ATP-PC system for ATP production is glycolysis.  As 
discussed by Miller (1992), glycolysis is the 10-reaction catabolism of the 6-C glucose in 
the cytosol into two 3-C molecules of pyruvate.  Glycolysis generates a net of two ATP 
(i.e. 4 ATP created, minus 2 ATP utilized).  Glycolysis is a process of energy transfers 
where the phosphate is carried from substrate to ADP to ATP via the phosphate ion itself, 
and thus, is termed ‘substrate-level phosphorylation’.  Glycolysis does not require oxygen.  
Two NADH molecules are produced, which result in six additional ATP produced by the 
electron transport chain (ETC).  Intense muscular activity (e.g. where exhaustion occurs in 
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less than 2 minutes) accelerates glycolytic rate and produces (and utilizes) a relatively large 
amount of ATP in a short period.  As a potent activator of the glycolytic rate-limiting 
enzyme phosphofructokinase (PFK), elevated [NH3] concentrations accelerate glycogen 
depletion, ATP production, and ATP hydrolysis (Felig and Wahren, 1971; Lowenstein, 
1972; Sugden and Newsholme, 1975). 
Pyruvate metabolism is dependent upon ATP supply and demand.  When conditions 
favor pyruvate oxidation (e.g. during moderate continuous physical activity), pyruvate is 
converted into acetyl-CoA by the pyruvate dehydrogenase complex (PDH) within the 
mitochondria.  The PDH complex is a series of the three enzymes E1 (pyruvate 
dehydrogenase), E2 (lipoate acyltransferase), and E3 (dihydrolipoyl dehydrogenase).  Also 
termed ‘oxidative decarboxylation’, the PDH sequence is important in highly oxidative 
tissue such as muscle and heart, by promoting pyruvate conversion into acetyl-CoA for 
entry into the TCA cycle.  The PDH complex converts the 3-C pyruvate molecule to 2-C 
acetyl-CoA, NADH, releasing CO2, as summarized as follows: 
                                     PDH complex 
Pyruvate + NAD+ + CoASH <==========> Acetyl-CoA + NADH + H+ + CO2  
 
Advantages of pyruvate decarboxylation include 1) more ATP produced per unit glucose 
and 2) reduced lactate, H+, and ammonia accumulation.  However, a noteworthy 
disadvantage is the slower rate of ATP production with pyruvate oxidation. 
On the other hand, when ATP needs are accelerated during short bursts of intense 
activity, hydrogens accumulate and combine with pyruvate.  In this case, lactate and NAD+ 
form rapidly, due to the near equilibrium of lactate dehydrogenase (LDH) reaction.  Lactate 
may be converted back (i.e. gluconeogenesis) into 1) glucose in the liver, or 2) pyruvate by 
the heart or oxidative fibers (Broberg and Sahlin, 1988).  Advantages of lactate production 
include 1) faster rate of ATP production and 2) the recycling of NAD+ into NADH for 
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anaerobic production of ATP to continue, and 3) providing NAD+ to accept additional 
hydrogens generated in glycolysis.  However, the disadvantages of accelerated lactate 
formation include: 1) very fast depletion of a very limited supply (~ 500g) of carbohydrate, 
and 2) rapid accumulation of lactic acid, H+ and subsequent ammonia from ATP hydrolysis 
– each inhibiting muscular contraction and promoting fatigue.  Therefore, the responses to 
accelerated glycolytic fiber activity include 1) faster production and utilization of ATP and 
NADH, 2) elevated lactate and H+ production, 3) elevated ammonia (from ATP 
hydrolysis), and 4) excitatory feedback activation of PFK by ammonia (Felig and Wahren, 
1971; Lowenstein, 1972; Sugden and Newsholme, 1975).   
 1.2.5 Tricarboxylic Acid (TCA) Cycle  
The primary purpose of the TCA cycle is to provide high energy reducing 
equivalents (NADH, FADH2) for the electron transport chain for ATP production within 
the mitochondria.  Acetyl-CoA is the common entry point into the TCA cycle for 
carbohydrate, fat, and protein catabolism.  In this process, the 4-C TCA intermediate 
oxaloacetate (OAA) condenses with the 2-C acetyl-CoA to yield the 6-C TCA intermediate 
citrate.  Summarizing, the TCA cycle strips the hydrogens and carbons from the acetyl Co-
A shell, producing: 
1) 2 molecules of CO2 
2) 1 ATP equivalent 
3) Eight hydrogen atoms in the form(s) of NADH and FADH2, carrying high 
energy transfer potential to the electron transport chain for NAD+ and ATP 
production.  
 
1.2.6 Electron Transport Chain 
In 1961, a paper by Peter Mitchell introduced the chemiosmotic hypothesis (i.e. ‘the 
electron transport chain’) for the production of ATP within the mitochondria (Mitchell, 
1961).  The electron transport chain (ETC) is the process of ATP production within the 
mitochondria utilizing the high-energy potential of the electrons of the hydrogen atoms in 
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the transfer to molecular oxygen.  The reducing equivalents NADH and FADH2  (produced 
in various metabolic pathways) transfer this high-energy potential (Miller, 1992) across the 
inner mitochondrial membrane.  As described below, the energy transfers promote ATP 
production at three ‘sites’, utilizing specific electron carriers, respectively.  Each site 
phosphorylates ADP into ATP (i.e. 'oxidative phosphorylation'), liberating a large amount 
of energy. 
The passage of electrons to the final carrier of oxygen occurs at three sites with 
ATP produced at each.  ADP is phosphorylated into ATP by electrical gradients created by 
the pumping of H+ across the inner mitochondrial wall and cristae through the ATPases.  
NADH electrons enter the ETC at site #1, while that of FADH2 enter at site #2.  At site #3, 
the electrons of NADH and FADH2 both combine with oxygen to produce ATP and H2O.  
The remaining energy is released as heat.  Three ATP are produced for each NADH, while 
two ATP are produced with each FADH2.  The electron source(s) and transfer 
characteristics for each site are:  
Site #1 -  NADH electrons are transferred to coenzyme Q by NADH 
dehydrogenase (producing 1 ATP) 
Site #2 -  NADH and FADH2 electrons are transferred from coenzyme Q, to 
cytochrome b, to cytochrome c1 (producing a second ATP) 
Site #3 -  NADH and FADH2 electrons are transferred from cytochrome c1, to 
cytochromes c, a, a3, to oxygen (producing a third ATP, and water) 
 
The energy released during the transfers promotes the phosphorylation of ADP into ATP, 
producing H2O, and releasing heat.  Oxygen is the final electron acceptor.  The effects of 
NH3 on the coupling of electron transport, proton gradients, and ATP production are 
unknown.  However, as discussed in the following paragraph, ammonia and aspartate 
fluctuations may affect the malate-aspartate shuttle for reducing equivalent transport in the 
ETC. 
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The inner mitochondrial membrane is impermeable to NADH.  To participate in the 
ETC, NADH is shuttled across the membrane to site #1 or site #2 by one of two 
mechanisms: 1) the malate aspartate shuttle and/or 2) the glycerol phosphate shuttle 
(Miller, 1992).  Site #1 of the ETC utilizes the malate aspartate shuttle to transfer electrons 
from NADH to NAD+ resulting in 38 ATP from one glucose molecule.  Site #2 utilizes the 
glycerol phosphate shuttle to transfer electrons from NADH to NAD+, resulting in 36 ATP 
from one glucose molecule.  Since the site using the aspartate shuttle produces more ATP 
per glucose molecule, it appears advantageous for bioenergetics to have more aspartate 
available for the ETC. 
Therefore, as discussed by Miller (1992) aspartate availability may enhance ETC 
productivity by: 
1) Promoting the shuttling of reducing equivalents across the inner 
mitochondrial membrane,  
2) Producing 2 additional ATP via ETC site #1 versus site #2, and 
3) Providing substrate for the PNC for the maintenance of total adenine 
nucleotides. 
 
1.2.7 β-Oxidation 
The conversion of fat (triacylglycerol) for ATP integrates several metabolic 
pathways, and culminates in the splitting of the fatty acid molecule into 2-C acetyl 
fragments, NADH and FADH2 for utilization by the TCA cycle and the ETC (McArdle et 
al., 1996).  Although fatty acid oxidation is slower than glycolysis, the relative (and 
absolute) amount of ATP produced from it is much higher (~130 ATP per 16-C palmitate) 
than glycolysis.  Ammonia is not a product of β-oxidation, nor are fatty acids a substrate 
for glucose synthesis.  However, glucose and fatty acid oxidation link ATP production.  For 
example, a prolonged shortage of the 4-C TCA intermediate OAA results in 1) undesirable 
ketone (acetone, acetoacetate, β-hydroxybutyrate) formation from excess acetyl-CoA 
buildup, and 2) decreased OAA for gluconeogenesis TCA continuity.  As described by 
 13 
  
 
Brooks et al. (1996), the sequence for lipid catabolism for ATP production (beginning with 
triacylglycerol cleavage) is as follows: 
1)  Mobilization - initiation of exercise triggers a release of epinephrine, 
promotes triacylglycerol breakdown (by hormone sensitive lipases, HSL) 
into three fatty acids and a glycerol backbone, per triacylglycerol.  Glycerol 
may contribute carbons for glucose synthesis, or enter glycolysis as 3-
phosphoglyceraldehyde.  The complete breakdown of glycerol yields 19 
ATP, synthesized from substrate level phosphorylation and release of 
hydrogen atoms to NAD+ with subsequent pyruvate oxidation  
2)  Circulation - free fatty acid (FFA) transport via the blood to muscle (usually 
with albumin as the carrier) 
3)  Uptake - the entry of free fatty acids (FFA) into muscle 
4)  Activation - resembling the first step in glycolysis, ATP and coenzyme A 
activate the fatty acid in the cytoplasm, forming fatty acyl-CoA for transport 
into the mitochondria 
5)  Translocation - carnitine shuttles the fatty acyl-CoA into the inner 
mitochondria 
6) β-oxidation - a cycle where the carbons of the activated fatty acid chain (e.g, 
palmitate, 16-C) are stripped away two at a time (between the first carbon 
from the carboxyl end - the α; and the second carbon - the β) producing a 2-
C acetyl-CoA, NADH, and FADH2 per turn of the cycle.  This process is 
repeated until the entire carbon chain of the fatty acyl-CoA is utilized.  The 
final spin of the cycle (when only 2 C are left) produces acetyl-CoA only.  
Combining subsequent mitochondrial oxidation (TCA cycle and ETC), each 
acetyl-CoA yields 12 ATP (TCA and ETC); each NADH yields 3 ATP 
(ETC); and each FADH2 yields 2 ATP (ETC).  The total amount of ATP 
produced, depends on the number of carbons in the fatty acid. 
7) Mitochondrial Oxidation - the TCA cycle and ETC produce ATP from 
acetyl-CoA, NADH, and FADH2.  For example, the complete oxidation of a 
16-C palmitate FA yields a net total of 130 ATP [(12 x 8 = 96 ATP from 
acetyl-CoA) + (7 x 3 = 21 ATP from NADH) + (7 x 2 = 14 ATP from 
FADH2) - 1 ATP invested for activation], or approximately 390 ATP per 
palmitic triglyceride (exclusive of glycerol). 
 
Thus, for a 16 carbon FA, the first seven cycles of β-oxidation yield: 
1) 7 Acetyl-CoA (= 84 ATP),  
2) 7 NADH (= 21 ATP), and  
3) 7 FADH2 (= 14 ATP). 
 
The last revolution of β-oxidation yields one acetyl Co-A (= 12 ATP), producing a total of 
131 ATP, (minus 1 ATP invested for FA activation), for a net of 130 ATP per molecule of 
palmitate. 
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1.2.8 Amino Acids: Digestion, Bioenergetics, Ammonia, and Aspartate 
Carbohydrate, fat, and protein are the primary food sources for mammals with each 
providing carbons for energy (Miller, 1992).  Of these, only proteins contain nitrogen, 
producing ammonia from catabolism.  Proteins are polypeptide chains of the 20 different 
amino acids, arranged in any order, up to thousands of AA's long.  AA's are composed of 
carbon, hydrogen, oxygen, nitrogen, and occasionally sulfur.  Each AA has four 
components: 
1) An amine group (NH2), 
2)  A carboxyl group (COOH-),  
3) A unique side "R" chain, and 
4) A hydrogen.   
 
The amino group of each AA is attached to the α carbon (the carbon next to the 
carboxyl carbon) of a carboxylic acid (Brooks et al., 1996).  Peptide bonds attach the amine 
group of one AA to the carboxyl group of another, forming long strands called proteins.  
Metabolism of proteins and AA’s has several key bioenergetic characteristics, including: 
1) No significant storage pool specific for energy, analogous to storage of 
glycogen or triacylglycerol 
2) AA carbons are precursors for gluconeogenesis 
3) AA’s catabolize to produce other AA’s 
4) Substrate of anaplerosis for the TCA cycle (supply TCA intermediates) 
5) Ammonia as a product. 
 
The digestion of protein into AA’s begins in the stomach.  Here, pepsin (under the 
influence of HCl) splits the large protein molecules into smaller units, called polypeptides.  
Proteinases and peptidases degrade the polypeptides into individual AA's in the small 
intestine.  AA’s are absorbed primarily by the microvilli, and transported to the liver via the 
hepatic portal system.  Data in laboratory animals from Neame and Wiseman (1956) and 
Finkelstein et al. (1983) indicate that portal absorption of aspartic acid, for example, begins 
about 10 minutes after introduction to the small intestine lumen, peaking at 30 minutes, and 
remaining above resting levels for 1-2 hours.  During the absorptive state, AA’s are utilized 
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for hepatic protein synthesis, and conversion into triacylglycerol.  In contrast to the storage 
fate(s) for CHO (i.e. glycogen) and fat (i.e. triacylglycerol), there are no bioenergetic 
storage depot(s) specific for protein or AA.  Fates of excess digestive protein are: 
1) Conversion into triacylglycerol, and 
2) Degradation into ammonia and urea by the liver, or 
3) Degradation into ammonia by the intestinal flora by urease.  
 
As pointed out by McArdle "all protein exists as important constituents of 
metabolic, transport, and hormonal systems" (McArdle et al., 1996).  During exercise, 
glucagon, glucocorticoids, and catecholemines work together to catabolize proteins, 
particularly muscle proteins, for energy production.  AA bioenergetic activity is promoted 
by: 
1) Glucagon and catecholemines (e.g., a high protein, low carbohydrate diet) 
2) Glucocorticoids (severe stress, e.g. burns, exercise, trauma, surgery, disease) 
3) Low fuel reserves. 
 
Glucagon (released from the pancreas) promotes hepatic glycogenolysis and blood glucose 
elevation.  Catecholemines (released from the medulla of the adrenal glands), activate 
catabolism of stored substrate (e.g. lipolysis, glycogenolysis) for energy production.  
Glucocorticoids (released from the adrenal glands) cause proteins (e.g. actin, myosin) from 
muscles and connective tissue to be broken down into AA’s to make glucose for energy.  
The bioenergetic effect(s) of glucagon and epinephrine are more immediate than 
glucocorticoids. 
As illustrated below in reactions (1), (2), and (3) the two primary processes for 
stripping AA carbons for bioenergetics are transamination and oxidative deamination.  
Glutamate serves as a substrate (and nitrogen carrier) in all three reactions.  In 
transamination, the amino group of an amino acid is transferred to a keto acid, thus 
producing a second amino acid and keto acid.  The two major routes of transamination are 
glutamate-pyruvate transaminase (SGPT) (reaction 1), and SGOT (serum glutamate-OAA 
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transaminase, or aspartate aminotransferase) (reaction 2), each requiring pyridoxal 
phosphate as a coenzyme.  Since transamination occurs in muscle and (in particular) the 
liver, both SGPT and SGOT are useful for analysis of bioenergetics and acute liver 
function.  Mole’ and Johnson (1971) have demonstrated elevated SGPT (also called alanine 
transaminase, or alanine aminotransferase, ALT) with endurance activity, activating 
alanine metabolism and production (reaction 1). 
     SGPT 
Pyruvate + Glutamate <==========> Alanine + α-ketoglutarate (1) 
(liver)        (muscle) 
 
As illustrated in reaction (2), the second transamination reaction, SGOT, links the 
amino acid(s) glutamate and aspartate with the TCA intermediates OAA and α-
ketoglutarate.  In addition to linking bioenergetics, aspartate is a major carrier of catabolic 
nitrogen to the urea cycle for excretion.  The terminal nitrogen products of ammonia and 
urea leave the body via sweat, the lungs, and/or diluted in urine (Czarnowski et al., 1995).  
SGOT 
OAA + Glutamate <==========> Aspartate + α-ketoglutarate (2) 
 
Oxidative deamination occurs in the mitochondrial matrix, utilizing NAD+ as the 
oxidizing agent.  As illustrated in reaction (3), oxidative deamination assists the excretion 
of amino acid nitrogen from the body.  Glutamate is converted by oxidative deamination to 
α-ketoglutarate and NADH, a reaction catalyzed by glutamate dehydrogenase (GDH).  
NH4+ serves as the nitrogen product.  In amino acid catabolism, glutamate is a common 
nitrogen carrier, serving as an intermediate in both transamination (reactions 1 and 2) and 
oxidative deamination (reaction 3). 
GDH 
H2O + Glutamate + NAD+ <==========> α-ketoglutarate + NH4+ + NADH  (3) 
 
 
 17 
  
 
Reactions 1 - 3 illustrate the concept of anaplerosis - how OAA, aspartate, 
glutamate, α-ketoglutarate, and ammonia link AA metabolism, gluconeogenesis, while 
regenerating TCA cycle intermediates.  Aspartate is converted to OAA via transamination, 
i.e. transfers the amine group to glutamate while providing the carbon backbone for OAA.  
Aspartate is also converted to fumarate in the PNC, and the urea cycle, once again 
providing carbons for anaplerosis.  Fumarate re-enters the TCA cycle, and is converted to 
OAA by TCA cycle enzymes.  High ammonia levels drive the α-ketoglutarate GDH 
reaction (reaction 3) toward glutamate formation, thus depleting α-ketoglutarate, an 
essential TCA cycle intermediate. 
AA carbon chains contribute to bioenergetics by providing the carbon backbone(s) 
for pyruvate, TCA cycle intermediates, or acetyl-CoA (and derivatives).  AA’s are 
classified by either function (intake need) or bioenergetic point of entry.  The functional 
classifications are: 
1) Nonessential – dispensable 
2) Essential – indispensable (mammalian cells lack enzymes to synthesize the 
carbon skeletons)  
3) Conditionally essential – essential under certain conditions (e.g. infancy) 
 
The bioenergetic classifications are: 
1) Glucogenic – AA carbon chains enter as pyruvate, or TCA cycle 
intermediate(s),  
2) Ketogenic – AA carbon chains enter as acetyl-CoA or acetoacetate  
 
The bioenergetic entry points for glucogenic AA’s are:  
1)  Pyruvate - cysteine, alanine, glycine, serine 
2)   α-ketoglutarate - glutamate, glutamine, histidine, proline, arginine 
3) Succinyl-CoA - isoleucine, methionine, threonine, valine 
4) Fumarate - tyrosine, phenylalanine, aspartate 
5) OAA - asparagine, aspartate 
 
The bioenergetic entry points for ketogenic AA’s are:  
1)  Acetyl-CoA - isoleucine, leucine, tryptophan 
2) Acetoacetyl-CoA - phenylalanine, lysine, leucine, tyrosine 
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Therefore, tyrosine, phenylalanine, and isoleucine are classified both glucogenic and 
ketogenic, because their carbons may enter bioenergetics in either category. 
FA's yield exclusively acetyl-CoA in β-oxidation; therefore, ketogenic AA (e.g., 
leucine) carbons are not a source of carbohydrate for gluconeogenesis.  Gluconeogenesis 
does not result from the carbons of ketogenic AA’s because: 1) the irreversible nature of 
PDH prevents pyruvate formation from acetyl-CoA, and 2) the 2-C atoms of acetyl-CoA 
are released as 2 molecules of CO2 in the TCA cycle, and thus are eliminated.  However, 
the catabolism of ketogenic AA’s also produces NADH and FADH2, thus providing high 
energy reducing equivalents for ATP production via gluconeogenesis and the ETC. 
Fasting, starvation, and/or prolonged exercise deplete glycogen and blood glucose 
levels.  In response to hypoglycemia, the body synthesizes new glucose (gluconeogenesis) 
via lactate, glycerol and AA’s.  Data from Mole and Johnson (1971), and Jungas et al. 
(1992), indicate that ~ 60% of the ATP produced from gluconeogenesis occurs in the liver, 
35% from AA oxidation in muscle and small intestine, and ~ 5% from oxidation of 
acetoacetate. 
Gluconeogenesis is a reversal of glycolysis, producing glucose as the end product of 
pyruvate catabolism.  The process is costly, requiring six ATP for the conversion of 
pyruvate to glucose (compared to two ATP for glycolysis, and one ATP for β-oxidation) 
(Miller, 1992).  The three irreversible glycolytic enzyme(s) of pyruvate kinase, PFK, and 
hexokinase are bypassed and substituted for in gluconeogenesis.   
To bypass pyruvate kinase in gluconeogenesis, pyruvate is converted to 
phosphoenolpyruvate in a two-reaction process, with the 4-C TCA intermediate OAA 
serves as the intermediate.  In the first reaction, pyruvate is converted to OAA by pyruvate 
carboxylase (PCB), driven by ATP and the cofactor biotin.  
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          PCB 
  Pyruvate + CO2 + ATP <================> OAA + ADP + Pi (1) 
         Biotin 
 
In the second reaction, OAA is converted to phosphoenolpyruvate (PEP) via PEPCK, 
driven by GTP: 
   
PEPCK 
OAA + GTP <==============> PEP + CO2 + GDP   (2) 
 
Gluconeogenesis then proceeds as a reversal of glycolysis, in the process bypassing two 
more irreversible glycolytic enzymes: 1) PFK by fructose 1-6 diphosphatase, and 2) 
hexokinase by glucose 6-phosphatase, eventually forming glucose as the product of 
gluconeogenesis.   
Summarizing, beginning with pyruvate, gluconeogenesis is a reversal of the 
reversible glycolytic reactions, bypassing the highly exergonic glycolytic reactions of:  
1) Pyruvate kinase (via pyruvate carboxylase and PEPCK);  
2) PFK (via fructose 1-6 diphosphatase), and  
3) Hexokinase (via glucose 6-phosphatase). 
 
Gluconeogenesis is activated during impaired glucose availability, and/or 
insufficient ATP production (by the TCA cycle and the ETC) to meet demand.  Important 
gluconeogenesis products (nitrogen and/or carbon) include ammonia, alanine, pyruvate, 
lactate, OAA, glucose, and ATP.  As noted by Stryer (1995), accumulation of acetyl-CoA 
and pyruvate shifts bioenergetics in the direction of OAA formation and gluconeogenesis, 
by the action of pyruvate carboxylase.  Further, data in animal models (Lancha et al., 1995) 
suggests that training status affects pyruvate carboxylase activity.  For example, in 
response to high-intensity exercise, pyruvate carboxylase activity is higher in untrained 
(12x vs. rest) rat soleus versus trained (3x vs. rest).  This suggests a glycogen sparing effect 
with training, in contrast to a greater rate of gluconeogenesis (versus β-oxidation) with 
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reduced training.  Therefore, lesser-trained subjects exhibit higher exercising blood 
ammonia values, due in part to accelerated activity of BCAA catabolism for 
gluconeogenesis.   
The branched chain AA's leucine, valine, isoleucine constitute a large percentage 
(20 - 30%) of dietary protein.  During exercise, BCAA’s are the primary AA's recruited for 
oxidizable substrate, and are catabolized more readily in peripheral tissues such as skeletal 
muscle, heart, adipose tissue, and kidney.  On the other hand, human intestine and the liver 
have low levels of BCAA transaminase activity and BCAA keto acid dehydrogenase 
complex (Taniguchi et al., 1996).   
Breakdown of BCAA’s results in additional substrate (ketogenic and glucogenic) 
for energy, and as such, results in comparatively higher blood ammonia levels (Darmaun 
and Dechelotte, 1991) versus that say, of glycolysis or β-oxidation, because of the 
metabolism of the nitrogen skeleton.  Working muscle releases the nitrogen component 
primarily in the form(s) of the amino acid(s) glutamine and alanine.  BCAA catabolism 
begins with the transamination of the BCAA (leucine, valine, isoleucine) reacting with α-
ketoglutarate, producing the following bioenergetic branched chain keto acid(s):  
1)  HMG-CoA, then acetoacetate and acetyl-CoA  (via leucine) 
2) Propionyl-CoA, then succinyl-CoA  (via valine) 
3) Propionyl-CoA and acetyl-CoA  (via isoleucine) 
 
BCAA catabolism also yield(s) NADH and FADH2 via gluconeogenesis and the 
TCA cycle, thus providing high energy reducing equivalents for the ETC and ATP 
production.  However, catabolism of the purely ketogenic BCAA leucine yields 2 carbon 
atoms (as acetyl-CoA), which are eventually released as CO2 in the TCA cycle.  Valine and 
isoleucine are both precursors to propionyl-CoA (a substrate for the TCA intermediate 
succinyl-CoA) and thus enter gluconeogenesis via OAA.  However, catabolism of 
isoleucine yields both propionyl-CoA and acetyl-CoA, and therefore is both ketogenic and 
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glucogenic.  Valine, yielding exclusively succinyl-CoA as a product, is purely glucogenic.  
Ketogenic AA’s are not a source of glucose via gluconeogenesis for two reasons: 1) the 
irreversible nature of PDH prevents pyruvate formation from acetyl-CoA, and 2) the 2-C 
atoms of acetyl-CoA are released as two CO2 in the TCA cycle, thus leaving no remaining 
carbons for gluconeogenesis.   
The transfer of carbons between alanine and pyruvate between muscle and liver is 
termed the glucose-alanine Cori Cycle.  The Cori Cycle links gluconeogenesis, 
alanine/pyruvate transamination, and liver and muscle bioenergetics (Babij et al., 1983; 
Eriksson et al., 1985).  This process assists the transport of glucogenic carbons back to 
working muscle, while also serving as a nitrogen reservoir and buffer for elevated ammonia 
(Jungas et al., 1992).  During exercise, the transamination of pyruvate into alanine in 
muscle via SGPT (i.e. alanine aminotransferase) elevates alanine in proportion to exercise 
intensity, duration, and BCAA catabolism   (equation (1)) as follows: 
SGPT 
Pyruvate + Glutamate <==========> Alanine + α-ketoglutarate (1) 
    (liver)        (muscle) 
 
Alanine is the primary carrier of nitrogen and carbon atoms to the liver for the 
bioenergetic transfer to pyruvate.  In the liver, alanine is transaminated (via SGPT) back to 
pyruvate (glutamate serving as the nitrogen carrier), which may be transported back to the 
working muscle for energy. 
AA catabolism for energy production yields ammonia as a direct product, and 
therefore, contributes to both exercise hyperammonemia and OAA depletion (by draining 
the precursor α-ketoglutarate).  This is important, because catabolism of glucogenic AA’s 
characteristically provide the carbon backbone for pyruvate or TCA cycle intermediates (α-
ketoglutarate, succinyl-CoA, fumarate, OAA), while ketogenic AA’s provide bioenergetic 
carbons for acetyl CoA (or derivatives).  In situations of excessive ammonia production, 
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such as during high-intensity exercise and/or elevated AA catabolism, draining of the TCA 
intermediate α-ketoglutarate occurs in the process of glutamate (α-ketoglutarate + NH3 <=> 
glutamate) and glutamine  (glutamate + NH3 <=> glutamine) production (Goldstein, 1976; 
Levin et al., 1969; Tannen, 1978).   
Thus, hyperammonemia and α-ketoglutarate availability limit the desirable 
production of OAA by the TCA cycle.  Further, Ohira et al. (1987) demonstrated that 
aspartate aminotransferase activity increases with exercise.  Therefore, aspartate 
aminotransferase activity assists OAA homeostasis for maintenance of TCA cycle 
continuity and efficiency.  Additionally, concerning training status, Miller et al. (1987) 
demonstrated lower aspartate levels with exhaustive exercise and lack of training, 
indicating regulation of performance by aspartate availability.  Further, Lancha et al. (1994) 
demonstrated with exhaustive exercise in trained and untrained rats supplemented with 
aspartate and asparagine, a three-fold greater conversion (vs. placebo) of acetyl-CoA and 
OAA into citrate and coenzyme-A.  In another study, Lancha et al. (1995) demonstrated 
increased plasma aspartate, glycogen content, FFA’s, and prolonged (+42%) swim time to 
exhaustion with supplementation of aspartate, asparagine, and carnitine.  These data 
suggest that OAA and aspartate metabolism link exercise performance, training, and 
aspartate supplementation by promoting efficiency of TCA cycle bioenergetics with 
continuity of glycolysis, β-oxidation, and gluconeogenesis. 
1.2.9 Ammonia Removal: Glutamine, Alanine, Urea Cycle, Pyrimidines 
Minor fluctuations in blood ammonia concentration are a normal response to 
digestion, mild-moderate muscular contraction, and/or elevated AA catabolism (e.g. 
BCAA’s).  However, as blood ammonia rises to levels observed in clinical 
hyperammonemia and intense exercise (> [100 µM/L]), the risk increases for impaired 1) 
clinical status, 2) metabolic function, and 3) exercise performance.  It is therefore desirable 
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to reduce excess blood ammonia as quickly and efficiently as possible.  The following 
sections summarize the major biochemical mechanisms for the removal of blood ammonia 
for homeostatic maintenance.   
The physiological and nutritional state of the individual affects the flow of carbons 
(for ATP production) and nitrogens, and the subsequent clearance of waste products such 
as ammonia.  The amino acid(s) glutamine and alanine are the major metabolic depots of 
ammonia in muscle and blood during exercise (Nurjhan et al., 1995).  Both assist the 
reduction of hyperammonemia, by transporting nitrogen and ammonia in a less-toxic form 
between the working muscle and liver.  While alanine is the major transport form of 
glucose to and from muscle and the liver, glutamine is the major AA carrier of nitrogen out 
of muscle, in response to elevated intramuscular ATP and AA metabolism.  An increase in 
blood glutamine concentration and changes in pH promote a shift in glutamine synthetase 
to produce ammonia in vitro (i.e. glutamine => glutamate + NH3).  According to Tannen 
(1978), the amide groups of glutamine account for 30 - 40% of the NH3 excreted in the 
urine. 
The shifting of the reversible glutamine synthetase (glutamate + NH3<=> 
glutamine) to the right indicates excessive ammonia in the form of muscle, plasma, or 
blood glutamine (Babij et al., 1983; Duda and Handler, 1957; Eriksson et al., 1985).  
During exercise, as ammonia levels rise and arterial glutamate declines, working leg 
muscles exhibit a significant glutamate uptake -- promoting a rise in muscle and blood 
glutamine concentration (Babij et al. 1983; Dudley et al., 1983; Eriksson et al., 1985).  In 
addition, the transamination of α-ketoglutarate to glutamate (α-ketoglutarate + NH3 <=> 
glutamate) supplies additional glutamate substrate for glutamine formation.  Therefore, 
hyperammonemia and the associated glutamate and glutamine sinks drain the TCA 
intermediate α-ketoglutarate of carbons, and as suggested by data from Lancha et al. 
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(1994), suggests reduced aspartate and OAA availability with exhaustive exercise, thus 
inhibiting TCA cycle continuity and athletic endurance. 
The primary metabolic pathway for the detoxification of blood ammonia is urea 
production in the liver by the Krebs-Henseleit urea cycle (Krebs and Henseleit, 1932; 
Onstad and Zieve, 1979).  Urea cycle activity is promoted by elevated concentrations of 
blood ammonia.  The purpose of the urea cycle is to convert (the more toxic) ammonia into 
(the less toxic) urea for dilution and excretion by the kidneys.  The urea cycle becomes 
more active during exercise, to clear elevated blood ammonia into urea nitrogen to preserve 
metabolic function.  Ammonia enters the urea cycle by reacting with HCO3- and two ATP 
to form carbamoyl phosphate (Katunuma et al., 1966).  Carbamoyl phosphate donates the 
NH3 component as inorganic nitrogen to the urea cycle, while aspartate donates the amino 
nitrogen while releasing the carbon chain as fumarate.  Carbamoyl phosphate then reacts 
with ornithine to form citrulline (Grossi et al., 1967).  Citruilline reacts with incoming 
aspartate (which donates a nitrogen group, and carries the carbons for fumarate) to form 
argininosuccinate, producing arginine and fumarate (Briggs and Freedland, 1976).  
Arginine is cleaved into ornithine and urea, while fumarate is utilized as a substrate in the 
TCA cycle.  Ornithine may combine again with carbamoyl phosphate from ammonia entry, 
while the less toxic urea (versus that of ammonia) is transported to the kidneys for dilution 
and excretion in the urine. 
Urea synthesis is controlled by the concentration(s) of urea cycle intermediates, and 
activity of the enzymes carbamoyl phosphatase, argininosuccinate synthetase, and arginase 
(Buttery and Roswell, 1974; Katunuma et al., 1966; Kramer and Freeland, 1972; Ratner, 
1975).  Laboratory data indicates that argininosuccinate synthetase has the lowest activity 
of the urea cycle enzymes (Briggs and Freedland, 1976; Brown et al., 1959; Freedland and 
Sodikoff, 1962).  Together with citrulline accumulation and low concentrations of 
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succeeding intermediates (argininosuccinate and arginine), these data suggest a limiting 
rate of argininosuccinate synthetase activity under conditions of hyperammonemia (Brown 
et al., 1959; Buttery and Roswell, 1974; Ratner, 1975).   
At rest, protein intake and urea cycle activity are the controlling factors for blood 
NH3 levels (Levin et al., 1969).  However, during intense exercise decreased hepatic blood 
flow up to 30% - 70% below normal data (Rowell et al., 1964) and enzyme limitation 
(Cohen, 1981) restrict urea production (Ferreira et al., 1998).  Therefore, urea production is 
reflective of blood ammonia levels, removal capacity (and efficiency) of the urea cycle, and 
the physiological state and efficiency of the individual.  Progressive symptomatic 
complications of hyperammonemia result, if ammonia remains highly elevated for 
prolonged periods.   
Clinical studies of hyperammonemia (Batshaw, 1984; Maestri et al., 1996) reveal 
that additional ammonia detoxification pathways assist the urea cycle for conversion of 
ammonia into less toxic compounds for excretion.  For instance, these pathways are 
recruited with high ammonia levels produced by 1) excess protein intake, and/or 2) 
insufficient urea cycle conversion of ammonia into urea.  In particular, formation of serial 
glutamine (glutamine synthetase) and urinary pyrimidines (e.g. hippurate, 
phenylacetylglutamine, and orotic acid) assist the urea cycle to clear ammonia.  In 
response, the urinary pyrimidine products of orotic acid, uridine, and uricil are elevated 
(Levin et al., 1969).  As noted by Visek (1982), ‘the quantity of orotic acid in the urine of 
rats and man is inversely related to the capacity of the organism for urea synthesis’.  
Further, data from Visek (1979) demonstrate that orotic acid formation by intoxication with 
ammonium salts is reduced if animals are pretreated with ornithine, citrulline, or arginine.  
In addition, Milner and Visek (1974) showed that orotate excretion tends to increase as the 
percentage of dietary arginine decreases.  Thus, medical clinicians suspect urea cycle 
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defects or insufficiency when, in the resting state, excessive amounts of ammonia, 
glutamine, and pyrimidine metabolites are excreted indicating saturation of the Km of urea 
production.  On this note, clinical data from Batshaw (1984) and Maestri et al. (1996) have 
shown drops in mortality due to hyperammonemia with acute administration of lactulose, 
sodium benzoate, or sodium phenylacetate to enhance pyrimidine production.  However, 
there are no published reports to date concerning lowering of EIH by sodium benzoate or 
lactulose, while only one paper to date (Eto et al., 1994) has investigated the effects on 
blood ammonia during exercise following administration of glutamate (with arginine).  
Results of this study showed blood ammonia was significantly lower, by up to 40%, during 
steady-state exercise at ~ 75% VO2max following ingestion of 20 grams of a glutamate-
arginine salt in healthy young adult males. 
1.2.10 Summary 
The rise in blood ammonia concentration is a normal response to exercise and 
elevated AA catabolism (e.g. BCAA’s).  However, it is apparent that as blood ammonia 
levels rise to that observed in clinical hyperammonemia (> [100 µM/L]), the risk increases 
for undesirable metabolic function and impaired clinical status.  Therefore, it is desirable to 
lower and/or remove excess ammonia as quickly and efficiently as possible.  Ammonia and 
aspartate link ATP hydrolysis, AA bioenergetics, and urea metabolism, summarized as 
follows: 
1) NH3 is a by-product of ATP hydrolysis, AA catabolism, and urea formation  
2) Aspartate is a substrate in the PNC for AMP resynthesis, promoting desirable 
maintenance of total adenine nucleotides (AMP + ADP + ATP)  
3) Aspartate shuttles high-energy equivalents into the inner mitochondria for 
ATP production via the electron transport chain 
4) The PNC and urea cycle both utilize aspartate to produce the anaplerotic 
TCA intermediate fumarate 
5) Aspartate is an amino nitrogen donor and substrate in transamination, the 
PNC, and the urea cycle. 
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1.3 Blood Ammonia Response to Exercise 
In apparently healthy individuals, resting fasting blood ammonia levels are 
normally < 50 µM/L (Batshaw, 1984).  Strenuous physical activity may elevate blood 
ammonia concentrations 10-fold and higher, both during and following the period of 
contraction.  Values observed during intense exercise are often well above the minimum of 
[100 µM/L] for the interpretation of clinical hyperammonemia (Bessman and Bradley, 
1955; Katz et al., 1986; Rennie et al., 1981).  As reviewed recently by Yuan and Chan 
(2000), the major bioenergetic sources for NH3 during exercise are AMP deaminase, PNC 
activity, and/or catabolism of branched chain amino acids (BCAA's).  Though muscular 
ammonia concentrations are several-fold higher versus that of blood ammonia during 
intense exercise, it is unclear whether the difference reflects primarily the accelerated 
production in muscle, insufficient intramuscular buffering, or impairment in serial 
clearance (e.g. restricted hepatic conversion to urea). 
Table 1.2 lists various factors that affect blood ammonia concentrations in clinical 
situations and in response to exercise.  Blood levels of ammonia and lactic acid follow 
similar courses during various levels of exercise intensity.  Well-documented phenomena, 
each is produced (more predominantly) in fast-twitch Type IIb skeletal muscle fibers vs. 
Type I fibers (Banister, 1983; Banister et al., 1985; Meyer and Terjung, 1979).  Blood  
lactate and ammonia are moderately correlated (r = .6 - .82) during high-intensity work (> 
70% VO2max) (Babij et al., 1983; Buono et al., 1984; Eriksson et al., 1985).  Further, Buono 
et al. (1984) noted a strong correlation (r = .96) between the alinear rise in blood ammonia 
and the lactate anaerobic threshold.  During intense exercise, blood ammonia 
concentrations rise 4 to 20 fold, usually reaching ~ 100 - 500 µM/L at exhaustion (Banister 
et al., 1983; Katz et al., 1986; Wilkerson et al., 1977). 
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Table 1.2. Factors affecting blood ammonia levels. 
 
Factor [NH3] change Reference(s) 
Gender Male > Female Derave et al. (1997) 
Modality Bike > Treadmill Bouckaert and Pannier (1995) 
Wilkerson et al. (1975) 
Exercise Duration ↑ Brouns et al. (1990),  
Graham et al. (1995a) 
(Table 1.2 continued) 
Exercise Intensity ↑ Hegeloch et al. (1990) 
Endurance Training  ↓ (training specific) Graham et al. (1997) 
FT vs. ST Fibers FT > ST Gerez and Kirsten (1965) 
DuRuisseau et al., (1956) 
Winder et al. (1974) 
High PRO Diet ↑ Czarnowski et al. (1995) Jungas 
et al. (1992) 
Ambient Heat ↑ Snow et al. (1993 
Arm training ↓ (training specific) Nelson (unpublished data) 
Leg training ↓ (training specific) Nelson (unpublished data) 
Creatine Loading ↓ Greenhaff et al. (1993) 
β-blockade ↑ Jensen-Urstad et al. (1993) 
Urea Cycle Disease ↑ Lockwood et al. (1979) 
McArdles Disease ↑ Wagenmakers et al. (1990) 
BCAA ingestion ↑ Calders et al. (1997) 
Urea Cycle Substrate 
Supplementation 
No change Edwards and Day (2000) 
Urea Cycle Substrate 
Supplementation 
↓  (clinical) Greenstein et al. (1956) 
Urea Cycle Substrate 
Supplementation ↓  (clinical) 
Grossi et al. (1967) 
Carnitine 
Supplementation 
↓ Costell et al. (1984) 
Sarhan et al. (1994) 
Benzoate ↓ Kubota and Ishizaki (1993) 
Aspartate 
Supplementation 
↓ Kendrick (1976) 
Zinc Supplementation ↓ Riggio et al. (1992) 
 
 
On the other hand, immediately following intense exercise blood ammonia 
concentrations are more variable versus lactate (Babij et al., 1983; Buono et al., 1984; 
Meyer and Terjung, 1979; Schwartz et al., 1958).  Blood NH3 may rise, stabilize, or decline 
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rapidly versus the well-known lactate rise following intense exercise (Banister et al., 1983; 
Schwartz et al., 1958; Wilkerson et al., 1977).  NH3 clearance is affected by specificity of 
training, status of conditioning, terminating intensity, and exercise duration.  In general, a 
more efficient metabolic state (i.e. a higher level of state of training) lowers blood 
ammonia concentration at submaximal exercise intensities, enhances ammonia reduction 
during recovery, and enhances performance (Graham et al., 1997).  Concerning training 
status and blood ammonia concentrations, Graham et al. (1995a) and Graham et al. (1997) 
note that highly-trained subjects exhibit: 
1) Lower blood ammonia at a given exercise intensity (vs. untrained), 
2) Faster clearance following exercise, 
3) Longer endurance at a given ammonia level, and 
4) Longer time (vs. untrained) to reach a given ammonia blood level at 
exhaustion. 
 
1.4 Physiological Impact of Elevated Ammonia 
Several physiological, metabolic, and nutritional factors mediate blood ammonia 
levels.  For example, the following raise blood ammonia concentration:  
1) Increasing exercise intensity (i.e. increasing AMP deaminase, PNC activity) 
(Hellsten et al., 1999),  
2) Male gender (versus females) (Lynch et al., 2000),  
3) Glycogen depletion (Broberg and Sahlin, 1988),  
4) High protein/low carbohydrate diet (i.e. ammonia produced by gut flora 
urease, BCAA metabolism) (Greenhaff et al., 1991; MacLean et al., 1992; 
Snow et al, 2000),  
5) Heat (Snow et al., 1993),  
6) β-blockade (Jensen-Urstad et al., 1993), and 
7) BCAA ingestion (MacLean et al., 1996). 
 
Further, as reviewed by Mutch and Banister, (1983), ammonia is produced endogenously in 
the brain due to the GABA cycle and the deamination of brain catecholemines, and as 
suggested by data from Cooper et al. (1979) and Lockwood et al. (1979) NH3 may cross the 
blood brain barrier.  Additional data from Hindfelt (1983), Lockwood et al., (1979), and 
Najarian et al. (1958) indicate that elevated brain ammonia affects energy metabolism and 
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leads to mental confusion, ataxia, convulsion, and cramps in both animals and man.  With 
prolonged exertion, and/ metabolic and contractile stimuli blood ammonia levels rise, and 
fatigue results.  Fatigue is generally agreed to be due to a variable combination of 1) a 
depleted substrate supply (i.e. ATP, phosphocreatine, glycogen, glucose), 2) accelerated 
undesirable metabolite (e.g. lactate) and waste (CO2, NH3, H+) formation, and 3) disruption 
of central nervous system function (e.g. buildup of tryptophan and seratonin).  
Figure 1.1 highlights the deleterious effects of hyperammonemia.  The 
cascading deleterious effects of ammonia on exercise metabolism are largely a result of 
a lack of training coupled with accelerated sympathetic discharge.  For instance, 
epinephrine, cortisol, and/or hypoxia increase ammonia output, in part, because of the 
catabolism of the protein/AA content (i.e. muscle proteins, BCAA’s, aspartate) of the 
tissue (Goodman and Lowenstein, 1977) to keep up with ATP demand.  The major rate-
limiting enzyme of glycolysis, phosphofructokinase (PFK), is inhibited by 
physiological levels of ATP at acidic pH values (Lowenstein, 1972; Mutch and 
Banister, 1983), but, is stimulated by [NH3].  Work by Felig and Wahren (1971), 
Lowenstein (1972), and Sugden and Newsholme (1975) indicate that stimulation of 
PFK by ammonia occurs without a change in pH, thus increasing the availability of 
pyruvate for the pyruvate/alanine cycle which further depletes glycogen and glucose. 
  Ammonia further inhibits liver mitochondrial respiration (and citrate and 
isocitrate oxidation).  Data from Katanuma et al. (1966) and Brylla and Nidzwiecka 
(1979) indicate that NH3 accumulation inhibits both pyruvate carboxylation and 
decarboxylation - the initial steps in 1) gluconeogenesis, and 2) the conversion into 
acetyl Co-A for TCA entry via glycolysis, respectively.  Thus, elevated blood ammonia 
accelerates non-oxidative carbohydrate metabolism for ATP production, as well as 
inhibiting oxidative ATP production. 
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HYPERAMMONEMIA 
Blood [NH3] > 100uM/l 
Inhibits 
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CNS toxicity may 
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Symptoms include 
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Strong link with 
physiological fatigue 
 
 
 
Figure 1.1. Deleterious effects of hyperammonemia. 
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Ammonia flux thus affects the ATP/ADP ratio, acid base balance, glycolytic 
activity, pyruvate carboxylation and decarboxylation, and tricarboxylic acid cycle 
activity (Banister et al., 1985; Hindfelt, 1983; Lowenstein, 1972).  Further, ammonia 
increases VE, and contributes to hyperventilation (Hindfelt, 1983; Mutch and Banister, 
1983).  Mechanisms include elevated activity of respiratory muscles, and/or direct 
stimulation/interference of humoral input to the respiratory center (Hindfelt, 1983; 
Mutch and Banister, 1983).  Ammonia is a weak base, and reacts reversibly with H+ to 
produce ammonium (NH3 + H
+
   <=> NH4+).  Exercising muscle retains up to 90% of 
NH3 within the muscle cell as NH4+ (Katz et al., 1986; Rosado et al., 1962).  The 
cellular membrane is highly permeable to NH3, but has a poor permeability to NH4+.  
Thus, the release of NH3 into the circulation is associated with a net loss of hydrogen 
ions (Katz et al., 1986).  As demonstrated by Heald (1975), it appears desirable to 
reduce high levels of intramuscular ammonia to maintain electrical excitability and 
tension of individual muscle fibers.   
Historically, as reviewed by Lantigua et al. (1980) and Felig (1984), concerns have 
arisen over the adverse effects (e.g. ‘electrocardiographical abnormalities’, ‘serious 
arrhythmias’, and ‘cardiac disturbances’) in 3 of the 6 cases precipitating death, from 
accompanying nutritional hyperammonemia in those on high liquid protein diets.  Despite 
the high rate of success for achieving weight reduction, results from these cases indicate 
that those on very low calorie (< 500 kcal per day) protein diets utilizing a base protein 
with very low biological value (e.g. collagen hydrosylate) are at an even higher risk for 
adverse consequences.  According to Felig (1984), in the 1970’s when liquid-protein diets 
were the rage for the ‘over the counter’ treatment of obesity, 60 deaths were reported in 
over 100,000 participants using this protein as the primary source of nutrition.  Further 
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inspection by Isner et al. (1979) found that in (at least) 17 of the cases, use of the liquid 
protein (with low biological value) diet for two months was implicated as the basis for the 
ventricular arrhythmias that precipitated death.  Further, in some of these cases, extended 
hyperammonemia was considered a precipitating factor exacerbating adverse metabolic 
effects.  According to Jackson (1999), the most toxic of the individual amino acids is 
methionine; and, the adverse effects of methionine are more evident on a low protein diet 
than with adequate protein intake.  Furthermore, data from Riggio et al. (1992) suggests a 
link between zinc deficiency and impairment of the urea cycle enzyme ornithine 
transcarbamylase.  Thus, the lack of dietary zinc inherent in a low protein diet reduces the 
efficiency of ammonia removal.  Therefore, the potential for hyperammonemia (and 
associated adverse effects) increases with elevated protein intake, and especially in those 
on low calorie diets using a higher percentage of protein.  In these situations, it is apparent 
that the use of a protein with high biological value is of greater importance, as is 
consideration of supplementation with minerals and ammonia reducing amino acids (e.g. 
aspartate, arginine, ornithine, citrulline). 
1.5 Impact of Reducing Hyperammonemia: Clinical Trials and Exercise Trials 
1.5.1 Clinical Trials 
Historically, treatment for reducing clinical hyperammonemia (Batshaw, 1984; 
Najarian et al., 1958) targets: 
1) Inhibition of bacterial urease (i.e. neomyocin), 
2) Supplementation with ammonia reducing amino acid(s) in the pathways of 
transamination (glutamate therapy, i.e. NH3 + glutamate  <=> glutamine) and 
urea synthesis (e.g. aspartate, arginine, and ornithine), and 
3) Administration of agents (e.g. sodium benzoate, phenylacetate, lactulose) to 
enhance pyrimidine synthesis (e.g. orotic acid).  
 
Current clinical methods to lower hyperammonemia (i.e. in cases of hepatic 
encephalopathy) include 1) restricting dietary protein intake, 2) enhancing the 
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detoxification reactions in the body (transamination, urea cycle, pyrimidine production) 
(Levin et al., 1969; Mutch and Banister, 1983), and 3) correcting the metabolic etiology.  In 
humans, administration of up to 25 grams of arginine, ornithine, glutamate, and/or benzoate 
reduces clinical hyperammonemia (CH) and associated symptoms (Artz et al., 1958; 
Najarian et al., 1958; Strauven et al., 1976).  Clinical settings currently utilize ammonia-
reducing amino acid(s) (e.g. aspartate, ornithine, glutamate, and arginine) in combination 
with metabolic agents (i.e. sodium benzoate, carnitine, and lactulose) to significantly and 
consistently reduce CH and hepatic encephalopathy and improve prognosis.  The following 
paragraphs discuss the rationale and clinical impact of reducing hyperammonemia and 
treating fatigue with supplementation of ammonia reducing (and/or urea producing) amino 
acids. 
The addition of the urea cycle intermediate(s) arginine or ornithine in vitro 
accelerates urea formation in liver slices (Krebs and Henseleit, 1932; Kubota and Ishizaki, 
1993).  In clinical trials, Fahey (1957) and Fahey et al. (1958) further demonstrate that 
administration of arginine (or other urea cycle intermediates such as ornithine, citrulline, 
aspartate) eliminates NH3 accumulation and the associated toxic effects (death, 
convulsions).  Data in laboratory animals from Winitz et al. (1956) and Salvatore et al. 
(1964) show that elevations in blood ammonia and urea accompany a lethal dose of 
ammonium acetate, and, the toxic effects are removed once arginine, ornithine, and/or 
aspartate are administered.  Fahey (1957) and Fahey et al. (1958) demonstrated in humans 
that administering an essential amino acid (AA) infusion that lacked arginine and histidine 
exacerbated CH in patients without 'any evidence of liver disease'.  Further, the associated 
symptoms of hyperammonemia – (e.g. nausea and retching) were reduced or eliminated 
when L-Arginine, L-Ornithine, or L-Citrulline were added at a molar concentration of 1-
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2%.  L-Ornithine appeared to be equally as effective as L-Arginine, L-Citrulline slightly 
less effective, while D-Arginine and L-Glutamate had no protective effect.   
These cases illustrate that the severity of clinical hyperammonemia and associated 
symptoms are reduced when the L-amino acids in the urea cycle are supplemented in an 
AA infusion.  As shown by Fahey et al. (1958), when no urea cycle substrate is 
supplemented in an AA infusion, AA’s peak immediately after infusion, blood ammonia 
peaks 2 hours after, and plasma urea peaks 4 hours after.  However, when the infusion 
includes urea cycle L-AA’s (such as L-Arginine), 1) the alpha amino changes are not 
altered, 2) urea peaks earlier, and 3) ammonia does not rise at all (Fahey et al., 1958).  
Further, the administration of amino acids whose metabolism is outside of the urea cycle 
(e.g. BCAA's) exhibit little or no effect toward the reduction of ammonia, and in fact, some 
AA’s raise NH3 levels and exacerbate associated symptoms further (Fahey, 1957; and 
Fahey et al., 1958). 
Clinical studies in the 1950’s and the early 1960’s revealed improvements in 
clinical prognosis of hyperammonemia following administration of aspartate and/or urea 
cycle intermediates.  Shortly thereafter, aspartate supplementation was found effective for 
the clinical treatment of fatigue (New drugs and Spartase, 1963).  Prescribed initially in a 
dosage of 1g x BID for the management of fatigue syndrome (New drugs and Spartase, 
1963), the theoretical basis for aspartate treatment is to provide additional substrate to the 
urea cycle, enhancing the clearance of the more toxic metabolic ammonia into the less toxic 
urea, and thus improve clinical outlook.  The following series of papers trace the 
development of aspartate supplementation for the treatment of clinical fatigue. 
In a 4-week double-blind study by Shaw et al. (1962), 57 patients complaining of 
fatigue without demonstrable organic disease received potassium and magnesium 
aspartates, while 28 similar patients received a placebo.  By the end of the study, 49 of the 
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57 patients (86%) receiving aspartates noted improvement both during the day and after a 
full day’s schedule, compared to 7 of 28 (25%) with placebo.  Response in the 
experimental group generally took about 4 days to take effect.   
Fornica (1962) conducted a placebo-controlled study involving 84 women and 16 
men with persistent tiredness believed to be unrelated to depression.  Some of the patients 
had been symptomatic for more than two years.  Aspartate was administered to 6% of the 
group for 2 weeks, and to 68% for 4-6 weeks.  The remaining 26% received placebo.  A 
positive therapeutic response developed gradually over 4 - 10 days in 87% of the aspartate 
treated patients.  After 4-6 weeks, most improved patients stopped the supplements and 
continued to do well. 
Hicks et al. (1964) conducted a double-blind study of 145 patients, whose fatigue 
had a variety of bases, including anxiety neuroses, gastrointestinal disturbances, 
menopause, the postpartum period and fatigue as a sequel to influenza.  Of those, 85% of 
those given potassium and magnesium aspartates reported an increase in strength or 
physical activity compared to only 9 % of patients on the placebo.  
In conclusion, as reviewed by Gaby (1982), clinical trials have shown that in nearly 
3,000 patients, 75-91% experienced pronounced relief of fatigue with supplements of 
potassium and magnesium aspartate.  In general, one gram of aspartate daily improves 
prognosis from clinical fatigue within 4 - 10 days of supplementation.  Therefore, results 
from these studies suggest that 1 gram QD of aspartate is generally effective in the 
treatment of clinical fatigue. 
1.5.2 Exercise Trials:  Introduction 
It is well documented that physical activity elevates blood ammonia (Parnas, 1929; 
Wilkerson et al., 1975; and Edwards and Day, 2000;).  Exercise-induced hyperammonemia 
(EIH) is detrimental to short-term maintenance of optimal high-intensity physical function 
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and performance (Heald, 1975; Washio and Mashima, 1963).  Historically, clinical therapy 
for hyperammonemia has utilized administration of urea cycle intermediates (i.e. arginine, 
ornithine, aspartate), glutamate, and conjugated conversion (e.g. via administration of 
sodium benzoate, lactulose) of ammonia into urinary pyrimidines (Kubota and Ishizaki, 
1993).  Despite clinical success for reducing hyperammonemia by the intake of ammonia-
reducing amino acids in the urea cycle (e.g. arginine, ornithine, aspartate, citrulline), only a 
handful of investigations report the possible performance enhancement of these in healthy 
populations.  Exercise studies show little or no effect (Denis et al., 1991; Eto et al., 1994; 
and Edwards and Day, 2000) for reducing EIH, and no effect on performance 
enhancement, with supplementation of ammonia-reducing amino acids in the urea cycle. 
On the other hand, animal studies report success with aspartate supplementation to 
improve exercise performance; however, reproduction of results is inconsistent.  The most 
popular theory for performance enhancement is that aspartate supplementation reduces 
blood ammonia accumulation during exercise (Washio and Mahima, 1963; Heald et al. 
1975; and Mutch and Banister, 1982).  However, as presented in Table 1.3, the anaplerotic 
roles of aspartate may provide clues for the mechanisms of how aspartate supplementation 
improves exercise performance.  These include 1) contributing carbons to the TCA cycle 
(i.e. OAA, fumarate), and/or 2) contributing metabolic substrate (aspartate) for the PNC 
(i.e. AMP maintenance) and transamination (i.e. carbon and nitrogen transfer).   
Overall, methodologies, biochemical mechanisms, and target groups for aspartate 
supplementation for performance improvement are not established.  Animal studies are 
presented in Table 1.4, and are discussed in Section 1.5.3; human studies are presented in 
Table 1.5, and discussed in Section 1.5.4.  An overall summary and conclusions from the 
animal and human studies is presented in Section 1.6.  
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Table 1.3. Anaplerotic roles of aspartate.  
 
Metabolic 
Pathway(s) Aspartate Role Key Enzyme(s) 
Bioenergetic 
Result______ 
Oxidative 
deamination 
Carbons for OAA GDH ↑ [OAA] 
Transamination Transfer of amino 
group to glutamate 
SGOT ↑ sparing of  
α-ketoglutarate  
Urea Cycle Substrate Argininosuccinate 
synthetase 
↓ [NH3] 
↑ [Fumarate] 
Malate/Aspartate 
Shuttle 
Shuttle NADH 
across inner 
mitochondrial 
membrane in the 
ETC 
NADH 
dehydrogenase 
↑ ETC 
efficiency 
↑ [ATP]   
Purine nucleotide 
cycle 
Substrate Adenylosuccinate 
synthetase  
AMP deaminase 
TAN 
maintenance 
↑ [Fumarate] 
AMP 
regeneration 
SGOT – serum glutamate oxaloacetate transaminase; OAA – oxaloacetate 
GDH – glutamate dehydrogenase; NADH – nicotinamide adenine dinucleotide 
ETC – electron transport chain; ATP – adenosine triphosphate; 
AMP – adenosine monophosphate 
 
1.5.3 Exercise Trials: Animal Models 
Table 1.4 summarizes the studies of aspartic acid supplementation to improve 
performance in animals.  The first reported study of aspartic acid supplementation for 
exercise performance in either animals or man was conducted by Laborit et al. (1958).  In 
this study, administration of aspartic acid prolonged swim time to exhaustion in rats while 
lowering blood NH3, which indicated that exhaustion was related to the level of blood NH3.   
Additional animal studies have shown blood ammonia reduction and performance 
enhancement with dosages up to 500 mg/kg (Barnes et al., 1964; Kendrick, 1976; Glass et 
al., 1994).  However, above this amount, the beneficial effect (i.e. reducing  
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Table 1.4. Summary of studies of L-Aspartic Acid and performance in animals. 
 
 
Group 
 
Protocol Dosage (daily) 
 
Performance 
 
Reference 
Rats Swim to 
exhaustion 
50 mg/kg ↑ Laborit et al. 
(1958) 
Rats Swim to 
exhaustion 
1000 mg/kg ↑ Rosen et al. 
(1962) 
Rats Swim to 
exhaustion 
500 mg/kg ↑ Barnes et al. 
(1964) 
Rats/ dogs Swim to 
exhaustion 
500-2000 
mg/kg  
no change Matoush et al. 
(1964) 
Rats Swim to 
exhaustion 
12.5 mg/kg ↑ Kendrick (1976) 
Rats Swim to 
exhaustion 
12.5 mg/kg ↑ Tangsakul 
(1977) 
  125 mg/kg ↑  
  250 mg/kg no change  
  1000 mg/kg ↓  
 
Rats 
 
Swim to 
exhaustion 
 
1000 mg/kg 
 
no change 
Trudeau and 
Murphy (1993) 
Rats Swim to 
exhaustion 
6.25 mg/kg ↑ Glass et al. 
(1994) 
  12.5 mg/kg  ↑  
  100 mg/kg ↑  
Rats Swim to 
exhaustion 
45 mg/kg each 
aspartate, 
asparagine, 
carnitine 
↑ Lancha et al. 
(1995) 
Rats Swim to 
exhaustion 
200 mg/kg ↑ Nichols et al. 
(1998) 
Rats Swim to 
exhaustion 
500 mg/kg ↑ Winters et al. 
(1998) 
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 hyperammonemia and/or enhancing performance) appears to taper off, and then have no 
benefit at all, with dosages equaling or exceeding 1000 mg/kg (Matoush et al., 1964; 
Tangsakul, 1977; and Trudeau et al., 1993).  Results from the animal studies are discussed 
in the next paragraph in chronological order. 
Rosen et al. (1962) investigated the effects of aspartate administration on two 
groups of 40 untrained male rats swimming to exhaustion in 29 degrees C water.  Results 
showed that 1000 mg/kg aspartate administration increased time to exhaustion by 15% in 
the aspartate group (195 minutes, placebo vs. 224 minutes, aspartate).  Blood ammonia 
concentrations were not reported.  Results from this study suggest that 1000 mg/kg 
aspartate supplementation improves long-duration time to exhaustion in swimming rats  
Barnes et al. (1964) investigated the effects of aspartate administration on blood 
ammonia and time to exhaustion in a series of three studies.  One hundred and twelve male 
(trained and untrained) rats were utilized in a swimming protocol in groups of n = 4 - 10 
each.  In studies 1 and 2, the supplementation was a twice-administered dose of 500 mg/kg, 
while study 3 utilized a single dose, 500 mg/kg.  Water temperature was 25 degrees C for 
all experiments.  In study 1 (untrained rats), time to exhaustion increased from ~16 minutes 
to ~ 23 minutes with aspartate administration vs. placebo.  Blood ammonia concentrations 
were lower with aspartate treatment, (61 vs. 113 [µM/L]).  In study 2, investigating the 
effects of prior training, time to exhaustion again responded favorably with 
supplementation, from 20 min (placebo) to 25 min (aspartate).  Blood ammonia 
concentrations in the trained group (3 weeks training) were also lower with aspartate 
treatment, 48 µM/L (placebo) vs. 42 µM/L (aspartate).  In study three, with one dose of 
aspartate (500 mg/kg) in untrained rats, blood ammonia levels after a short period (~ 10 
minutes) of swimming were lower, [49 µM/L] versus [103 µM/L], respectively.  These 
results indicate that both trained and untrained rats responded favorably (in both exercise 
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performance and blood ammonia clearance) with short-term supplementation of 500 mg/kg 
aspartate. 
Matoush et al. (1964) investigated the effects of ~ 2000 mg/kg aspartate 
supplementation on swim time to exhaustion in 40 rats (trained and untrained) and four 
dogs in 17 degrees C and 25 degrees C water.  There were no significant differences in any 
of the groups, trained or untrained, in response to aspartate treatment.  Although no blood 
ammonia values were reported, one may speculate from this and other studies (Tangsakul, 
1977; and Trudeau et al., 1993) that a dosage of 2000 mg/kg may be too high to elicit a 
positive effect on exercise-induced hyperammonemia, or have a beneficial effect on 
performance, regardless of training status. 
Cutinelli et al. (1970) investigated the effects of 200 mg/kg ornithine-aspartate 
(versus 0.9 % saline) administered 30’ prior to swimming 10 to 60 predetermined minutes 
in 165 male untrained rats.  Blood ammonia concentrations were higher than at 20 degrees 
C, than at 28 degrees C, with no significant difference between treatments.  Further, in the 
10 minute swim test at 20 Co, supplementation with ornithine-aspartate (versus placebo) 
decreased ATP, decreased creatine, and decreased GPT, with no difference in AMP and 
ADP.  However, versus a control group who received no treatment or exercise, these values 
were all significantly higher in the supplemented group.  Thus, these results suggest that 
ornithine-aspartate supplementation can enhance ammonia clearance and maintain AMP 
and ADP nucleotides in response to high-intensity exercise. 
In two unpublished doctoral dissertation(s), Tangsakul (1977) and Kendrick (1976) 
demonstrated improved exercise tolerance in rats treated with chronic and acute aspartate 
administration.  In support of the findings of Matoush et al. (1964), animals treated over a 
10-day period with a large aspartate dose (~ 4g/kg/day) exhibited no change (or a 
decrement in) in WTE.  Further, an acute injection of aspartate, in smaller dosage(s) one-
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hour before exercise, demonstrated the following dose-dependent responses in work time to 
exhaustion (WTE) (Kendrick, 1976): 
1) 1g/kg reduced WTE by ~ 41% below that of control  
2) 250 mg/kg did not alter WTE; 
3) 125 mg/kg increased WTE by ~37%, and 
4) 12.5 mg/kg K-aspartate increased WTE 90%. 
 
These data indicate that L-Aspartic Acid intake affects WTE in a dose-dependent 
fashion, and secondly, as in the Matoush et al. (1964) study, dosages exceeding 500 mg/kg 
intake may inhibit and deter metabolism and performance, respectively.  Results have 
found that rats pretreated with aspartate, buffer the hyperammonemia brought by both 
exercise and ammonium injection (Barnes et al., 1964; Kendrick, 1976).  Additional results 
from Kendrick (1976) indicate that aspartate administration may not alter the rise in the 
muscle ammonia concentration during exercise to the degree that blood ammonia is 
lowered.  The authors speculated that the reduction in [blood ammonia] versus [muscular 
ammonia] was likely due to a greater uptake of ammonia by the liver for urea synthesis.  
This contention was supported when the administration of K-aspartate significantly 
increased blood urea during work, with no effect on muscle ammonia (Kendrick, 1976).  
Therefore, these results suggest the acute reduction of excessive [blood ammonia] and 
accompanying symptoms (e.g. inhibition of muscular contraction, muscular dysfunction, 
and central fatigue) are associated with an increase in exercise performance.  Further, this 
study, like several others, showed that improvements in swim time to exhaustion in rats 
may occur with aspartate supplementation as low as 12.5 mg/kg (Glass et al., 1994) versus 
the ~100 - 1000 mg/kg observed in previous experiments. 
Trudeau and Murphy (1993) investigated the effects of 1000 mg/kg aspartate on 
swimming performance in a 58 rats in a six-group double blind study investigation.  Time 
to exhaustion was not significantly different with aspartate supplementation (174 ± 45 min) 
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versus saline treatment (179 ± 38 min).  Plasma [FFA] were significantly lower (p < 
0.0001) with aspartate supplementation (0.7 ± 0.3 mM vs. 1.2 ± 0.5 mM).  There were no 
significant differences between treatments for plasma ammonia, glucose, lactate, or muscle 
(or liver) glycogen.  Results from this study fail to support the prior contentions of Ahlborg 
et al. (1968), and Wesson et al. (1988), that the performance benefit of aspartate 
supplementation is due to a general glycogen sparing.  It is possible, that although lower 
plasma [FFA] were found in this study, a dose of 1000 mg/kg may be too high (versus the 
~ 70 – 150 mg/kg in Ahlborg et al., (1968), and Wesson et al. (1988)) to elicit beneficial 
effects in other hypothesized markers (blood ammonia concentration, muscle and liver 
glycogen) and long duration exercise performance.   
A series of three abstracts by Drexel University reported the effects of various 
aspartate dosages on the exercise performance of rats.  Glass et al. (1994) examined the 
effect of 0, 6.25, 12.5, or 100 mg/kg aspartate on swim time to exhaustion in 24 female 
rats.  Aspartate supplementation was associated with a ‘dose-related increase in swim time 
(< 2-fold) in all rats’.  Water temperature was a constant 30 degrees C.  Nichols et al. 
(1998) investigated the effects of 200 mg/kg of aspartate supplementation, and/or 
carbohydrate loading, on swim time to exhaustion in untrained rats.  Carbohydrate loading 
resulted in a 50% increase, aspartate loading resulted in a 3-fold increase, while the 
combination of the two resulted in a 3.4-fold increase.  Winters et al. (1998) investigated 
the effects of 500 mg/kg of aspartate supplementation on swim time to exhaustion in 
female untrained rats, one hour after oral gavage.  The aspartate treatment resulted in a 
two-fold increase in time to exhaustion versus water intake only.  Water swim temperature 
was 30 degrees C.  These results are in general agreement with the previous investigations 
of aspartate supplementation < 500 mg/kg in rat studies (Laborit et al., 1958; Barnes et al., 
1964; and Nichols et al., 1998) to improve swimming performance.  
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Therefore, the regime of aspartate supplementation to improve exercise tolerance in 
rats (trained and untrained) appears to be 12.5 mg/kg - 500 mg/kg BID, over the 24 hours 
preceding exhaustive exercise.  Of note is that: 1) most of the animal studies utilized 
swimming methodology, and 2) improvements in performance and reductions in 
ammonemia are independent of both training status and gender.  A possible explanation for 
the performance benefit observed in these studies is that aspartate supplementation may 
delay the onset of an ammonia threshold by lowering exercise ammonia (similar to the 
lowering of the lactate threshold by training), and thus prolong high-intensity endurance 
and performance.  Further, serial data from Wesson et al., (1988), Trudeau and Murphy 
(1993), and Lancha et al. (1995) demonstrate that aspartate supplementation reduces 
plasma [FFA] in response to intense medium-to-long duration exercise.  The mechanism 
and the impact of this are unclear.  However, Trudeau and Murphy (1993) found no 
differences in muscle or liver glycogen (between aspartate supplementation and placebo) at 
rest or exhaustion, to support a glycogen sparing effect.  Two other possibilities exist for 
the lowering of [FFA] by aspartate supplementation: one, as cited by Brooks et al. (1996), 
is reduced epinephrine activity on adipose tissue which reduces lipase; two, aspartate 
supplementation may provide substrate for TCA cycle intermediates and the malate 
aspartate shuttle, enhancing transport of reducing equivalents across the inner 
mitochondrial membrane for ATP production.  As evidenced recently (Gibala et al., 1997) 
in short-term (< 5 min) activity, large increases in succinate, malate, and fumarate (> 90% 
of the total TCA cycle substrate pool) are observed during the first minute of muscular 
contraction.  Therefore, TCA cycle activity is accelerated during short-term intense 
exercise.  Further, additional aspartate substrate in these circumstances may increase 
production of fumarate by the PNC and urea cycle.  Additional work is needed to provide 
further insight into the etiology of the lowering of FFA and improvement of performance 
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with aspartate supplementation.  In conclusion, results from the animal studies suggest that 
supplementation with ~ 12.5 – 200 mg//kg of aspartate over 24 hours improves swimming 
performance in rats, independent of gender and training status. 
1.5.4 Exercise Trials: Human Models 
Table 1.5 summarizes the studies of aspartic acid supplementation to improve 
performance in humans.  In comparison to the animal studies, the results from human 
studies of aspartate supplementation are more widely variable.  In contrast to the animal 
studies which use primarily swimming as the testing modality, the human studies have used 
cycling (e.g. Maughan and Sadler, 1983; and Wesson et al., 1988), treadmill (Hagan et al., 
1982), weight lifting (Fallis et al., 1963; and Tuttle et al., 1995), field training (Consolazio 
et al., 1964), outdoor running (Ritter et al., 1998; and Colombani et al., 2000), and static 
arm force (DeHaan et al., 1985).  Though inconclusive, the most significant reductions in 
EIH and improvements in exercise performance with aspartate supplementation occur with 
1) subjects that are highly-trained to the modality, 2) short term high-intensity exercise 
with large muscle groups, and 3) a protocol that produces a sufficient amount of ammonia 
to be classified as exercise-induced hyperammonemia.  The first reported study of aspartic 
acid supplementation for enhancement of exercise performance in humans was by Fallis et 
al. (1963).  In general, aspartate dosages have ranged from 1 - 15g QD, with the most 
significant findings for improving performance occurring with dosages between 5 - 15g 
(e.g. Ahlborg et al., 1968; Wesson et al., 1988), although significant improvements have 
occurred with smaller dosages (Gupta and Srivastava, 1973; and Franz and Chintanaseri, 
1977).  Critique of the human studies is presented in the following paragraphs in 
chronological order. 
Fallis et al. (1963) published a study that investigated the effects of 1g of daily 
aspartate supplementation versus placebo on weight lifting performance.  Twenty-six 
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Table 1.5. Summary of studies of L-Aspartic Acid and performance in humans. 
 
Protocol 
Dosage 
(daily) Performance Reference 
Weight lifting 1000 mg no change Fallis et al. (1963) 
Field training 2000 mg no change Consolazio et al. (1964) 
~80% VO2max to 
exhaustion (cycling) 7000 mg ↑ Ahlborg et al. (1968) 
60% VO2max to 
exhaustion (cycling) 3500 mg ↑ 
Gupta and Srivastava 
(1973) 
73.5% W170/kg to 
exhaustion 2200 mg ↑ 
Franz and 
Chintanaseri(1977) 
62% VO2max to 
exhaustion (treadmill 
walking) 7200 mg no change Hagan et al. (1982) 
75% VO2max to 
exhaustion (cycling) 6000 mg no change 
Maughan and Sadler 
(1983) 
40% max static arm force 7640 mg no change De Haan et al. (1985) 
75% VO2max to 
exhaustion(cycling) 10,000 mg  ↑ Wesson et al. (1988) 
Weight lifting 150 mg/kg no change Tuttle et al. (1995) 
One mile run time 1440 mg ↑ Ritter et al. (1998) 
Marathon run  15,000 mg no change Colombani et al. (2000) 
 
 
inmates of the Maryland State Penitentiary volunteered for the study.  Subjects were 
experienced weight lifters, considered to be at peak performance.  In a counterbalanced 
order, the subjects were given placebo for 10 days, and aspartate for 10 days, and recorded 
the maximum daily number of bench presses, squats, and recovery time.  No significant 
differences were found between treatments.  Blood ammonia concentrations were not 
reported in this study. However, exercise protocols of this type (i.e. weight training) in 
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general do not raise blood ammonia to the levels of hyperammonemia for a sustained 
period for aspartate to have an effect.   
Consolazio et al. (1964) investigated the effects of 2 grams of daily 
supplementation of aspartic acid on the respiratory responses to 5 weeks of aspartate 
intake.  Twelve healthy young men were matched for body weight, and randomly assigned 
to an aspartate group or a placebo group.  A 9-week study, with two weeks of initial 
training, revealed no significant differences between groups in VO2, VCO2, O2 debt, RQ, 
recovery after an all-out run, maximal breathing capacity, or timed vital capacity.  The 
authors concluded that there was no convincing evidence of the beneficial effects of 
aspartate therapy for delaying the onset of physiological fatigue in humans, in terms of 
respiratory parameters.  Unfortunately, neither blood ammonia nor blood urea values 
reported, nor was there a high-intensity exhaustive component to assess effectiveness of 
treatment.  Thus, aspartate supplementation coupled with a training regime has no effect on 
improvement in respiratory parameters. 
Ahlborg et al. (1968) conducted a controlled study on six moderately-trained men, 
who exercised to exhaustion on a bicycle ergometer for 4 consecutive days at a workload 
designed to elicit exhaustion at ~ 90 minutes.  Placebo was administered on days 1, 2, and 
4, and 7 grams of aspartate was administered on day 3.  Mean work times to exhaustion 
were not significantly different between days 1, 2, and 4; however, on day 3, subjects 
cycled for ~ 128 min. - an increase in endurance by ~ 50%.  There were no significant 
differences in heart rate, respiratory rate, or weight change.  It was hypothesized by the 
authors, that the administration of aspartate decreased the rate of glycogen utilization and 
therefore prolonged exercise time.  However, the study did not utilize a double blind 
design, nor report blood ammonia or urea to substantiate these conclusions.  
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A similar follow-up study on five subjects (VO2max - 42.5 ml/kg/min) by Gupta and 
Srivastava (1973) demonstrated an increase in exercise work time to exhaustion with 
aspartate intake.  Five healthy young volunteers with a baseline VO2max of 42.5 ml/kg/min 
exercised at a continuous workload of 60% VO2max on a bicycle ergometer, with a 22.6% 
improvement (68.4 min vs. 83.6 min) in WTE following 3.5 g (.875 g x 4) of aspartate 
supplementation versus placebo.  VO2, HR, O2 debt, urinary creatine, blood sugar, and 
urinary 17-hydroxycorticosteroids were not significantly different between trials.  The 
subjects in both the Ahlborg et al. (1968) and Gupta and Srivastava (1973) studies were 
allowed intake of cold water ad libitum during exercise to avoid dehydration.  Blood 
ammonia and urea concentrations were not reported, nor was the single or double-blind 
nature specified.  Therefore, other than no change in blood glucose, the possible 
mechanisms for improvement in this study are difficult to ascertain.  
Hagan et al. (1982) investigated physiological responses to treadmill walking for 90 
minutes at approximately 62% VO2max  in response to K+Mg+2 aspartate treatment (7.2g 
over 24 hours), placebo, or no treatment in seven healthy males (VO2max 59.5 ml/kg/min).  
No significant differences were observed in VO2, VCO2, R, HR, and BP; and for pre- and 
post-exercise changes in rectal temperature, serum lactic acid, creatine kinase, lactic 
dehydrogenase, and percentage change in plasma volume.  However, the methodology 
protocol was not of sufficient intensity or duration to produce exhaustion.  This study 
reveals that physiological responses to low to moderately-intensity protocols are not 
affected by aspartate ingestion. 
Maughan and Sadler (1983) investigated the effects of 6 grams per day of aspartate 
ingestion (versus placebo) on eight healthy young male subjects, who exercised to 
exhaustion on a bicycle ergometer at a constant workload requiring approximately 75% 
VO2max using a double-blind protocol.  Exhaustion was reached after 82.7 ± 23.5 minutes 
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(mean ± SD) following aspartate treatment and after 85.4 ± 26.5 minutes following the 
placebo.  There were no significant differences across treatments for blood glucose, lactate, 
ammonia, or FFA concentrations.  As in the Hagan et al. (1982) study, results from this 
study suggest that aspartate supplementation has no effect on ammonia levels and 
performance response with moderate exercise. 
De Haan et al. (1985) examined the effects of 7.64 g of daily K+ Mg+2 aspartate 
supplementation on force production and endurance time for arm exercise.  In a series of 
twelve sessions, twenty healthy male students (19-26 yr) performed arm exercise at 40% of 
maximal force until exhaustion, and repeated the effort following a 5-minute recovery 
period.  Each session lasted 10 - 15 min. Following session three, the subjects were divided 
into three groups (control, placebo, and aspartate) for the remaining 9 trials.  Results 
between groups indicated no significant increases in either the exerted force or endurance 
time.  Blood parameters were not reported.  Once again, it is speculated that the low 
relative exercise intensity failed to raise ammonia levels to the point where aspartate could 
exert a beneficial effect; further, blood ammonia was not reported. 
Wesson et al. (1988) investigated high-intensity cycling endurance in response to 
aspartate intake, and measured blood ammonia, glucose, and FFA.  Seven healthy young 
male athletes (VO2max - 53.1 ml/kg/min) performed leg exercise to exhaustion at a 
workload ~75% VO2max at 50 rpm on a bicycle ergometer.  The test was administered after 
ingestion of 10g of potassium-magnesium aspartate or placebo over a 24-hour period 
utilizing a double-blind design.  Time to exhaustion significantly (p < 0.01) increased by 
~14% following aspartate ingestion (87.6 min vs. 75.7 min) vs. placebo.  Further, blood 
ammonia levels were lower in the aspartate condition at rest, during exercise, 15 min post 
exercise, but not at exhaustion ~ [110 µM/L].  This may indicate an improvement in the 
efficiency of ammonia removal, or in bioenergetic metabolism to prolong high-intensity 
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endurance and performance.  The aspartate group also had higher (p < 0.05) blood [FFA] at 
exhaustion (0.74 mM vs. 0.60 mM), with no difference at the other time points.  Other 
findings of note were: 1) a higher HR at exhaustion (168 bpm vs. 163 bpm) for the 
aspartate treatment vs. placebo trial, and 2) a significant reversal 15 min post-exercise with 
the aspartate condition having a significantly lower HR (90 bpm vs. 98 bpm) vs. placebo.  
Blood glucose remained stable ~ [5 mM/L] across treatments.  The conclusions from this 
study were that aspartate is an ergogenic aid due to the ammonia lowering effect and the 
glycogen sparing of increased availability of FFA’s.  
Work by Denis et al. (1991), and Eto et al. (1994) investigated the effects of other 
AA combination(s) designed to lower the ammonia response to steady state high-intensity 
(~80% VO2max) cycling.  However, in these studies, there was neither an exhaustive 
component nor a performance measure.  In the Eto et al. study (n=3), ingestion of 20g of 
arginine-glutamate (AG) two hours prior to cycling significantly lowered (p <  0.01) blood 
[NH3] in the AG group at 60 min (98 ug/dl) vs. placebo (67 ug/dl).  Resting blood ammonia 
concentrations were not different across treatments.  Conversely, Denis et al. (1991) found 
no difference in blood [NH3] at 45’ of cycling at 80% VO2max following chronic ingestion 
of 20g of chronic arginine + aspartate (AA) ingestion (5g x QID x 10 days) vs. placebo.  Of 
note, in both of these high-intensity (but steady state) studies, blood ammonia levels did not 
rise to [100 µM/L].  These results indicate, that in humans, blood [NH3] > 100 µM/L 
during exercise is not tolerated well by the body, and work stoppage occurs quickly.  
Furthermore, these human studies also show that when blood NH3 concentrations during 
high-intensity steady-state work are below 100 µM/L (e.g. 60 – 80 µM/L), work may be 
tolerated much longer (i.e. hours), without exceeding the critical balance between ammonia 
buildup, ammonia removal, and onset of fatigue. 
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Tuttle et al. (1995) investigated the effects of 150 mg/kg of daily aspartate 
supplementation (versus placebo) on weight lifting performance and blood ammonia, 
lactate, and RPE response in twelve healthy young men utilizing a double blind, 
counterbalanced protocol.  The exercise testing phases (65% of one repetition maximum, 
bench press to failure) were administered one week apart, with a week long weight-training 
regime that consisted of 3-5 sets, at approximately 70% of 1 repetition maximum, for 8 
repetitions per set.  At the conclusion of the study, no significant differences in blood 
ammonia concentrations [µM/L] with (aspartate versus placebo) were found at rest, during 
exercise, or post exercise.  Exercise blood ammonia concentrations ranged from 66.3 – 88.5 
µM/L with no difference between treatments.  As expected, post-exercise blood ammonia 
concentrations were higher in both groups versus pre-test, however, there was no change in 
lactate versus baseline with either treatment.  There was no difference in the number of 
repetitions completed (9.5 versus 10.3, respectively) during the exercise test following the 
aspartate or placebo treatments.  These results indicate aspartate supplementation has no 
effect on blood ammonia concentrations or performance in response to weight training. 
Columbani et al. (1999) investigated the effects of 15 grams of arginine aspartate 
supplemented daily for two weeks before a marathon run in 20 endurance-trained males in 
a double-blind crossover design.  Blood samples were collected at four time points, as 
follows: 1) before the run, 2) after 31 km, 3) at the end of the run, and 4) during recovery.  
Results indicated that carbohydrate, fat metabolites, cortisol, and ammonia were unaffected 
by supplementation.  However, plasma somatotropic hormone, glucagon, and urea were 
significantly increased, and most of amino acids were reduced.  The mean running time 
was 194 minutes (placebo) and 196 minutes (supplement), and not significantly different.  
This study demonstrated no obvious benefit with chronic arginine-aspartate 
supplementation and marathon performance.   
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Ritter et al. (1999) investigated the effects of five consecutive days (4 x 360 mg 
QD) aspartate supplementation (or placebo) on one mile run time in endurance-trained 
men.  Mean mile run time improved in the aspartate group from 6:01 to 5:53.  However, in 
the placebo group, mean times also improved from 5:47 pre-treatment to 5:43 post 
treatment.  These results suggest that aspartate treatment may result in significant ergogenic 
benefits in trained athletes, however, this protocol failed to utilize a double blind protocol 
nor report blood ammonia values to validate the findings.  Results from human studies are 
discussed inclusively with the animal studies in Section 1.6 below. 
1.6 Summary and Conclusions 
The merit of aspartic acid as an ergogenic aid in humans is unresolved.  Findings 
indicate that species, testing modality, testing intensity, training specificity, and training 
status affect blood ammonia concentrations and physical performance in response to L-
Aspartic Acid ingestion.  Of these, it appears that exercise intensity and status of training in 
reference to the testing modality has the greatest influence upon the metabolism of 
ammonia and aspartate and performance response.  The effect of gender is unknown.   
Possibly, a more consistent or specific subject pool (i.e. testing subjects in training 
specific modalities) might reveal a consistent pattern in results or differences between 
groups.  Measurements of plasma catecholemines, cortisol, insulin, glucagon, amino acids, 
nitrogen metabolism enzymes (SGPT, SGOT, GDH), adenine nucleotides, blood lactate, 
and ammonia would provide additional metabolic and endocrine data.  The review of 
literature suggests that in order for aspartate supplementation to have an effect on EIH, the 
exercise intensity should be a minimum of 75% VO2max, and total daily dosage of aspartate 
should be ~ 5 to 15 grams.  Finally, there may be unknown factors affecting the results, 
such as diet, weight, gender, and purity of the amino acid, and protocol of aspartate 
administration. 
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As mentioned previously, administration of aspartic acid improves the status and 
symptoms of clinical fatigue.  There are strong indications that aspartate supplementation 
improves performance in the swimming rat.  On the other hand, the effectiveness of 
aspartate supplementation for reducing EIH and improving exercise performance in 
humans is inconsistent.  The studies demonstrating the most dramatic improvements in 
humans (Ahlborg et al., 1968; Franz et al., 1977; Gupta and Srivastava, 1973) did not 
report blood ammonia, FFA, or assess serial nitrogen biochemistry or assess glycogen 
sparing.  On the other hand, Kendrick (1976) and Tangsakul (1977) reported in rats 
supplemented with 12.5 mg/kg aspartate a 90% increase in swim time to exhaustion and 
concurrent reductions ammonia and increases in blood urea.  In contrast, Matoush et al. 
(1964), found no effect of aspartic acid salts on swimming performance on rats or dogs, 
however, the dosages of aspartate in this study were relatively high, i.e. 2000 mg/kg.  
Subsequent investigations in humans, tried various dosages and protocols, but no consistent 
successful trends in methodology were established.  Endurance protocols (e.g. walking at 
62% VO2max) low-moderately-intensity arm work (40% of maximal force), weightlifting, 
and cycling at 75% VO2max have revealed no change in work time to exhaustion following 
similar doses of aspartate treatment (De Haan et al., 1985; Hagan et al., 1982; Maughan 
and Sadler, 1983).  Further, data from Fallis et al. (1963) and Tuttle et al. (1995) indicates 
that short-term weight lifting protocols may not elevate ammonia to the point (e.g. > [100 
µM/L]) where aspartate ingestion for reduction in hyperammonemia can be effective. 
As presented previously in Table 1.3, the anaplerotic roles of aspartate provide 
clues into the bioenergetic mechanisms for enhanced work capacity with supplementation.  
As noted by Gibala et al. (1997), ammonia and aspartate metabolism link (i.e. 
‘anaplerosis’) the PNC and TCA cycle.  However, as cited by Graham et al. (1997) in 
reference to the PNC, it is unclear as to “what stimulates the key enzymes, or how the 
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tissue manages to obtain adequate amounts of aspartate, a key substrate”.  As evidenced 
recently (Gibala et al., 1997) in short-term (< 5 min) activity, large increases in succinate, 
malate, and fumarate (> 90% of the total TCA cycle substrate pool) are observed during the 
first minute of muscular contraction.  Therefore, accelerated activity of the TCA cycle is 
promoted in short-term intense exercise.  Further, Lancha et al. (1995) found increases in 
pyruvate carboxylase activity (and time to exhaustion) in swimming rats with aspartate 
supplementation.  However, the human studies exhibiting enhancements in performance 
via aspartate ingestion lack measurements of appropriate blood values (e.g. enzyme, NH3, 
urea, AA, FFA) to discern the appropriate physiological mechanism(s) (Ahlborg et al., 
1968; Franz and Chintanaseri, 1977; Gupta and Srivastava, 1973).   
As demonstrated by Lancha et al. (1995) and Wesson et al. (1988) aspartate intake 
increases FFA utilization during long exhaustive high-intensity (i.e. > 75% VO2max) 
exercise thus sparing muscle glycogen (vs. placebo).  Animal studies have utilized 
swimming as the primary mode, while human studies have concentrated on moderately-
intensity long duration stationary cycling and walking, with a further shortage of studies on 
females and highly-trained subjects.  Bicycling studies are the most promising in humans 
with regard to aspartic acid supplementation and performance, possibly because of the 
prolonged localized recruitment of Type IIa - IIb muscle fibers at high workloads, 
promoting high levels of blood NH3. 
Summarizing, postulated mechanisms of aspartate supplementation to increase 
work tolerance include:  
1) Reducing blood ammonia 
2) Increasing urea synthesis 
3) Increasing aspartate substrate in the PNC, promoting the regeneration of 
AMP and maintenance of total adenine nucleotide levels 
4) Providing OAA for the TCA cycle via the transamination of aspartate to 
OAA (aspartate + α-ketoglutarate  <=> OAA + glutamate) 
5) Increasing aspartate availability for the urea cycle, thus promoting 
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conversion into less-toxic urea 
6) Providing carbons for fumarate for the TCA cycle, via anaplerotic 
production by the PNC and urea cycle 
7) Increasing glycogen synthesis 
8) Increasing FFA availability, thus sparing muscle glycogen (Lancha et al., 
1995; Stubbs and Krebs, 1975) 
9) Providing substrate for gluconeogenesis (via fumarate, OAA)  
10)  Shuttling reducing equivalents across the inner mitochondrial membrane for 
the ETC. 
 
Therefore, the available literature in animals and humans suggests that ~ 5 - 12.5 g 
x 2 of aspartate ingested over a 24-hour period preceding intense exercise may enhance 
exercise performance.  As shown by Cutinelli et al. (1970), aspartate supplementation 
promotes the maintenance of AMP (by the PNC), thus enhancing the desirable maintenance 
of the total adenine nucleotide pool (ATP + ADP + AMP).  Further, aspartate may increase 
the anaplerotic availability of the TCA cycle intermediate fumarate by promoting fumarate 
formation in both the PNC and urea cycle.  Unfortunately, there are limited studies 
investigating this area during high-intensity exercise performance, when aspartate levels 
decline and blood ammonia levels continue to rise.  Thus, the mechanisms, dosage regime, 
and potential of aspartate supplementation to improve ammonia clearance and high-
intensity exercise performance in humans are unresolved.  To address the above concerns, 
it is hypothesized that 5 - 15 grams of aspartate BID over a 24-hour period preceding high-
intensity exercise will decrease blood ammonia levels, and increase short term exhaustive 
bursts in power.   
In summary, although the impact of aspartate supplementation on performance 
appears reflective of specificity of training, the degree of effectiveness on gender is 
unclear.  Secondly, the reliability of the blood ammonia assay across exercise sessions is 
unclear as well, as is the dose-response effect of variable L-Aspartic Acid supplementation 
on exercise hyperammonemia.  Third, the effect of aspartate on high-intensity performance 
and hyperammonemia is unclear comparing well-trained versus lesser-trained men.  
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Therefore, to test these areas and hypotheses, the dissertation consisted of a preliminary 
phase of three studies (summarized in the introduction to Chapter 2), followed by a second 
phase of three experiments (presented in Chapters 2, 3, and 4, respectively).  Each 
experiment utilized an incremental arm ergometer protocol, accompanied by a 24-hour 
supplementation regime of aspartate or placebo.  The purposes of the three experiments 
were: 
Experiment 1:  a)  Assessed the reliability of blood ammonia in college-age subjects 
across five high-intensity exercise testing sessions holding duration 
and power constant 
 b) Assessed the blood ammonia response in college-age subjects to 
aspartate intake vs. placebo, counterbalanced across five high-
intensity exercise sessions holding duration and power constant 
 
Experiment 2:  Assessed high-intensity exercise performance over two sessions in 
highly-upper body trained and moderately upper body trained 
college-age men, following aspartate supplementation or placebo, 
utilizing a double blind counterbalanced design. 
 
Experiment 3: Assessed high-intensity exercise performance over two sessions in 
moderately upper body trained college-age women, following 
aspartate supplementation or placebo, utilizing a double-blind 
counterbalanced design. 
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CHAPTER 2.  PRELIMINARY STUDIES OF BLOOD AMMONIA REDUCTION 
AGENTS AND THE RELIABILITY OF THE AMMONIA ASSAY ACROSS EXERCISE 
SESSIONS 
 
2.1 Introduction and Rationale 
Short-term and long-term decreases in blood ammonia concentration are associated 
with improvements in high-intensity exercise performance (Wesson et al., 1988; Graham et 
al., 1995).  Assessment of blood [NH3] during high-intensity exercise is becoming an 
increasingly prevalent marker for 1) status of activity-specific conditioning, 2) protein and 
amino acid metabolism, 3) degree of effort and 4) assessment of performance.  
Furthermore, the symptoms of high-intensity exercise-induced hyperammonemia (i.e. 
ataxia, dizziness, confusion, nausea), mimic that of clinical hyperammonemia where blood 
[NH3] exceeds 100 µM/L (Batshaw, 1994).  The reduction of hyperammonemia, and 
associated symptoms, is desirable for optimal physiological function and athletic 
performance. 
Data from Barnes et al. (1964), Kendrick (1976), and Wesson et al. (1988), suggest 
that reduced hyperammonemia and improved exercise performance are in some cases, 
associated with the acute intake (~5 - 15 grams) of the ammonia reducing L-amino acids 
(e.g. aspartate, arginine, ornithine, glutamate).  However, there is insufficient information 
on the 1) overall reliability of the blood ammonia assay across multiple exercise sessions, 
and 2) dose-response effect of amino acid ingestion (e.g. aspartic acid) on blood ammonia 
reduction to validate the blood ammonia measurement with high-intensity exercise.  
Therefore, the purpose of this chapter is to 1) summarize three pilot studies investigating 
blood ammonia reduction and high-intensity performance with ingestion of the ammonia-
reducing amino acids, providing background and rationale for 2) a reliability investigation 
of the blood ammonia assay across exercise sessions. 
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2.1.1 Summary of Pilot Work 
Reliability studies involving invasive biochemical assays, high-intensity exercise, 
dietary control, and humans are difficult to accomplish with an adequate number (i.e. n > 
10) of subjects due to 1) the invasiveness of blood draws and/or muscle biopsies, 2) the 
required control of diet, caffeine, tobacco, exercise habits, and other factors, 3) the high 
dropout rate, 4) the higher likelihood of an adverse physiological or medical event, and 5) 
the intrinsic subject motivation to complete the study.  In this regard, publications in 
exercise biochemistry often appear with sample sizes considered ‘smaller than usual’ (i.e., n 
< 6) in contrast to non-exercise biochemistry disciplines.  Consequently, publications of this 
type (e.g. the reliability of the blood ammonia assay during exercise across time) of exercise 
physiology research are rare, of higher risk, and difficult to conduct.  However, biochemical 
reliability investigations are necessary to validate potential biochemical changes in response 
to treatment.  With this in mind, three pilot studies each with sample sizes < 10 were 
conducted (preceding a more thorough reliability investigation) to assess the potential 
trends of selective amino acid ingestion to lower blood ammonia and/or increase blood urea 
and performance during high-intensity exercise.  
The first pilot study (i.e. pilot study 1, double-blind) investigated the effects of 
supplementation of 2g each of glutamate, arginine, ornithine, and aspartate (versus placebo) 
on high-intensity leg ergometry performance, resting and post-exercise blood [NH3], lactate, 
and urea in moderately-trained college-age males (n = 3).  With treatment, there was a 
significant drop in blood [NH3], an increase in urea, and no significant change in lactate or 
performance in response to treatment (For detailed methodology and results, see appendix 
B.). 
A second pilot study (i.e. pilot study 2) in healthy college students (n = 8) isolated 
the effects of ingestion of 10g each of arginine and ornithine (urea cycle substrates) on 
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resting and post-exercise blood NH3, lactate, creatinine, total protein, urea and time to 
exhaustion in response to incremental treadmill exercise.  Results indicated ~ 40% increase 
in urea with treatment (versus placebo), with no significant differences in blood ammonia, 
LA, total protein, creatinine, or time to exhaustion.  These results suggest 1) isolated urea 
cycle substrate ingestion has a greater effect on blood urea elevation than on blood NH3 
reduction, and 2) high-intensity performance is not affected by short-term ingestion of 
isolated urea cycle amino acids (For detailed methodology and results, see appendix C.). 
A third pilot study (i.e. pilot study 3) investigated the effect of variable dosage of 
aspartate (0, 5, 10, 15g) on immediate post-exercise blood NH3 and lactate in surfers (n = 
5).  Work time and power output were constant per subject across four exercise sessions 
utilizing an incremental arm ergometer protocol.  Results indicated a dose-dependent drop 
in blood NH3 in response to L-Aspartic Acid supplementation, with no change in lactate 
(For detailed methodology and results, see appendix D.).  Results from this study indicated 
10 - 15g L-Aspartic Acid prior to intense arm-crank activity as the optimal dose (of 0, 5, 10, 
or 15g) to lower blood ammonia concentration in moderately-trained subjects.  However, 
yet to be resolved from these pilot studies and previous work with the reduction of exercise-
induced hyperammonemia and improvement in performance with aspartate supplementation 
(Barnes et al., 1964; Kendrick, 1976; and Wesson et al., 1988) is the reliability of the blood 
ammonia assay across exercise sessions under placebo and/or L-Aspartic Acid treatment. 
Therefore, to 1) assess the reliability of the blood ammonia assay under either 
placebo or L-Aspartic Acid condition(s) across exercise sessions, and 2) validate the pilot 
study results of blood ammonia reduction with L-Aspartic Acid treatment; and 3) provide 
reference for future exercise-induced hyperammonemia studies, the following reliability 
experiment (with sample size > 10) was conducted. 
 60 
  
 
2.2 Methods 
2.2.1 Subjects 
Fifteen recreationally upper body trained (e.g. weight training, surfing, swimming) 
college-age male (n = 11) and female (n = 4) students attending Brigham Young University 
– Hawaii (BYU-H) volunteered for the study, approved by the Institutional Review Board 
of the university.  Subjects were informed of the nature of the study, the possible risks 
associated with participation, and of their right to withdraw at any time before providing 
written consent.  Subject characteristics (mean, SEM, SD, minimum, and maximum) for 
these fifteen students are presented in Table 2.1.  Subjects were instructed to abstain from 
alcoholic beverages, caffeine, and tobacco for the duration of the study and to keep dietary 
and exercise habits consistent across sessions.  All reported at least one year of experience 
of upper body recreational training 2-3x/week (i.e. weight training, surfing, swimming).  
None were members of intercollegiate athletic teams.  Training status was measured in 
wattage (W·min-1) at an RPE of 17 (6-20 scale) on an incremental arm ergometer protocol.    
2.2.2 Protocol 
A counterbalanced latin square design determined the order of L-Aspartic Acid (A) 
or placebo (P) supplementation prior to five exercise sessions.  Figure 2.1 illustrates 
regimen for supplementation assignment.  Subjects were assigned to either protocol (a), (b), 
or (c) in that order, upon registration.  Two sessions followed 12.5g x 2 QD of L-Aspartic 
Acid supplementation, while three followed placebo.  A 48-hour washout separated each 
session.  Of the initial pool of 25 registrants, 15 completed at least four sessions, which 
included three placebo sessions.  Of the 15 subjects, seven were assigned to protocol (a), 
four to protocol (b), and four to protocol (c).  Due to technical difficulties, bloodwork was 
available for only ten subjects who completed the two sessions of L-Aspartic Acid 
supplementation.  Therefore, complete blood ammonia data was available for fifteen 
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Table 2.1. Descriptive characteristics of the subjects (n = 15) in experiment 1. 
 
Subject 
Initials 
Subject # 
(M/F) 
Age 
(yr) 
Height 
(cm) 
Weight 
(kg) 
Dosage 
(mg/kg) 
W.min-1 
@RPE17 
NN 1F 20 167.6 59.1 211.5 75.0 
CS 2F 22 167.6 57.3 218.3 125.0 
JS 3F 22 162.6 68.2 183.3 100.0 
KU 4M 23 193.0 88.6 141.0 150.0 
AH 5F 20 165.1 52.3 239.1 100.0 
NG 6M 22 170.2 68.2 183.3 150.0 
JB 7M 22 172.7 77.3 161.8 175.0 
KN 8M 22 170.2 68.2 183.3 150.0 
MR 9M 22 172.7 77.3 161.8 175.0 
JA 10M 24 182.9 85.5 146.3 200.0 
JS 11M 22 175.3 75.0 166.7 200.0 
DN 12M 24 170.2 66.8 187.1 150.0 
JE 13M 22 180.3 83.2 150.3 150.0 
SA 14M 33 180.3 94.1 132.9 150.0 
YN 15M 27 177.8 70.5 177.4 175.0 
       
Mean  23.1 178.4 73.8 171.3 158.3 
SEM  0.8 2.6 2.9 6.6 9.3 
SD  3.2 7.8 8.7 19.7 28.0 
Minimum  20.0 170.2 61.4 141.0 100.0 
Maximum  33.0 193.0 88.6 203.7 200.0 
RPE - Rating of perceived exertion (6-20) scale 
mg/kg – Relative dosage per kg body weight of 12.5 grams of L-Aspartic Acid 
 
sessions following placebo, and ten sessions following L-Aspartic Acid supplementation.  
Two drink powder packets (either two of A, or two of P) were distributed to the subject(s) 
24 hours prior to each session.  Subjects were instructed to mix the contents of each in 8 - 
12 ounces of water, and ingest one packet mixed in water 24 hours and ingest the other 
packet 1 hour before testing, respectively.  Of the five sessions, two followed ingestion of 
A, while three followed ingestion of P. Contents of packet A were 12.5g of L-Aspartic 
Acid (Source Naturals, Inc., Scotts Valley, CA) mixed in 20g of powdered Powerade© 
(The Minute Maid Company for Coca-Cola USA, Northlake, IL).  Packet P contained 
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Protocol (a) 
 
  Ingestion  P     P       A     A     P       P     A     A    P     P 
    
    
 
  Session # -       1         2          3         4             5 
    
 
 
 
Protocol (b) 
 
  Ingestion  P     P       P     P      A        A     P     P    A     A 
    
    
 
  Session #        1         2          3         4             5 
    
 
 
  Protocol (c) 
 
  Ingestion  A   A       P     P      A        A     P      P    P     P 
    
    
 
  Session #        1         2          3         4             5 
    
           
 
 
 
 
 
 
Figure 2.1. Order and regime of three counterbalanced protocols for supplementation 
assignment (P – placebo; A – L-Aspartic Acid) across five exercise sessions.  
Subjects were assigned to protocol (a), (b), or (c) in the order of signup for participation. 
(            = ingestion ~ 24 hours pre-test;                = ingestion ~ 1 hour pre-test) 
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20g of powdered Powerade© only.  Powders were weighed to within 0.1g on a VWR 
Sargent Welch Calibrated Scale (VWR Scientific Products #WLS2648-30).  Staff 
instructions for distributing L-Aspartic Acid (A) or placebo (P) packets packet(s) to 
subjects are presented in Appendix D. 
Subjects reported to the laboratory for five sessions of seated incremental arm 
ergometry (Monark Model #881) testing.  At least 48 hours separated each session.  
Testing began at 25 W·min-1, and increased in 25 W·min-1 increments every 30 seconds at a 
constant 100 rpm.  The test was terminated upon stage completion when rating of perceived 
exertion of 17 (6-20 scale) was achieved.  The individual duration time achieved in session 
1 was recorded, and all subsequent tests went the same length of time with the same 
workload ramp.  Cadence and revolutions were monitored and tracked, respectively, via an 
integrated electronic readout.  Verbal feedback was used to help subjects stay at target 
cadence.  Revolutions achieved were used to calculate wattage output.  The intra-subject 
exercise protocol duration time and number of stages completed was kept the same across 
sessions.  Inter-subject number of stages completed varied.  Protocol duration, total 
revolutions, and mean terminal wattage in the RPE 17 stage (W·min-1) were tabulated and 
recorded.  
Seated blood samples were drawn 3 minutes post exercise.  Following alcohol 
preparation of skin, a 21 gauge 1" Vacutainer© (Becton Dickinson and Co. Vacutainer 
Systems, Franklin Lakes, NJ) double-sided blood collection needle (#36-7212) was 
inserted into a superficial antecubital vein.  A red top Vacutainer© tube with sterile interior 
was then inserted into the surrounding needle hub, and a 4-6 ml blood sample drawn for 
about 15 seconds.  Blood samples were placed immediately into an ice bath for 10 minutes, 
and centrifuged for 10' at 3400 rpm (Fisher Scientific Centrific Model 228).  Serum was 
transferred via disposable 3.2 ml polyethylene transfer pipettes (#13-711-7, Fisher 
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Scientific, Pittsburgh, PA) into labeled 1.5 ml micro polypropylene metal-free test tubes (# 
223-9480, Bio-Rad Laboratories, Hercules, CA), sealed with attached caps, and frozen 
immediately at 20 degrees Celsius for subsequent batch analysis.  Serum [NH3] was 
determined via a Kodak Ektachem Analyzer (Eastman Kodak Company, Rochester, NY) 
using Ektachem NH3/Amon Clinical Chemistry Slides (Johnson and Johnson Clinical 
Diagnostics, Rochester, NY) using a phenol hypochlorite colorimetric technique. 
2.2.3 Statistical Analyses 
The SPSS statistical package was used to assess the intraclass correlation 
coefficient (ICC) between placebo sessions 1,2, and 3 (i.e. P1, P2, P3) and between the two 
L-Aspartic Acid sessions (i.e, A1, A2).  An analysis of variance with repeated measures 
was used to assess differences between sessions of placebo treatment (P1, P2, and P3) and 
L – Aspartic Acid supplementation (A1 and A2), using GB-STAT software.  Tukey’s post-
hoc t-tests were utilized when the overall F value was significant.  Individual intraclass 
correlation coeffecients were calculated also between the individual placebo sessions  (P1 
vs. P2, P1 vs. P3, and P2 vs. P3), and between the L-Aspartic Acid supplementation 
sessions (A1 vs. A2).  α was set apriori at .05. 
2.3 Results 
As specified per analyses, results are presented as the actual value, or as mean ± 
SEM.  Figure 2.2 illustrates the consistency of the individual blood ammonia responses 
[µM/L] across the three exercise sessions with placebo treatment.  Figure 2.3 illustrates the 
individual blood ammonia responses [µM/L] to two exercise sessions with L-Aspartic Acid 
supplementation.  The ICC was highly significant (r = 0.90, p < 0.0001) for the blood 
ammonia concentrations [µM/L] across the three placebo sessions.  The intraclass 
correlation coefficient between the two sessions for L-Aspartic Acid treatment was also 
significant, r = 0.76, p < 0.01.  The individual intraclass correlation coefficients   
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Figure 2.2. Individual responses in blood NH3 [µM/L] following treatment with placebo 
across three exercise sessions (n = 15). 
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Figure 2.3. Individual responses in blood NH3 [µM/L] following treatment with L-Aspartic 
Acid across two exercise sessions (n = 10). 
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between P1, P2, and P3 were also highly significant (P1 vs. P2, r = 0.91, p < 0.0001; P2 vs. 
P3, r = 0.90, p < 0.0001; P1 vs. P3, r = 0.89, p < 0.0001).  There were no significant within-
group differences (p > 0.05) between the placebo sessions or the L-Aspartic Acid sessions.   
Figure 2.4 illustrates the significantly reduced blood ammonia concentrations with 
the sessions of L-Aspartic Acid treatment versus placebo (F = 25.6   p < 0.0001).  The 
means  ± SEM of blood [NH3] across the treatments were: P1 = 180 ± 13, P2 = 190 ± 14; 
and P3 = 184 ± 13, and A1 = 165 ± 14, and A2 = 163 ± 14.  There were no significant 
differences (p > 0.05) in [blood ammonia] between P1, P2, and P3, or between A1 and A2.  
The lowest blood [NH3] per subject was with L-Aspartic Acid supplementation.   
2.4 Discussion 
This investigation is the first to report the test-retest reliability of the blood 
ammonia assay across high-intensity exercise testing sessions.  Results indicate that the 
urease/phenol hypochlorite method (with the Kodak© Ektachem Vitros II Analyzer) is 
highly reproducible across three separate testing days in a controlled environment with 
recreationally-trained college-age males and females.  However, until future information 
becomes available, one should exercise caution for application across additional testing 
methods, dietary fluctuations, subject populations, and/or exercise habits.  These results 
show the blood ammonia assay to be highly reliable (i.e., r > .90, p < 0.0001) across 
multiple exercise sessions with placebo treatment in the short term (i.e. < two weeks).  The 
present investigation suggests also a greater variability in the reproducibility of the blood 
ammonia assay with L-Aspartic Acid supplementation.  Although statistically significant, 
the reliability of the ammonia assay across exercise sessions with L-Aspartic Acid 
supplementation is less significant (i.e. r = 0.74, p < 0.05) than that of placebo.  This 
difference may be due to greater aspartate intake in foodstuffs (e.g. meat), and/or intra- and 
intersubject variability in metabolic aspartate bioefficiency associated with training status.  
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Figure 2.4. Mean blood NH3 [µM/L] across three placebo sessions (P1, P2, P3) and two L-
Aspartic Acid treatment sessions (A1, A2). 
*p < 0.05, (A1, A2 versus each of P1, P2, P3) 
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For instance, it is well known that moderately-trained subjects (similar to those trained in 
this study) have reduced ammonia clearing capabilities versus that of highly-trained 
subjects (Graham et al., 1997).  Although the sample sizes in the present study differed 
between the two treatments (i.e., placebo, n = 15 x 3; L-Aspartic Acid, n = 10 x 2), the 
blood ammonia concentrations were significantly lower (as hypothesized) with L-Aspartic 
Acid supplementation versus placebo, while keeping intra-subject power output constant 
across sessions. 
To conclude, these results show the blood ammonia assay to be a highly 
reproducible short-term tool across exercise sessions under controlled conditions.  
However, until sufficient information becomes available, one should exercise caution when 
applying these results to subject groups undergoing changes in diet or training status.  
Further, though significantly reproducible but more variable versus placebo, this 
investigation provides evidence also that the blood ammonia assay is a reliable 
measurement in exercise studies utilizing L-Aspartic Acid supplementation, particularly 
with recreationally-trained college students.  To apply this reproducibility to other subject 
pools, regimes of amino acid supplementation, dietary or testing protocols, and/or long 
term changes in training statuses needs to be investigated further. 
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CHAPTER 3.  IMPACT OF L-ASPARTIC ACID SUPPLEMENTATION ON EXERCISE 
HYPERAMMONEMIA AND PERFORMANCE IN HIGHLY-TRAINED AND 
MODERATELY-TRAINED MEN 
 
3.1 Introduction 
Ammonia, a product of dietary and exercise metabolism, is inversely associated 
with exercise performance.  Symptoms of clinical hyperammonemia, such as those 
described by Batshaw (1984) (e.g.. nausea, ataxia, dizziness), mimic those observed during 
intense exercise, where normal resting blood [NH3] of ~10-40 µM/L may exceed 500 µM/L 
(Fischbach, 1988).  Data from Barnes et al. (1964), Kendrick (1976), and Wesson et al. 
(1988) indicate that acute intake (~5 - 15 grams over 24 hours) of the non-toxic amino acid 
aspartate is among the techniques known to reduces exercise-induced  hyperammonemia 
and in some cases improves exercise performance.  However, the effect of aspartate on 
performance is unknown comparing well-trained versus lesser-trained men.  Therefore, this 
experiment was conducted to investigate the effect of aspartate ingestion on high-intensity 
exercise hyperammonemia and performance in highly-trained and moderately-trained men. 
Strenuous physical activity elevates blood ammonia concentrations primarily by 
accelerating activity of the purine nucleotide cycle (i.e. AMP deaminase) and deamination 
of branched chain amino acids (Lowenstein, 1972, MacLean et al., 1996).  As determined 
by Lo and Dudley (1987) and Levin et al. (1969), blood ammonia levels are inversely 
associated with exercise training status and performance, and rise during intense exercise to 
levels included in the diagnostic criteria (i.e. > [100 µM/L]) for clinical hyperammonemia.  
The undesirable symptoms of exacerbated clinical hyperammonemia (i.e. oncoming 
nausea, ataxia, dizziness) are likewise observed during intense exercise, where a normal 
resting blood [NH3] of ~10-40 µM/L rises to well over [100 µM/L].  
The non-essential amino acid L-Aspartate is one of several amino acids (Najarian et 
al., 1958) known to reduce the hyperammonemia associated with hepatic disorders, and, in 
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some instances improve exercise performance in healthy populations (Ahlborg et al., 1968; 
Gupta et al., 1973; Wesson et al., 1988).  Though controversial, a review of literature of the 
past 40 years indicates that an acute reduction in transient hyperammonemia in trained 
individuals may enhance performance during high-intensity exercise, where blood 
ammonia levels peak.  The regimen for supplementation at present indicates dosage QD 
between 5 - 15 grams over 24 hours to be most effective; however due to a myriad of 
testing modalities, subject characteristics, and dosage regimes the acute application of L-
Aspartic Acid to reduce exercise-induced hyperammonemia (EIH) to enhance high-
intensity performance is unclear (Gupta et al., 1973; Wesson et al., 1988). 
This study investigated the hypothesis that acute aspartic acid intake will 1) lower 
hyperammonemia and 2) improve high-intensity arm-crank power in both highly upper 
body trained intercollegiate male water polo players and moderately upper–body trained 
college students. 
3.2 Methods 
3.2.1 Subjects 
Nine highly upper body trained intercollegiate water polo players (WP) and nine 
moderately upper body trained (MOD) college-age male students attending Brigham 
Young University – Hawaii (BYU-H) volunteered for the study, which had the approval of 
the Institutional Review Board of the university.  Subject characteristics (mean, SEM, SD, 
minimum, and maximum) for WP and MOD are presented in Table 3.1 and Table 3.2, 
respectively.  Subjects were fully informed of the nature of the study, the possible risks 
associated with participation, and their right to withdraw at any time.  Their understanding 
of this was provided by written informed consent.  WP consisted of in-season 
intercollegiate water polo athletes, who supplemented daily swim workouts with weight 
training 3-5x/week.  MOD subjects were recreationally-trained in activities including 
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Table 3.1. Descriptive characteristics for intercollegiate water polo (WP) players (n = 9). 
 
Subject 
Initials 
Subject # 
(M/F) 
Age 
(yr) 
Height 
(cm) 
Weight 
(kg) 
Dosage 
(mg/kg) 
W.min-1 
@end of 
warm-up 
CS 1 18 180.3 79.5 157.1 200.0 
CA 2 18 180.3 84.1 148.6 200.0 
JB 3 18 182.9 84.1 148.6 200.0 
KD 4 18 172.7 65.9 189.7 200.0 
RS 5 18 190.5 72.7 171.9 200.0 
SP 6 18 180.3 77.3 161.8 200.0 
VM 7 19 190.5 93.2 134.1 200.0 
AW 8 23 180.3 84.5 147.8 200.0 
DY 9 18 180.3 84.1 148.6 200.0 
       
Mean  18.7 182.0 80.6 156.5 200.0 
SEM  0.6 1.8 2.6 5.4 0.0 
SD  1.7 5.5 7.9 16.3 0.0 
Minimum  18.0 172.7 65.9 134.1 200.0 
Maximum  23.0 190.5 93.2 189.7 200.0 
mg/kg – relative dosage of 12.5 grams of L-Aspartic Acid per kg body weight 
 
Table 3.2. Descriptive characteristics for moderately-trained (MOD) subjects (n = 9). 
 
Subject 
Initials 
Subject # 
(M/F) 
Age 
(yr) 
Height 
(cm) 
Weight 
(kg) 
Dosage 
(mg/kg) 
W.min-1 
@RPE 17 
AM 1 22 185.42 72.7 171.9 150.0 
CJ 2 23 172.72 61.4 203.7 100.0 
EM 3 24 180.34 71.4 175.2 175.0 
DN 4 23 193.04 88.6 141.0 150.0 
RO 5 20 177.80 72.7 171.9 175.0 
DN 6 24 170.20 66.8 187.1 150.0 
JA 7 24 182.90 85.5 146.3 200.0 
NG 8 22 170.20 68.2 183.3 150.0 
JB 9 22 172.70 77.3 161.8 175.0 
       
Mean  22.7 178.4 73.8 171.3 158.3 
SEM  0.4 2.6 2.9 6.6 9.3 
SD  1.3 7.8 8.7 19.7 28.0 
Minimum  20.0 170.2 61.4 141.0 100.0 
Maximum  24.0 193.0 88.6 203.7 200.0 
RPE - rating of perceived exertion (6-20) scale 
mg/kg – relative dosage of 12.5 grams of L-Aspartic Acid per kg body weight 
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 tennis, swimming, surfing, and weight training.  Pertaining to diet, subjects were instructed 
to abstain from alcoholic beverages, caffeine, and tobacco for the duration of the study, and 
further, to keep dietary and exercise habits consistent across sessions.  Training status was 
assessed by wattage (W·min-1) achieved at an RPE of 17 (6-20 scale) on an incremental 
arm ergometer protocol.   
Arm ergometry was chosen as the testing modality because it was specific to the 
upper body training status of the subjects.  In addition, arm ergometry involved a smaller 
muscle mass, and therefore less endurance and less lab time.  Further, testing via arm crank 
limited the confounding factors, which might have been observed due to inter-individual 
variations in day-to-day leg activity patterns. 
3.2.2 Protocol  
A counterbalanced double blind design determined order of L-Aspartic Acid (A) or 
placebo (P) supplementation, while a third party distributed two drink powder packets to 
the subject(s) prior to each session.  Subjects were instructed to mix the contents in 8 
ounces of water, and ingest one packet 24 hours and the second packet 1 hour prior to 
testing.  One session followed ingestion of 12.5g x 2 of aspartate (Source Naturals, Inc., 
Scotts Valley, CA) mixed in 20g of powdered Powerade© (The Minute Maid Company for 
Coca-Cola USA, Northlake, IL), while the other session followed ingestion of 20g of 
powdered Powerade© only.  Powders were weighed to within 0.1g on a VWR Sargent 
Welch Calibrated Scale (VWR Scientific Products #WLS2648-30).   
Subjects reported to the laboratory for two sessions of incremental seated arm 
ergometry (Monark Model #881).  At least 48 hours separated each session.  The exercise 
protocol consisted of two parts: 1) an incremental warm-up at a constant 100 rpm 
immediately followed by 2) all-out performance (sprint to volitional exhaustion).  The 
purpose of the warm-up was to have the subject achieve an RPE of 17 (very hard) to 
 74 
  
 
precede the sprint.  The warm-up consisted of a series of 30-second stages, at an initial 
intensity of 25 W·min-1, with an increase of 25 W·min-1 each stage.  The all-out power test 
to exhaustion began at the 4-minute mark for WP, and at completion of the RPE 17 (6-20 
scale) stage for MOD.  Warm-up duration across sessions was kept the same intra-subject, 
while inter-subject the warm-up duration varied for MOD.  Cadence (rpm) was monitored 
during warm-up by both technician and subject via electronic readout to maintain the 
correct cranking rate.  Rpm and total revolutions were monitored and tracked, respectively, 
via an integrated electronic readout.  Verbal feedback was used to help subjects stay at 
target cadence during warm-up.  The warm-up portion ended, and the performance phase 
began, when the subject completed the stage in which the RPE of 17 was attained.  At that 
point, with a countdown of 5-4-3-2-1, at a command of “GO!”, the subjects turned the 
crank “as fast as possible for as long as possible” until volitional exhaustion where 
cadence, total revolutions, and time achieved were not visible to the subject.  Warm-up 
duration (seconds), performance duration (seconds), warm-up revolutions, and performance 
revolutions were tabulated, and from this data, warm-up and performance power (W·min-1) 
were calculated via: 
 
W·min-1  = (standard ergometer wattage / standard revolutions) x  (revolutions /  seconds) x  
(60 seconds / 1 minute) 
 
Seated blood samples were drawn 3 minutes post exercise.  Following alcohol 
preparation of skin, a 21 gauge 1" Vacutainer© (Becton Dickinson and Co. Vacutainer 
Systems, Franklin Lakes, NJ) double-sided blood collection needle (#36-7212) was 
inserted into a superficial antecubital vein.  A red top Vacutainer© tube with sterile interior 
was then inserted into the surrounding needle hub, and a 4-6 ml blood sample drawn for 
about 15 seconds.  Blood samples were placed immediately into an ice bath for 10 minutes, 
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and centrifuged for 10' at 3400 rpm (Fisher Scientific Centrific Model 228).  Serum was 
transferred via disposable 3.2 ml polyethylene transfer pipettes (#13-711-7, Fisher 
Scientific, Pittsburgh, PA) into labeled 1.5 ml micro polypropylene metal-free test tubes (# 
223-9480, Bio-Rad Laboratories, Hercules, CA), sealed with attached caps, and frozen 
immediately at 20 degrees Celsius for subsequent batch analysis.  Serum [NH3] were 
determined via a Kodak Ektachem Analyzer (Eastman Kodak Company, Rochester, NY) 
using Ektachem NH3/Amon Clinical Chemistry Slides (Johnson and Johnson Clinical 
Diagnostics, Rochester, NY) using a phenol hypochlorite colorimetric technique. 
3.2.3 Statistical Analyses 
Performance power (W·min-1) and blood [NH3] were compared across treatments 
and groups using a 2 x 2 ANOVA with repeated measures, with post-hoc differences 
determined using Tukey’s test.  All statistical analyses were conducted using GB-STAT 
software.  Significance was considered at p < 0.05. 
3.3 Results 
As specified per analyses, results are reported as the mean ± SEM, the actual value, 
the absolute change, or the percentage change in response to treatment.  Figure 3.1 shows 
the individual blood ammonia concentrations [µM/L] following exercise in response to L-
Aspartic Acid (L-Asp) supplementation or placebo in intercollegiate water polo players 
(WP).  Eight of the 9 of WP, or 89% demonstrated lower blood ammonia concentration 
with L-Aspartic Acid supplementation (versus placebo).  Figure 3.2 shows individual blood 
ammonia concentrations [µM/L] following exercise in response to L-Aspartic Acid (L-Asp) 
or placebo in moderately-trained college males (MOD).  As observed with WP, eight of the 
9 of MOD, or 89% demonstrated lower blood ammonia concentration with L-Aspartic Acid 
supplementation.
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Figure 3.1. Individual responses in blood NH3 [µM/L] following treatment with either L-
Aspartic Acid (L-Asp) or placebo in intercollegiate water polo players (n = 9).
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Figure 3.2. Individual responses in blood NH3 [µM/L] following treatment with either L-
Aspartic Acid (L-Asp) or placebo in moderately-trained college-age males (n = 9).  
 
  
 
 
Figure 3.3 illustrates the individual responses in performance power (W·min-1) to L-
Aspartic Acid treatment versus placebo in intercollegiate water polo players.  Seven of the 
9 WP subjects, or 77%, demonstrated greater power production with L-Aspartic Acid 
supplementation.  Figure 3.4 illustrates the individual responses in power production 
(W·min-1) to L-Aspartic Acid treatment versus placebo in moderately-trained college 
males.  Only four of the 9 MOD subjects, or 44%, demonstrated greater power production 
with L-Aspartic Acid supplementation.   
Figure 3.5 illustrates the comparative percentage change in blood NH3 [µM/L] and 
performance power (W·min-1) in WP and MOD in response to L-Aspartic Acid 
supplementation vs. placebo.  Blood NH3 [µM/L] dropped significantly (F = 23.19, p < 
0.0001) with A (versus P) in WP by 16.7% (241.0 ± 18.4 vs. 200.6 ± 20.5, p < 0.01) and in 
MOD by 15.5% (219.7 ± 20.8 vs. 185.6 ± 27.5, p < 0.05).  On the other hand, performance 
power (W·min-1) increased significantly (p < 0.01) with A (versus P) in WP by 22.7% (270 
± 19.7 vs. 227.6 ± 14.3) with no significant change (p > 0.05) in MOD at 11.5% (220.1 ± 
9.1 vs. 204.4 ± 8.3).  There was no significant difference (p > 0.05) in mean warm-up 
terminal wattage (W·min-1) between treatments (175 aspartate vs. 177 placebo).   
Figure 3.6 illustrates individual changes (vs. placebo) in blood ammonia [µM/L] 
relative to the L-Aspartic Acid dose adjusted for body weight (mg/kg) in WP.  As the 
relative L-Aspartic Acid dose (mg/kg) decreased in WP, to below 160 mg/kg, there was a 
tendency for blood ammonia concentration to drop (vs. placebo) by as much as [100 
µM/L], which occurred at about 130 mg/kg.  Figure 3.7 illustrates the individual changes 
(vs. placebo) in blood ammonia [µM/L] relative to the L-Aspartic Acid dose adjusted for 
body weight (mg/kg) in MOD.  As observed in WP, blood ammonia [µM/L] tended to drop 
with lower dosages, however, with a higher degree of variability in MOD versus WP.
 79 
  
 
100
200
300
400
Po
w
er
 (W
·m
in
-1
)
1 2 3 4 5 6 7 8 9
Subject #
 
Placebo
L-Asp
 
Figure 3.3. Individual responses in performance power (W·min-1) following treatment with 
either L-Aspartic Acid (L-Asp) or placebo in intercollegiate water polo players (n = 9).
 80 
  
 
100
200
300
400
Po
w
er
 (W
·m
in
-1
)
1 2 3 4 5 6 7 8 9
Subject #
Placebo
L-Asp
 
 
 
Figure 3.4. Individual responses in performance power (W·min-1) following treatment with 
either L-Aspartic Acid (L-Asp) or placebo in moderately-trained college-age males (n = 9).
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Figure 3.5. Mean percentage changes (vs. placebo) in blood NH3 [µM/L] and performance 
power (W·min-1) in response to L-Aspartic Acid supplementation in water polo players 
(WP) and moderately-trained males (MOD). 
*p < 0.05 versus placebo. 
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Figure 3.6. Individual changes (vs. placebo) in blood NH3 [µM/L] relative to the L-Aspartic 
Acid dose adjusted for body weight (mg/kg) in intercollegiate water polo players. 
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Figure 3.7. Individual changes (vs. placebo) in blood NH3 [µM/L] relative to the L-Aspartic 
Acid dose adjusted for body weight (mg/kg) in moderately-trained males.  
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Figure 3.8 illustrates the individual changes (vs. placebo) in performance power 
(W·min-1) relative to the L-Aspartic Acid dose adjusted for body weight (mg/kg) in WP.  
There was a trend for a greater magnitude of performance enhancement (e.g. > 100 W·min-
1 improvement) as the relative supplementation dosage was reduced, e.g., to below 150 
mg/kg.  Figure 3.9 illustrates the individual changes (vs. placebo) in performance power 
(W·min-1) relative to the L-Aspartic Acid dose adjusted for body weight (mg/kg) in MOD.  
This figure contrasts smaller (and fewer) improvements in power in MOD versus WP, with 
a higher (mean ± SD) relative dose per unit body weight (mg/kg) noted for MOD versus 
WP (171.3 ± 19.7 vs. 156.6  ± 16.3 mg/kg, respectively). 
3.4 Discussion 
This investigation tested the hypothesis that acute aspartic acid intake would 1) 
lower hyperammonemia and 2) improve high-intensity arm-crank power in two groups of 
college-age males.  One group was highly-trained (i.e. in-season intercollegiate water polo 
players) for upper body activity, and the other was moderately-trained (i.e. weight training, 
surfing) for upper body activity.  Both test groups included comparison to a placebo.  We 
found a significant increase in short-term, high-intensity, upper body power output 
following L-Aspartic Acid supplementation in the highly-trained intercollegiate water polo 
players, but not in the moderately-trained group.  Blood ammonia concentrations were 
lower with L-Aspartic Acid supplementation in both groups.  
The current investigation found that 12.5 g x 2 QD of aspartate reduced exercise-
induced hyperammonemia and enhanced short-term power in highly-trained male 
intercollegiate water polo players.  On the other hand, acutely reducing NH3 by aspartate 
supplementation did not conclusively improve short-term arm power in moderately-trained 
males.  This suggests that hyperammonemia and performance response to aspartate 
supplementation are reflective of status and specificity of training.  These improvements in 
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Figure 3.8. Individual changes (vs. placebo) in performance power (W·min-1) relative to the 
L-Aspartic Acid dose adjusted for body weight (mg/kg) in intercollegiate water polo 
players. 
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Figure 3.9. Individual changes (vs. placebo) in performance power (W·min-1) relative to the 
L-Aspartic Acid dose adjusted for body weight (mg/kg) in moderately-trained males. 
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trained subjects agree with the data of Wesson et al. (1988) and Ritter et al. (1998), and are 
at odds with Columbani et al. (2000).  The small (i.e. ~10 - 20%) drop in hyperammonemia 
in the moderately-trained group may not have been great enough to create an observable 
increase in short-term power, which is in agreement with results with arm work by DeHaan 
et al. (1985) and Tuttle et al. (1995).  However, these studies with upper body activity were 
of low to moderate intensity, which tend to keep blood ammonia levels under [100 µM/L] 
(Tuttle et al., 1995).  In the current study, the L-Aspartic Acid dose (mean ± SD) expressed 
in terms of mg/kg body weight was 156.6  ± 16.3 versus 171.3 ± 19.7 in WP and MOD, 
respectively.  The finding of the successful reduction of hyperammonemia coupled with 
lack of performance improvement in the lesser-trained group warrants further work in 
moderately-trained subjects to possibly consider different doses (e.g. 5, 7.5, 10g x 2 QD, 
relative to body mass) of L-Aspartic Acid. 
Possibly, gluconeogenesis was activated to a greater extent in the moderately-
trained group (versus well-trained) to meet ATP demand.  This in turn would elevate the 
rate of production of alanine, pyruvate, lactate, OAA, glucose, ATP, and ammonia.  The 
effects of aspartate supplementation on the production of each are unclear, however, as 
noted by Stryer (1995), accumulation of acetyl-CoA and pyruvate shifts bioenergetics 
toward OAA formation and gluconeogenesis, and thus away from the TCA cycle by the 
action of pyruvate carboxylase.  Furthermore, studies conducted on animals show aspartate 
supplementation in untrained subjects (in singular and in combination) accelerates pyruvate 
carboxylase activity more than in well-trained individuals (Lancha et al., 1995, Lancha, 
1997).  For example, in response to high-intensity exercise, pyruvate carboxylase activity is 
higher in untrained (12x vs. rest) rat soleus versus trained (3x vs. rest).  This suggests a 
glycogen sparing effect and less reliance on gluconeogenesis for ATP production with 
training, and a greater rate of gluconeogenesis for ATP production with reduced training.  
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However, as shown by Lancha et al. (1994), Lancha et al. (1995), and Lancha (1997), 
gluconeogenesis is accelerated at exhaustion.  Therefore, one would also expect higher 
submaximal NH3 values in lesser-trained subjects relative to power output, and more 
closely related ammonia values at exhaustion independent of training status.  This 
expectation is consistent with observations made in this study. 
It is possible that the ammonia removal response to aspartate supplementation was 
reduced in the moderately-trained subjects because the aspartate was used instead for 
gluconeogenesis.  Aspartate is a substrate in both transamination (i.e. for gluconeogenesis) 
and in the urea cycle (for ammonia removal).  During intense exercise, the bioenergetic 
flow of carbon and nitrogen changes to meet the primary demand for ATP production (i.e. 
gluconeogenesis).  As a result, ammonia removal is compromised and hyperammonemia 
ensues.  Previous work in our laboratory has found that isolating and enhancing urea 
production by supplementation with urea cycle amino acids (e.g. 10g each of L-arginine 
and L-Ornithine) did not improve high-intensity performance in moderately-trained 
subjects (Edwards and Day, 2000).  In the present study, aspartate was more likely utilized 
for gluconeogenesis in the moderately-trained subjects (versus the well-trained) than for 
ammonia removal, which would account for the small reduction in ammonia across 
treatments and lack of power improvement.  Therefore, there may be a threshold reduction 
in hyperammonemia (i.e. > 15%) required to create an observable performance 
improvement.  These results warrant measurements of blood aspartate, oxaloacetate, 
aspartate aminotransferase, and pyruvate carboxylase to assess carbon and nitrogen 
bioenergetic flow with aspartate supplementation and high-intensity exercise. 
An interesting sidelight from this research is the influence lactic acid has on high-
intensity fatigue.  Lactate levels and associated H+ release are associated with fatigue (Hill 
et al., 1924).  However, this dissertation found similar lactate levels for placebo and L-
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Aspartic Acid supplementation, with greater performance in highly-trained subjects with L-
Aspartic Acid supplementation.  This suggests that blood [NH3] (coupled with creatine 
phosphate depletion) may influence fatigue more than [blood lactate] in highly-trained 
individuals performing high-intensity arm work. 
In summary, L-Aspartic Acid supplementation yields a significant increase in short-
term, high-intensity, upper body power output in highly-trained intercollegiate water polo 
players, but not in moderately-trained subjects.  While blood ammonia concentrations were 
lower with L-Aspartic Acid supplementation in both groups, the reduction in the 
moderately-trained group may reflect a larger portion of the aspartate diverted for 
gluconeogenesis.  The metabolic ability of the higher trained subjects to remove blood 
ammonia and increase power in response to aspartate supplementation implies that 
hyperammonemia regulates fatigue more so than lactate in highly-trained subjects.  For 
supplementation to be effective in moderately-trained populations, future work should 
focus on defining the existence of NH3 reduction thresholds. 
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CHAPTER 4.  IMPACT OF L-ASPARTIC ACID SUPPLEMENTATION ON HIGH-
INTENSITY EXERCISE HYPERAMMONEMIA AND PERFORMANCE IN FEMALES 
 
4.1 Introduction 
Strenuous physical activity (i.e. short-term intense work) elevates blood ammonia 
concentrations primarily by accelerating activity of the purine nucleotide cycle (i.e. AMP 
deaminase) and deamination of branched chain amino acids (Lowenstein, 1972, MacLean 
et al., 1996).  As determined by Lo and Dudley (1987) and Levin et al. (1969), blood 
ammonia levels are inversely associated with exercise training status and performance, and 
rise during intense exercise to levels included in the diagnostic criteria (i.e. > [100 µM/L]) 
for clinical hyperammonemia (Batshaw, 1984).  Symptoms of exacerbated clinical 
hyperammonemia (i.e. nausea, ataxia, dizziness) are likewise observed during intense 
exercise, where a normal resting blood [NH3] of ~10-40 µM/L (Fischbach, 1988) rises to 
well over [100 µM/L].   
Intake of the amino acid L-Aspartate is one of several amino acids (Najarian et al., 
1958) that reduce the hyperammonemia associated with hepatic disorders, and, in some 
instances improves exercise performance in healthy populations (Ahlborg et al., 1968; 
Gupta et al., 1973; Wesson et al., 1988).  Though controversial, a review of literature of the 
past 40 years indicates that an acute reduction in transient hyperammonemia in males by ~ 
5 – 15 g QD of aspartate supplementation (Wesson et al., 1988, and Ritter et al., 1998) may 
enhance high-intensity exercise performance.  However, the ability of L-Aspartic Acid 
supplementation to reduce exercise-induced hyperammonemia to enhance high-intensity 
exercise performance is unknown in females.  Thus, the following experiment was 
conducted to address this concern.    
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4.2 Methods 
4.2.1 Subjects 
Eighteen recreationally upper body trained college-age females (FEM) attending 
Brigham Young University – Hawaii (BYU-H) volunteered for the study.  Subject 
characteristics (mean, SEM, SD, minimum, and maximum) are presented in Table 4.1.  
Body weight (mean ± SD) (kg) was 61±7 (51-75).  The study had the approval of the 
Institutional Review Board of the university, and subjects were informed of the nature of 
the study, the possible risks associated with participation, and of their right to withdraw at 
any time before providing written consent.   
Subjects were instructed to abstain from alcoholic beverages, caffeine, and tobacco 
for the duration of the study, and, further, to keep dietary and exercise habits consistent 
across sessions.  All subjects reported at least one year of experience of upper body 
recreational training 2-3x/week (i.e. weight training, surfing, swimming).  None were 
members of an athletic team involving strenuous upper body training (e.g. swimming, 
water polo).  Training status was characterized by the wattage (W·min-1) attained during the 
terminal stage of an incremental arm ergometer protocol at which an RPE of 17 (6-20 
scale) was achieved. 
Arm ergometry was chosen as the testing modality because it was specific to the 
upper body training status of the subjects.  In addition, arm ergometry involved a smaller 
muscle mass, and therefore less endurance and less lab time.  Further, testing via arm crank 
limited the confounding factors, which might have been observed due to inter-individual 
variations in day-to-day leg activity patterns. 
4.2.2 Protocol 
A counterbalanced double blind design determined the order of L-Aspartic Acid (A) 
or placebo (P) supplementation.  A third party (office secretary) distributed two drink 
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powder packets to the subjects prior to each session.  Subjects were instructed to mix the 
contents of each packet in 8 ounces of water, and ingest one drink 24 hours and the second 
 
Table 4.1. Descriptive characteristics for recreationally-trained (FEM) females (n = 18). 
 
Subject 
Initials 
Subject # 
(M/F) 
Age 
(yr) 
Height 
(cm) 
Weight 
(kg) 
Dosage 
(mg/kg) 
W.min-1 
@RPE 17 
AM 1 21 157.5 52.7 237.1 100 
AH 2 20 165.1 52.3 239.1 100 
CS 3 22 167.6 57.3 218.3 125 
EP 4 20 172.7 72.7 171.9 125 
EA 5 20 177.8 61.4 203.7 100 
HH 6 22 170.2 63.6 196.4 100 
JB 7 20 167.6 51.4 243.4 100 
JS 8 22 162.6 68.2 183.3 100 
KD 9 22 165.1 47.7 261.9 100 
KW 10 22 167.6 52.3 239.1 100 
LE 11 25 180.3 75.0 166.7 100 
MR 12 21 160.0 56.8 220.0 75 
NN 13 20 167.6 59.1 211.5 75 
SC 14 20 165.1 61.4 203.7 100 
SB 15 21 167.6 59.1 211.5 100 
SM 16 20 172.7 65.0 192.3 100 
TB 17 19 167.6 63.6 196.4 100 
TF 18 26 165.1 61.8 202.2 75 
       
Mean  21.3 167.8 60.1 211.0 98.6 
SEM  0.4 1.3 1.7 6.1 3.2 
SD  1.8 5.6 7.4 25.7 13.5 
Minimum  19.0 157.5 47.7 166.7 75.0 
Maximum  26.0 180.3 75.0 261.9 125.0 
RPE - Rating of perceived exertion (6-20) scale 
mg/kg – Relative dosage of 12.5 grams of L-Aspartic Acid per kg body weight 
 
 
 
drink 1 hour prior to testing.  One session followed ingestion of 12.5g x 2 of aspartate 
(Source Naturals, Inc., Scotts Valley, CA) mixed in 20g of powdered Powerade© (The 
Minute Maid Company for Coca-Cola USA, Northlake, IL), while the other session 
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followed ingestion of 20g x 2 of powdered Powerade© only.  Powders were weighed to 
within 0.1g on a VWR Sargent Welch Calibrated Scale (VWR Scientific Products 
#WLS2648-30).   
Subjects reported to the laboratory for two sessions of incremental seated arm 
ergometry (Monark Model #881).  At least 48 hours separated each session.  The exercise 
protocol consisted of two parts: 1) an incremental warm-up at a constant 100 rpm 
immediately followed by 2) all-out performance sprint to volitional exhaustion.  The 
purpose of the warm-up was to have the subject achieve an RPE of 17 (very hard) to 
precede the sprint.  The warm-up consisted of a series of 30-second stages, beginning with 
an initial intensity of 25W, and followed with an increase of 25W every 30 seconds until 
completion of the stage where an RPE of 17 was reached.  Warm-up duration across 
sessions was the same intra-subject, while inter-subject the warm-up duration varied.  
Cadence (rpm) was monitored via electronic readout and the subject encouraged to 
maintain the correct cranking rate.  RPM and total revolutions were monitored and tracked, 
respectively, via an integrated electronic readout.  Verbal feedback was used to help 
subjects stay at target cadence during warm-up.  The all-out power test to exhaustion began 
at completion of the warm-up stage where RPE reached 17 (6-20 scale).  At that point, with 
a countdown of 5-4-3-2-1, and at a command of “GO!”, the subjects turned the crank “as 
fast as possible for as long as possible”.  Warm-up revolutions, performance duration 
(seconds), and performance revolutions were recorded, and warm-up and performance 
power (W·min-1) were calculated via the formula: 
 
W·min-1  = (standard ergometer wattage / standard revolutions) x  (revolutions / seconds) x  
(60 seconds / 1 minute) 
 
 94 
  
 
Seated blood samples were drawn 3 minutes post exercise.  Following alcohol 
preparation of skin, a 21 gauge 1" Vacutainer© (Becton Dickinson and Co. Vacutainer 
Systems, Franklin Lakes, NJ) double-sided blood collection needle (#36-7212) was 
inserted into a superficial antecubital vein.  A red top Vacutainer© tube with sterile interior 
was then inserted into the surrounding needle hub, and a 4-6 ml blood sample drawn for 
about 15 seconds.  Blood samples were placed immediately into an ice bath for 10 minutes, 
and centrifuged for 10' at 3400 rpm (Fisher Scientific Centrific Model 228).  Serum was 
transferred via disposable 3.2 ml polyethylene transfer pipettes (#13-711-7, Fisher 
Scientific, Pittsburgh, PA) into labeled 1.5 ml micro polypropylene metal-free test tubes (# 
223-9480, Bio-Rad Laboratories, Hercules, CA), sealed with attached caps, and frozen 
immediately at 20 degrees Celsius for subsequent batch analysis.  Serum [NH3] was 
determined via a Kodak Ektachem Analyzer (Eastman Kodak Company, Rochester, NY) 
using Ektachem NH3/Amon Clinical Chemistry Slides (Johnson and Johnson Clinical 
Diagnostics, Rochester, NY) using a phenol hypochlorite colorimetric technique. 
4.2.3 Statistical Analyses 
Performance power (W·min-1) and serum [NH3] were compared across treatments 
and groups using a repeated measures analysis of variance, with potential post-hoc 
differences analyzed using Tukey’s t-tests.  GB STAT statistical software was used for all 
analyses.  Significance was set at p < 0.05. 
4.3 Results 
As specified per analyses, results are reported as the mean ± SEM, the actual value, 
the absolute change, or the percentage change (vs. placebo) in response to treatment.  
Figure 4.1 illustrates individual blood ammonia responses [µM/L] following either L-
Aspartic Acid (L-Asp) or placebo in recreationally-trained college-age females.  Nine of 
the eighteen subjects, or 50%, exhibited a reduction in blood ammonia concentrations with  
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Figure 4.1. Individual responses in blood NH3 [µM/L] following treatment with either L-
Aspartic Acid (L-Asp) or placebo in recreationally-trained college-age females (n = 18).  
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supplementation, indicating a higher degree of variability in response with recreationally-
trained college-age female subjects versus that observed in similar age males. 
Figure 4.2 shows individual responses in performance power (W·min-1) following 
treatment with either L-Aspartic Acid (L-Asp) or placebo in recreationally-trained college-
age females.  Thirteen of the 18, or 72%, demonstrated greater power production with L-
Aspartic Acid supplementation.  However, the increases were relatively small when 
compared to the power increases observed in the male studies.   
Figure 4.3 illustrates the comparative (%) change in power and NH3 with L-
Aspartic Acid supplementation versus placebo.  There was no significant difference in 
(mean ± SEM) post-exercise blood [NH3] between L-Aspartic Acid supplementation and 
placebo (204 ± 14 µM/L vs. 212 ± 10, respectively).  Additionally, there was no significant 
change in performance power (W·min-1) between L-Aspartic Acid supplementation and 
placebo  (172 ± 40 vs. 169 ± 36, respectively).  Finally, no significant difference (p > 0.05) 
existed between treatments in warm-up power (W·min-1).   
Figure 4.4 illustrates individual responses in absolute change (vs. placebo) in blood 
NH3 [µM/L] relative to the L-Aspartic Acid dose adjusted for body weight (mg/kg) in 
recreationally-trained females.  Further, Figure 4.5 illustrates individual responses in 
absolute change (vs. placebo) in performance power (W·min-1) relative to the L-Aspartic 
Acid dose adjusted for body weight (mg/kg) in recreationally-trained females.  These 
illustrations reflect the apparent randomness in response of blood ammonia and 
performance power at the prescribed dose.  In general, females have a higher relative 
(mg/kg)) dose versus males, thus, responses (or lack of) may be reflective of the relatively 
larger dose.  Of note, in the current experiment the relative dose (mean ± SD) for FEM 
expressed in terms of mg/kg was 211.0  ± 25.7.  At this average dose there was no trend for 
reduced hyperammonemia or performance improvement in recreationally-trained females. 
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Figure 4.2. Individual responses in performance power (W·min-1) following treatment with 
either L-Aspartic Acid (L-Asp) or placebo in recreationally-trained college-age females (n 
= 18). 
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Figure 4.3. Mean percentage changes (vs. placebo) in blood NH3 [µM/L] and performance 
power (W·min-1) in response to L-Aspartic Acid supplementation in recreationally-trained 
college-age females. 
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Figure 4.4. Individual changes in blood NH3 [µM/L] relative to the L-Aspartic Acid dose 
adjusted for body weight (mg/kg) in recreationally-trained females. 
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Figure 4.5. Individual changes (vs. placebo) in performance power (W·min-1) relative to the 
L-Aspartic Acid dose adjusted for body weight (mg/kg) in recreationally-trained females. 
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4.4 Discussion 
This investigation is the first to report the effects of L-Aspartic Acid 
supplementation on exercise-induced hyperammonemia and high-intensity performance in 
females.  We hypothesized that 12.5 g x 2 QD L-Aspartic Acid supplementation would 
increase short-term arm crank power and reduce associated hyperammonemia.  However, 
hyperammonemia and performance power showed no significant response to treatment in 
recreationally-trained females.  This is in agreement with the male studies of Hagan et al. 
(1982), Maughan and Sadler (1983), and De Haan et al. (1985), and is in contrast to the in 
studies in men that have shown performance improvement (Ahlborg et al., 1968; Franz and 
Chintanaseri, 1977; and Wesson et al., 1988), and the aforementioned investigation in this 
dissertation.  The lack of response may be due to body mass, training status (recreationally-
trained), testing modality, and/or training specificity.  The possible interactions of these 
factors with aspartate supplementation are discussed below. 
It is possible that the aspartate supplementation dose (12.5g x 2 QD, or ~ 205 mg/kg 
x 2 QD) in females was too high to the relative smaller body mass.  While the mechanisms 
and regimen are unclear in humans, rat studies show an inverted dose response with 
hyperammonemia and exercise performance with aspartate supplementation (Laborit et al., 
1958; Barnes et al., 1964; and Trudeau et al., 1993).  Animal studies generally show a 
favorable response with doses between 10 mg/kg – 500 mg/kg QD (Laborit et al., 1958; 
Barnes et al., 1964; and Kendrick, 1976); doses over 500 mg/kg either increase 
performance (Rosen et al., 1962), have no effect (Matoush et al., 1964; Trudeau et al., 
1993) or exacerbate hyperammonemia and worsen performance (Kendrick, 1976).  
Therefore, a lower dose of L-Aspartic Acid (i.e. 6g x 2 QD, or ~ 50 mg/kg - 100 mg/kg x 2 
QD) in recreationally-trained females may generate a more desirable dose-response benefit.  
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Finally, since females generally have less absolute lean mass versus males, the magnitude 
of ‘overdose’ may have been even greater.   
Training status (i.e. recreationally-trained) of the subjects may have also affected 
the lack of bioenergetic and performance response.  Ammonia is a well-known factor in 
fatigue, with trained individuals removing ammonia more efficiently versus lesser-trained 
subjects (Graham et al., 1995a, Graham et al. 1997).  Further, Lancha et al. (1995) 
demonstrated that pyruvate carboxylase activity is higher in untrained (12x vs. rest) rat 
soleus versus trained (3x vs. rest) with high-intensity exercise.  Consequently, accelerated 
branched-chain amino acid catabolism for ATP production promotes higher exercising 
blood ammonia values.  Additionally, Lancha (1997) found higher pyruvate carboxylase 
activity with aspartate and asparagine supplementation in untrained rats at all times in 
response to high-intensity exercise (versus control).  This finding however did not occur in 
trained rats.  Therefore, the L-Aspartic Acid supplement in the present study may have 
been recruited more as a substrate for gluconeogenesis instead of for ammonia removal.  
This in turn would 1) produce greater ammonia per unit of ATP, 2) reduce a major source 
of the ammonia removal mechanism, and 3) make less aspartate available as a substrate for 
ammonia removal in the urea cycle.  Therefore, the net result would be unchanged blood 
ammonia values (or slightly higher than anticipated) and lack of performance 
improvement. 
Additionally, the lack of specificity of the training of the subjects to the testing 
modality may have failed to affect the bioenergetic (and thus performance) response to 
aspartate supplementation.  As mentioned previously, Lancha et al. (1995), showed that in 
response to high-intensity exercise, pyruvate carboxylase activity is higher in untrained rat 
soleus versus trained.  Secondly, Lancha et al. (1994) demonstrated in both trained and 
untrained rats supplemented with aspartate and asparagine, a three-fold greater conversion 
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(vs. placebo) of acetyl-CoA and OAA into citrate and coenzyme-A during exhaustive 
exercise.  Third, Lancha et al. (1995) demonstrated increased plasma aspartate, glycogen 
content, FFA’s, and prolonged (+42%) swim time to exhaustion with supplementation of 
aspartate, asparagine, and carnitine.  Therefore, these data suggest that the bioenergetic 
response to aspartate supplementation is reflective of training status, promoting a much 
larger activity of both gluconeogenesis and the oxidative systems.  On the other hand, if 
one assumes recreationally-trained subjects have a reduced capacity of (or receptiveness to) 
the pathways affected by aspartate, then a greater (or lower) availability of aspartate may 
have no effect at all on ATP production or ammonia removal.  In other words, if high-
intensity exercise pathways are either not present (in greater amounts) or are unresponsive 
to aspartate supplementation, then no outward effect will be observed. 
Therefore, these results suggest that response to L-Aspartic Acid supplementation 
in recreationally-trained females may be dependent on both body mass and training status, 
either singularly or in combination.  In summary, the present investigation found no effect 
of L-Aspartic Acid supplementation on short-term power or hyperammonemia in 
recreationally-trained females.  For supplementation to be effective, future work may 
consider 1) a more highly-trained group of females, 2) a dose-response study in 
proportional to the lower body mass in females (i.e. 0 mg/kg, 50 mg/kg, 100 mg/kg, 150 
mg/kg ), and /or 3) a protocol more specific to the metabolic status of the subject group. 
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CHAPTER 5.  SUMMARY, QUESTIONS AND ANSWERS, AND CONCLUSION 
 
5.1 Summary 
This series of investigations is the first to report the effects of L-Aspartic Acid 
supplementation on ammonia reduction and high-intensity arm-power.  We found a 
significant increase in short-term, high-intensity, upper body power output following L-
Aspartic Acid supplementation in highly-trained intercollegiate water polo players, but not 
in moderately-trained or recreationally-trained subjects.  Previous reports in the literature 
have concentrated on medium to long duration time to exhaustion.  This dissertation is also 
the first series of studies to investigate the dose-response effect of L-Aspartate ingestion 
and blood ammonia, and assess the reliability of the ammonia assay across sessions.  
Results from this dissertation determined the ammonia assay to be reliable, validating the 
assessment of blood ammonia concentration in response to aspartate supplementation and 
high-intensity exercise.  
Pilot work provided general trends as to the metabolic (glycolytic and nitrogen) and 
performance effects of various combinations of ammonia reducing amino acids.  Pilot 
results suggest that blood urea elevation exclusively does not deter, nor promote exercise-
induced hyperammonemia nor increase exercise performance.  Secondly, of the ammonia 
reducing amino acids (i.e. glutamate, arginine, ornithine, and aspartate), L-aspartate 
appears to be the most effective for reducing short-term exercise-induced 
hyperammonemia, if ingested in the 5 - 15g x 2 range over the 24 hours preceding exercise.  
Furthermore, a carryover/storage effect with aspartate ingestion enhances blood ammonia 
reduction across consecutive days of high-intensity exercise.  Although previous work has 
shown that aspartate supplementation over the week preceding long duration exercise (e.g.. 
a marathon) is not beneficial, the performance effect of high-intensity exercise in response 
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to L-Aspartic Acid storage is unknown.  Results from this dissertation suggest that high-
intensity short-term power and blood ammonia response to aspartate supplementation are 
training status dependent.  This is in contrast with the hypothesis of a general lowering of 
exercise-induced hyperammonemia with L-Aspartic Acid supplementation and 
improvement in performance independent of training status.  The effect on exercise-
induced hyperammonemia by L-Aspartic Acid supplementation appears to be proportional 
to training status (i.e. the highly-trained water polo group had the largest drop, followed by 
the moderately-trained males, with no effect on blood [NH3] in recreationally-trained 
females).  In other words, the more highly-trained subjects responded more favorably in 
both reduction of hyperammonemia and improvement in performance with aspartate 
supplementation, while the lesser trained groups did not.  This drop in blood ammonia was 
associated with increased short-term power output in highly-trained intercollegiate water 
polo players.  Application of these results would include athletic events where small 
increases in power may be desirable, i.e. water-polo sprinting. 
The absolute aspartate (or placebo) dose regime per session per subject was 
identical across the three investigations in the dissertation.  Due to greater overall body 
weight, males therefore have a lower (mean ± SD) relative lower dosage (mg/kg) of 12.5 g 
of L-Aspartic Acid (156.6 ± 16.3, and 171 ± 19.7, WP and MOD, respectively) than the 
females (211.0 ± 25.7).  Therefore, as illustrated in Figure(s) 5.1 and 5.2,  it is conceivable 
that per unit of body weight (mg/kg) the 12.5 g dosage in the recreationally-trained females 
was too high to elicit favorable responses in either hyperammonemia or performance 
power.  Although human results are inconclusive, data in animal models (Matoush et al., 
1964; Kendrick, 1976; and Trudeau et al., 1993) suggest an inverted dose-response effect 
(lack of ammonia reduction and/or performance improvement) as dosages exceed a certain 
level (i.e. in animals, approximately 500 mg/kg, independent of training status or gender).  
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Figure 5.1. Individual changes (vs. placebo) in blood ammonia [µM/L] relative to the L-
Aspartic Acid dose adjusted for body weight (mg/kg) in males and females. 
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Figure 5.2. Individual changes (vs. placebo) in performance power (W·min-1) relative to the 
L-Aspartic Acid dose adjusted for body weight (mg/kg) in males and females. 
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 Results from the dissertation suggest this to be relative doses exceeding 175 mg/kg in 
college-age males and females, independent of training. 
The training status of the subjects may also have affected the metabolic response to 
aspartate supplementation.  Previous work by Neame and Wiseman (1957) shows that 
blood levels of aspartate peak in the circulation between 20 and 40 minutes following 
introduction to the intestinal lumen, with concurrent mesenteric alanine blood levels rising 
almost 2-fold.  Alanine is a major source of both bioenergetic carbon and nitrogen, which 
thus affects blood ammonia concentration.  Further, it is possible the relative lack of 
training in the oxidative systems in the lesser trained subjects, and increased activity of 
gluconeogenesis diverted aspartate away from the TCA cycle and the urea cycle.  This 
would explain the lack of an observable performance improvement or enhanced reduction 
of hyperammonemia with lack of training. 
This dissertation is also the first to report the impact of L-Aspartic Acid 
supplementation on blood ammonia concentration and high-intensity power response in 
females exclusively.  Figure(s) 5.1 and 5.2 illustrate the general favorable trend with a 
reduction in hyperammonemia and increase in power with a relatively lower L-Aspartic 
Acid supplementation dose expressed in terms of body weight (mg/kg).  However, these 
results indicate no treatment effect on either blood ammonia concentration or high-intensity 
power in recreationally-trained females with 12.5g x 2 QD of L-Aspartic Acid 
supplementation.  However, the females did not exhibit reduced hyperammonemia or an 
increase in power as observed in the more highly-trained men.  The possibility exists that 
the females were overdosed per unit of body weight, thus warranting more dosage titration 
work relative to total body mass (and lean mass as well).  Furthermore, more work is 
needed in females who are more specifically trained to the testing modality (e.g. cross-
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country runners, treadmill running, female surfers) to therefore rule out the possible effect 
of gender. 
The type of protocol may have affected the toleration of exercise above the 
anaerobic threshold in the lesser trained groups.  In addition, the lack of metabolic system 
response to aspartate supplementation in the lesser trained may also be due to lack of 
specific training to the arm crank movement.  The metabolic ability of the higher trained 
subjects to remove blood ammonia and increase power in response to aspartate 
supplementation, implies that hyperammonemia regulates fatigue more so than lactate in 
highly-trained subjects. 
Therefore, it appears that both ammonia clearance and aspartate bioenergetic 
metabolism (i.e. aspartate substrate, alanine, fumarate, OAA, adenine nucleotide 
production) affect power production in response to L-Aspartic Acid supplementation.  
Results from this dissertation suggest the impact is regulated by training status, relative 
aspartate dosage, and specificity of training.  Athletes participating in sports as competitive 
swimming, water polo sprinting, and wheelchair racing may benefit from supplementation.  
Although supplementation appears effective in well-trained subjects, the suggested amount 
of supplementation relative to body weight (mg/kg) and status of training is unclear, and 
warrants further work.  
In summary, these results suggest that aspartate ingestion may be an effective 
nutritional tool for highly-trained athletes in competitions requiring short-term power 
bursts (e.g. water polo sprinting), where a small improvement in power may be desirable.  
Caution should be exercised for applying a crossover effect into the other competitive 
athletic modalities, and for applications involving active recruitment of lesser-trained 
muscle groups of the trained populations. 
 110 
  
 
5.2 Questions and Answers 
5.2.1 Questions Answered 
The following questions were answered by this dissertation: 
 
1) Does aspartate supplementation reduce blood [NH3] and improve high-
intensity short-term power? 
 
Answer: In some cases. Yes in the well-trained test group.  No for the 
recreationally-trained group.  No for the moderately-trained group 
although small drops in NH3 levels were observed.   
 
2)   Is there a dose-response effect between variable ingestion (0,5,10,15g) of 
aspartate and high-intensity blood [NH3]?  
 
Answer:  Yes and No.  A general lowering of hyperammonemia is observed with 
5, 10, or 15 g of aspartate versus placebo.  However, it appears there is 
no difference in response between 10 and 15 grams.  Status and 
specificity of training affect the magnitude of response.  
 
3) Is there an inverse relationship between maximal performance indices and 
blood [NH3] at exhaustion, with state of training?  
  
Answer:  The relationship is unclear, but doubtful.  Present work showed similar 
NH3 levels (~ [200 – 250 µM/L]) across training status at exhaustion 
independent of that status - but higher power output with trained 
subjects.  
 
4)    Is there an 'ammonia tolerance' threshold, i.e. an absolute blood 
concentration or percentage change from rest, where the subject requests to 
stop? 
   
Answer:  Probably.  Ammonia tolerance seems to depend on training status, task 
familiarity, and intensity familiarity.  With short-term protocols, blood 
[NH3] between 200 and 250 µM/L are tolerated with difficulty; with 
NH3 > [250 µM/L] the subject requests to stop. 
 
5)   Is ammonia tolerance and power output during high-intensity exercise more 
reflective of status of specificity of training? 
   
Answer:  Yes.  The highly-trained test group were able to generate more power 
than the moderately-trained test group at similar NH3 concentrations and 
further, respond favorably to aspartate supplementation reduce blood 
ammonia, and increase power even more. 
 
6)   Is there a crossover effect of blood ammonia clearance, in regard to training 
status across testing modalities (arm ergometry testing vs. leg-trained 
subjects)? 
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Answer:   Not observed in the present study, marginal improvement at best. 
 
7)   Were the levels of NH3 at exhaustion lower in women versus men?  
 
Answer:  Yes and No.  In absolute terms, NH3 levels for the women in this 
dissertation were comparable to males.  Relative to power output, NH3 
levels for women were higher; however, the effect of gender is 
unknown, suggesting future work in a higher-trained group of females 
well-trained to the testing modality. 
 
8) How much blood ammonia reduction (%, [µM/L]) is required to observe 
changes in high-intensity power? 
 
Answer: Depends on training status.  In the highly-trained test group NH3 
reductions of least 15% yielded an observable increase in power output.  
In the other tests groups, supplementation did not result in appreciable 
decreases in NH3; warranting future dose-response work. 
 
5.2.2 Future Questions to be Investigated 
1) Is there a dose-response effect between variable ingestion (0,5,10,15g) of 
aspartate, and maximal short-term performance power? 
 
Answer:  Unknown 
 
2) Do females have a different ammonia tolerance capacity versus males? 
 
Answer:  Unclear.  To address this, future work may consider 1) a more highly-
trained group of females, 2) a dose-response study in proportional to the 
lower body mass in females (i.e. 0 mg/kg, 50 mg/kg, 100 mg/kg, 150 
mg/kg), and /or 3) a protocol more specific to subject metabolic status. 
 
3) Do subjects have a crossover 'ammonia tolerance' threshold(s) of specificity 
of training, for arms vs. legs? 
 
Answer:  Doubtful, marginal at best 
 
5.3 Conclusion 
It appears from this dissertation that 12.5 g x 2 QD of aspartate reduces 
hyperammonemia and enhances short-term power in intercollegiate water polo players.  
However, in moderately-trained males or recreationally-trained females, 12.5 g x 2 QD of 
aspartate does not attenuate hyperammonemia to the degree to improve power. 
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APPENDIX A.  SUBJECT CONSENT 
 
The Impact of Aspartate Ingestion and Ammonia Reduction on Exercise Metabolism and 
Performance (Randy Day, Ph.D., William W. Edwards, M.S.) 
 
In order to investigate the effects of amino acid ingestion on upper body performance, I 
hereby volunteer to participate in an experiment conducted by the Dept. Of Biology of 
BYU-Hawaii.  I have been informed of the nature of the experiment, and of the risks 
involved in an exercise test.  I understand that an amino acid supplement will be mixed in a 
commercial performance beverage for consumption prior to testing, and agree to keep my 
dietary and exercise habits consistent across testing days, and to abstain from caffeine, 
alcohol, and tobacco use for the duration of the experiment.   
 
I acknowledge that a venous forearm blood draw will be performed following each exercise 
test by trained personnel.  The data obtained from my participation will receive impersonal 
statistical treatment, with my rights to privacy protected.  My personal identity remains 
anonymous unless permission is granted otherwise. 
 
Furthermore, I may withdraw from the experiment at any time.  Any questions concerning 
the experiment have been answered to my satisfaction, and I understand that I may ask 
further questions once the experiment is complete. 
 
                                                                     
 
___________________________________                                            
Name (printed) 
 
___________________________________   _______________________ 
Signature      Date 
 
 
___________________________________   _______________________ 
Witness       Date    
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APPENDIX B.  PILOT STUDY 1: THE EFFECTS OF SUPPLEMENTATION OF 
AMMONIA REDUCING AMINO ACIDS ON EXERCISE METABOLISM AND HIGH-
INTENSITY PERFORMANCE 
 
B.1 Introduction  
 
Previous work has suggested that an acute reduction in blood ammonia by ingestion 
of ammonia reducing amino acids may improve medium and long duration athletic 
performance.  However, it is unclear as to whether the reduction in blood ammonia in this 
manner may improve short-term high-intensity performance (endurance, strength, power, 
speed) where blood ammonia values peak.  Therefore, this study explored the effect of 
ingestion of a combination of ammonia-reducing amino acids on blood ammonia, urea, 
lactate, and exhaustion time in response to high-intensity cycling ergometry. 
B.2 Methods 
 
B.2.1 Subjects 
 
Three moderately-trained college-age males were informed of the nature of the 
study, and of the possible risks involved, before giving written consent in accordance with 
university guidelines and approval by the institutional review board of Louisiana State 
University, Baton Rouge, LA.  Descriptive statistics are presented in Table B.1.  
B.2.2 Protocol 
 
All exercise tests were performed on a calibrated friction-braked bicycle ergometer 
(Monark #860) at a pedal frequency of 80 rpm.  Each subject performed a preliminary 
incremental exercise test for assessment of VO2max.  Following instrument calibrations and 
a 2-minute exercise warm-up, the testing began at a resistance of 50 watts, and increased 50 
watts/minute until metronome cadence dropped to lower than 60 rpm with best effort. 
Oxygen consumption, carbon dioxide production (VCO2), and expired ventilation 
(VE) were measured via open-circuit spirometry.  Normoxic inspired gas volumes were 
monitored by a dry gas meter.  Subjects breathed through a low-resistance  (Rudolph) 
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Table B.1. Descriptive characteristics of subjects in pilot study 1. 
 
Variable 
Subject 1 
(MC) 
Subject 2 
(RM) 
Subject 3 
(BW) 
Age (yr) 26 27 26 
Weight (kg) 68.2 68.6 66.4 
VO2max 
(ml.kg.min-1) 55.3 61.5 52.1 
VO2max 
(L/min) 3.8 4.2 3.5 
VESTPDmax  
(L/min) 118 114 114 
RQmax 1.2 1.17 1.22 
HRmax 184 193 180 
kpmax 3.2 5 3.5 
 
 
non-rebreathing valve, with  expired  gases  passing  into and through a 5-liter mixing 
chamber.  O2 and CO2 gas fractions  (FEO2, FECO2) were analyzed by the Beckman OM-11 
and LB-2, respectively, and interfaced with an Apple IIe computer.  Heart rate was 
monitored by one-lead electrocardiography (CM5).  
A crossover method of experimentation was employed, and hence each subject 
served as his own control.  Testing was conducted at least 8 hours post-prandial, following 
a 12-hour period of ingestion of either placebo or 2g each of L-Aspartate, L-Ornithine, L-
Arginine, and L-Glutamate.  Half the dosage was consumed 12 hours before testing, with 
the other half consumed 1 hour before testing.  Corn starch served as the placebo.  A 
double-blind experimental design and a counterbalanced order of testing determined the 
order of active substance/placebo administration.  
Subjects exercised to exhaustion on two occasions on a bicycle ergometer at a 
power output corresponding to 120% VO2max, following placebo or amino acid ingestion.  
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Following a 2-minute warm-up at .75 kp, subjects pedaled at 120% VO2max until cadence 
fell below 60 rpm with best effort.   
B.2.3 Biochemical Analyses 
 
A 5 ml blood sample was collected from a superficial forearm vein via indwelling 
catheter with the subject in a seated position at rest, and at 1 and 4 minutes post-exercise.  
Each was assayed in duplicate for blood lactate (lactate dehydrogenase method), plasma 
NH3 (phenol hypochlorite method), and plasma urea (urease/phenol hypochlorite method) 
utilizing Sigma Chemical Co. (St. Louis, Mo.) diagnostic kits.  Each sample was injected 
immediately into a green-top Vacutainer@ tube (heparinized) and immediately placed 
within an ice bath.  One ml of the sample was then mixed with 2 ml of a cold 7% 
perchlorate solution, centrifuged (5000 rpm x 2 minutes), and the supernatant frozen for 
subsequent lactate determination.  The remainder of the blood sample was centrifuged 
(5000 rpm x 2 minutes), and the harvested plasma frozen (-20 Co) within 30 minutes after 
collection.                            
B.3 Results 
 
Results are presented in Table B.2.  Blood samples (seated, resting) acquired at rest, 
one minute post-exercise (X1) and four minutes post-exercise (X4) showed a general trend 
of lowering of blood ammonia and rising of blood urea with supplementation.  Time to 
exhaustion was not significantly different between treatments. 
B.4 Summary 
 
Results from this pilot study indicate that a combination of aspartate, glutamate, 
arginine, and ornithine supplementation increases blood urea production and reduces blood 
ammonia concentration versus placebo, but has no effect on high-intensity short term 
performance.  A larger sample size and isolation of these amino acids will further elucidate 
the clearance pattern and mechanisms of blood ammonia removal. 
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Table B.2. Individual plasma NH3 [µM/L], blood urea nitrogen [mg/dl], and time to 
exhaustion (seconds) in response to placebo (P) or L-Aspartate, L-Glutamate, L-Ornithine, 
and L-Arginine (A) supplementation.  
  
Subject P R [NH3] A R [NH3] P X1  [NH3] A X1 [NH3] P X4 [NH3] A X4  [NH3] 
1 MC 64 20 115 50 110 51 
2 RM 21 13 26 17 32 22 
3 BW 14 33 48 16 46 24 
       
Mean 33.0 22.0 63.0 27.7 62.7 32.3 
SEM 15.6 5.9 26.8 11.2 24.0 9.4 
SD 27.1 10.1 46.4 19.3 41.6 16.2 
Minimum 14 13 26 16 32 22 
Maximum 64 33 115 50 110 51 
       
       
Subject P R [BUN] A R [BUN] P X1 [BUN] A X1 [BUN] P X4 [BUN] A X4 BUN] 
1 MC 19 17 17 17 17 23 
2 RM 16 10 14 23 12 22 
3 BW 14 18 24 28 24 22 
       
Mean 16.3 15.0 18.3 22.7 17.7 22.3 
SEM 1.5 2.5 3.0 3.2 3.5 0.3 
SD 2.5 4.4 5.1 5.5 6.0 0.6 
Minimum 14 10 14 17 12 22 
Maximum 19 18 24 28 24 23 
       
       
Subject P WTE A WTE     
1 MC 89.9 82.4     
2 RM 171.4 178.4     
3 BW 154.5 148     
       
Mean 138.6 136.3     
SEM 24.8 28.3     
SD 43.0 49.1     
Minimum 89.9 82.4     
Maximum 171.4 178.4     
 P = placebo; A = amino acid supplementation; R = at rest; X1 = 1 minute post-exercise; 
X4 = 4 minutes post-exercise; NH3 = plasma ammonia concentration [µM/L]; BUN = 
blood urea nitrogen [mg/dl]; SEM = standard error of measurement; SD = standard 
deviation from the mean; WTE = work time to exhaustion (seconds). 
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APPENDIX C.  PILOT STUDY 2:  THE EFFECTS OF L-ARGININE AND L-
ORNITHINE SUPPLEMENTATION ON AMMONIA CLEARANCE AND EXERCISE 
PERFORMANCE 
 
C.1 Introduction 
 
The non-essential non-toxic amino acids L-Arginine (L-Arg) and L-Ornithine (L-
Orn) clinically attenuate hyperammonemia associated with hepatic encephalopathy (Fahey, 
1957; Salvatore et al., 1964; Batshaw, 1984).  Pilot work in our laboratory has also found 
sharp drops in blood ammonia and rise in blood urea nitrogen in response to short-term 
high-intensity cycle ergometry with supplementation of ammonia reducing amino acids 
including L-Arginine and L-Ornithine (i.e. aspartate, glutamate, arginine, ornithine).  
However, due to varying biochemical pathways, it is unclear as to the magnitude of the 
effect contributed by the different types of amino acids.  Further, to date there are no 
published scientific reports as to supplementation of the ammonia-clearing urea cycle 
amino acids L-Arginine and L-Ornithine to improve 1) exercise-induced hyperammonemia, 
2) time to exhaustion, and 3) urea cycle activity.  Therefore, the purpose of this pilot study 
was to isolate and explore the effects of L-Arginine and L-Ornithine supplementation on 
blood ammonia and urea, and time to exhaustion with ramp treadmill exercise. 
C.2 Methods 
 
Ten moderately-trained (VO2max 52.2 ml/kg/min ± 2.2 SEM) college males 
exercised to exhaustion on two occasions, using a modified Bruce protocol.  Subject 
characteristics are presented in Table C.2.  VO2max was measured using a Sensormedics 
2900 metabolic cart.  Subjects ingested either 10g L-Arginine and 10g L-Ornithine (A), or 
placebo (P), administered 12 hours and 30’ before the treadmill test.  Forearm venous 
samples were taken at 0, 1, 3, and 5 minutes during seated recovery, and centrifuged within 
one minute of collection.  Plasma samples were placed into an ice bath and assayed within 
five minutes for urea nitrogen [BUN] and [NH3] by a Kodak Ektachem DT60 analyzer. 
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Table C.1.  Descriptive characteristics of subjects in pilot study 2. 
 
Subject 
Age 
(yr) 
Weight 
(kg) 
VO2max 
(ml.kg.min-1) 
1 18 75 56.5 
2 23 74 49.2 
3 25 75 51.1 
4 22 65 56.7 
5 22 102 39.0 
6 25 79 54.9 
7 23 90 43.5 
8 20 75 60.5 
9 21 68 58.8 
10 21 61 51.3 
    
Mean 22.0 76.4 52.2 
SEM 0.7 3.8 2.2 
SD 2.2 12.0 6.8 
Minimum 18.0 61.0 39.0 
Maximum 25.0 102.0 60.5 
SEM – standard error of measurement; SD – standard deviation from the mean 
 
C.3 Results 
 
Table C.2 presents individual BUN responses [mg/dl] to 10g L-Arginine and 10g L-
Ornithine (A) and placebo (P), while Table C.3 presents individual blood ammonia 
responses [µM/L], respectively.  [BUN] was ~ 40% higher in the A group vs. placebo 
during recovery.  Blood [NH3] continued to rise after exercise, but did not differ between 
treatment groups.  Time to exhaustion and VO2max did not differ across treatments (10.63 
minutes, A; vs. 10.5 minutes, P). 
C.4 Summary 
 
This study was designed to examine the effects of L-Arginine and L-Ornithine 
supplementation on ammonia metabolism and urea cycle activity following maximal 
exercise.  We found a large significant increase in the output of urea following L-Arginine  
and L-Ornithine supplementation; however, a similar change in blood ammonia reduction 
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Table C.2. Individual blood urea nitrogen [mg/dl] at rest (R), exhaustion (X0), and during 
recovery (X1, X3, and X5) in response to placebo (P) or 10g L-Arginine and 10g L-
Ornithine (A) supplementation.  Complete bloodwork was available for n = 8. 
 
Subject P R [BUN] P X0 [BUN] P X1 [BUN] P X3 [BUN] P X5 [BUN] 
1 11 11 12 12 11 
2 11 11 12 11 10 
3 11 11 10 10 10 
4 12 11 9 11 10 
5 10 9 11 9 9 
6 12 10 11 10 10 
7 12 11 12 10 10 
8 11 11 11 10 10 
      
Mean 11.3 10.6 11.0 10.4 10.0 
SEM 0.2 0.3 0.4 0.3 0.2 
SD 0.7 0.7 1.1 0.9 0.5 
Minimum 10 9 9 9 9 
Maximum 12 11 12 12 11 
      
      
Subject A R [BUN] A X0 [BUN] A X1 [BUN] A X3 [BUN] A X5 [BUN] 
1 17 16 15 16 15 
2 13 11 11 11 11 
3 12 12 11 11 11 
4 19 17 17 17 17 
5 12 16 15 15 14 
6 18 16 16 16 16 
7 18 18 17 16 16 
8 16 15 15 15 14 
      
Mean 15.6 15.1 14.6 14.6 14.3 
SEM 1.0 0.9 0.8 0.8 0.8 
SD 2.9 2.4 2.4 2.3 2.2 
Minimum 12 11 11 11 11 
Maximum 19 18 17 17 17 
P = placebo; A = amino acid supplementation; X0 = exhaustion; X1 = 1 minute post-
exercise; X3 = 3 minutes post-exercise; X5 = 5 minutes post-exercise; BUN = plasma urea 
nitrogen [mg/dl]; SEM – standard error of measurement; SD – standard deviation from the 
mean 
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Table C.3. Individual blood NH3 [µM/L] at rest (R), exhaustion (X0), and during recovery 
(X1, X3, and X5) in response to placebo (P) or 10g L-Arginine and 10g L-Ornithine (A) 
supplementation.  Complete bloodwork was available for n = 7. 
 
Subject P R [NH3]  P X0 [NH3] P X1 [NH3] P X3 [NH3] P X5 [NH3] 
1 46 152 171 169 155 
2 57 188 191 196 281 
3 78 163 186 279 221 
4 71 165 241 244 227 
5 87 206 215 199 283 
6 59 206 228 250 282 
7 125 255 261 277 208 
      
Mean 74.7 190.7 213.3 230.6 236.7 
SEM 9.9 13.4 12.2 16.2 18.3 
SD 26.1 35.4 32.4 42.9 48.3 
Minimum 46 152 171 169 155 
Maximum 125 255 261 279 283 
      
      
Subject A R [NH3] A X0 [NH3] A X1 [NH3] A X3 [NH3] A X5 [NH3] 
1 78 105 145 130 123 
2 70 135 142 112 140 
3 47 193 209 233 239 
4 56 178 209 267 255 
5 49 195 222 224 248 
6 91 189 217 233 270 
7 112 196 214 255 190 
      
Mean 71.9 170.1 194.0 207.7 209.3 
SEM 9.0 13.5 13.2 23.1 22.2 
SD 23.8 35.8 34.8 61.2 58.8 
Minimum 47 105 142 112 123 
Maximum 112 196 222 267 270 
P = placebo; A = amino acid supplementation; X0 = exhaustion; X1 = 1 minute post-
exercise; X3 = 3 minutes post-exercise; X5 = 5 minutes post-exercise; NH3  = blood 
ammonia concentration [µM/L]; SEM – standard error of measurement; SD – standard 
deviation from the mean 
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was not observed.  The pattern for the attenuation of exercise-induced hyperammonemia 
varies.  Some studies have shown that ammonia clearance is rapid following exercise 
(Banister et al., 1983; Banister et al., 1985), while others have indicated that blood 
ammonia levels continue to rise after intense exercise (Wilkerson et al., 1975; Wilkerson et 
al., 1977).  Several studies have suggested that there are a number of factors that regulate 
ammonia clearance during recovery including muscle fiber type, training state, exercise 
mode, and terminating intensity (Graham et al., 1995; Graham et al., 1995a). 
Under normal, resting conditions, the majority of ammonia produced is excreted as 
urea, the principal nitrogen component of urine.  When the urea cycle is stressed during 
intense muscular work, accessory pathways (i.e. glutamate + NH3 <=> glutamine) are 
detected.  In addition, an accelerated conversion of ammonia into carbamoyl phosphate for 
entry into the urea cycle increases pyrimidine by-products.  Both glutamine and pyrimidine 
are present in urine. 
Ammonia is a factor in promoting fatigue.  However, the therapeutic impact and 
regime for short-term ammonia reduction during exercise is not clear.  L-Glutamate, L-
Arginine, and L-Ornithine have been administered to humans at rest with sharp drops in 
[NH3] (Salvatore et al., 1964; Fahey, 1957).  However, these results were in clinical 
situations, and thus a crossover effect to healthy, and highly-trained subjects, is 
questionable.  Though it appears from this study that 10g of L-Arg and 10g of L-Orn 
sharply elevate blood urea nitrogen, they did not attenuate exercise-induced 
hyperammonemia nor affect work time to exhaustion. 
Results from this study indicate: 
1) Supplementation with urea cycle intermediates is effective for short-term 
urea production from exercise-induced hyperammonemia, 
2) Blood [NH3] levels are not affected in the same magnitude as urea 
production with augmented short-term ureagenesis 
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3) Short-term work time to exhaustion and VO2max on the treadmill are not 
enhanced by accelerated ureagenesis and 
4) Additional ammonia metabolic pathways (i.e. synthesis of glutamine, 
alanine, hippurate, phenylacetylglutamine) clear blood [NH3] in response to 
intense exercise. 
 
Results from the preceding two pilot studies raised the following questions: 
1) Does a short-term reduction in blood [NH3] affect high-intensity physical 
performance indices (peak power); and, if so, what percentage of ammonia 
reduction ([µM/L]) is required? 
 
2) Is there a crossover effect of blood ammonia clearance, in regard to training 
status across testing modalities (arm ergometry vs. leg extension) in vivo?  
 
3) Is there a dose-response effect between variable ingestion (0,5,10,15g) of 
aspartate, blood [NH3] at exhaustion, and maximal physical performance 
indices? 
 
4) Is there an inverse relationship between maximal performance indices and 
blood [NH3] at exhaustion, with state of training? 
 
5) Is there an 'ammonia tolerance' threshold, i.e. an absolute blood 
concentration or percentage change from rest, where the subject requests to 
stop? 
 
6) Do subjects have different 'ammonia tolerance' threshold(s), for arms vs. 
legs?  Alternatively, is ammonia tolerance more reflective of status of 
specificity of training? 
 
To continue the investigation of these considerations, pilot study 3 was conducted. 
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APPENDIX D.  PILOT STUDY 3: THE EFFECTS OF VARIABLE AMOUNTS OF L-
ASPARTIC ACID ON BLOOD AMMONIA WITH HIGH-INTENSITY ARM WORK IN 
SURFERS 
 
D.1 Introduction 
 
Results from previous investigations and work in our laboratory (Edwards et al. 
MSSE; Edwards et al. MSSE 32(5): S329), indicate that supplementation of 10g each of L-
Arg and L-Orn sharply elevates blood urea nitrogen in response to intense short-term 
exercise.  However, in contrast to hypotheses in this study, neither short-term exercise-
induced hyperammonemia nor work time to exhaustion were significantly affected.  
Therefore, the metabolic and performance improvements reported in previous studies 
implicate isolation of the ingestion of L-Aspartic Acid.  In addition, it is well known 
(Graham et al. MSSE 29:646) that training status affect the blood ammonia and 
performance response to exercise.  However, it is unclear as to the responsiveness of 
training status to L-Aspartic Acid ingestion.  Therefore, the purpose of this pilot study was 
twofold: 1) to assess the dose-response relationship between 0,5,10, or 15g aspartate intake 
and blood ammonia concentration in a testing modality (arm ergometry) trained group 
(surfers), and 2) of these amounts, determine the dose most likely to lower blood ammonia 
to improve performance.   
D.2 Methods 
 
Four healthy well-trained college-age male surfers volunteered for the study.  They 
were informed of the nature of the study and the risks involved before giving their consent 
in accordance with university guidelines.  Subjects reported for five consecutive days of 
exercise testing, and instructed to keep diet consistent, and abstain from caffeine, tobacco, 
and alcohol.  Descriptive characteristics of the subjects are presented in Table D.1.  
Subjects reported to the lab for five consecutive days of exercise testing utilizing a 
seated incremental seated arm ergometry (Monark Model #881) protocol to exhaustion.  
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Table D.1. Descriptive characteristics of subjects in pilot study 3. 
 
Initials 
(Subject) 
Age 
(yr) 
Weight 
(kg) 
Height 
(cm) 
Years 
Surfing 
W·min-1 @ 
Exh 
WTE 
(sec) 
MA (a) 23 76.4 177.8 0.5 225 249 
JA  (b) 25 75 175.3 7 250 246 
DA (c) 24 79.5 185.4 3 225 272 
MI (d) 22 84.1 177.8 4 225 257 
       
Mean 23.5 78.8 179.1 3.6 231.3 256.0 
SEM 0.6 2.0 2.2 1.3 6.3 5.8 
SD 1.3 4.0 4.4 2.7 12.5 11.6 
Minimum 22 75 175.3 0.5 225 246 
Maximum 25 84.1 185.4 7 250 272 
WTE – time to exhaustion; SEM – standard error of measurement; SD – standard deviation 
from the mean 
 
The test began at an initial intensity of 25 W·min-1 at 100 rpm and increased 25 W·min-1 
every 30 seconds until exhaustion.  Total time and terminal watt rate achieved per subject 
on session 1 was used for all sessions.  Session(s) 1 and 2 subjects consumed 0 grams L-
Aspartic Acid, while on session(s) 3, 4, and 5, subjects ingested 5, 10, or 15g L-aspartate 
(Source Naturals, Inc, Scotts Valley, CA) in counterbalanced order.  The L-Aspartate was 
dissolved in a commercial performance beverage and divided for consumption 23 hours 
and 1 hour before testing.   
Blood was drawn from a forearm vein in a seated position at rest and exhaustion.  
Samples were centrifuged immediately and the supernatant analyzed immediately for 
ammonia and lactate.  Ammonia levels were determined using a Kodak (Eastman Kodak 
Company, Rochester, NY) Ektachem NH3-/Amon Clinical Chemistry Slide Analyzer 
(Johnson and Johnson Clinical Diagnostics, Rochester, NY).  The procedure employs a 
multilayered analytical system fixed onto a polyester support.  A 10 microliter plasma 
sample is added to a reagent layer consisting of a pH 9.2 buffer which effectively converts 
the ammonium ion (NH4+) to ammonia (NH3).  Uncharged, ammonia then passes through a 
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semipermeable membrane where it reacts with bromophenol blue to produce a blue dye 
which is read at a wavelength of 600 nanometers.  The amount of ammonia present in the 
sample is proportional to the amount of blue dye produced.  Control assays were conducted 
on dilutions of freeze-dried serum supplied by the company.  Blood lactate was analyzed 
via the Accusport@ Portable Analyzer.   
D.3 Results 
 
Complete bloodwork was available for three of the four subjects.  Data from the 
three sessions completed by subject 4 are included in the analyses.  Individual responses by 
day, and by dose, are presented in Table(s) D.2 and D.3, respectively.  Blood NH3 [µM/L] 
responses at exhaustion relative to 0, 5, 10, and 15 g of L-Aspartic Acid (A) 
supplementation are presented in Table D.4.  Subjects reached high levels of exercise-
induced hyperammonemia and lactic acidosis (mean ± SE) 197.7 ± 10.8 [µM/L], and 12.2  
± 0.3 [mM].  Further, as shown in Table D.4, there was a general trend for lowering of 
blood ammonia with increasing dose of L-Aspartic Acid, with no effect on lactate.   
D.4 Summary 
 
Results from this study suggest: 1) exercise hyperammonemia is attenuated by 
aspartate in a dose dependent manner, and 2) there is a tapering off of hyperammonemia 
reduction between 10 g and 15 g of aspartate, 3) there is a possible storage effect of daily 
aspartate supplementation, and 4) hyperammonemia is reduced without a concomitant 
change in lactate. 
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Table D.2. Individual blood NH3 [µM/L] and blood lactate [mM] responses at rest (R) and 
exhaustion (X) across five exercise sessions.   
 
Session/Sub R [NH3] X [NH3] R [LA] 
 
X [LA] 
1a 12 258 2.3 11.2 
1b 30 207 2.5 13.2 
1c 22 231 2.5 11.5 
1d 18 249 2.4 12.2 
2a 18 235 2.6 12.6 
2b 37 237 2.3 13.7 
2c 28 231 2.7 13.3 
2d 20 259 3.0 13.3 
3a 14 227 2.7 11.8 
3b 18 218 2.4 13.7 
3c 26 175 2.5 12.7 
3d 16 250 2.7 12.2 
4a 13 170 2.2 12.2 
4b 20 212 2.4 13.7 
4c 25 146 2.5 11.4 
5a 21 139 2.2 12.2 
5b 29 143 2.8 9.3 
5c 18 137 2.6 11.2 
     
Mean 21.4 206.9 2.5 12.3 
SEM 1.6 10.2 0.1 0.3 
SD 6.6 43.4 0.2 1.1 
Minimum 12 137 2.2 9.3 
Maximum 37 259 3 13.7 
LA – blood lactate [mM]; SEM – standard error of measurement; SD – standard deviation 
from the mean.
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Table D.3. Individual blood NH3 [µM/L] and blood lactate [mM] responses at rest (R) and 
at exhaustion (X) with 0, 0, 5, 10, and 15 g of L-Aspartic Acid (A) supplementation. 
 
A (grams) Session/Sub R [NH3] X [NH3] R [LA] X [LA] 
0 1a 12 258 2.3 11.2 
0 1b 30 207 2.5 13.2 
0 1c 22 231 2.5 11.5 
0 1d 18 249 2.4 12.2 
0 2a 18 235 2.6 12.6 
0 2b 37 237 2.3 13.7 
0 2c 28 204 2.7 13.3 
0 2d 20 259 3.0 13.3 
5 3a 14 227 2.7 11.8 
5 4b 20 212 2.4 11.8 
5 3c 26 175 2.5 12.7 
10 4a 13 170 2.2 10.2 
10 5b 29 143 2.8 9.3 
10 5c 18 137 2.6 11.2 
10 3d 16 250 2.7 12.2 
15 5a 21 139 2.2 12.3 
15 3b 18 218 2.4 13.7 
15 4c 25 146 2.5 11.4 
A – L-Aspartic Acid; Sub – Subject; R – rest; X – exhaustion; LA – blood lactate [mM] 
 
 
 
 
Table D.4. Blood NH3 [µM/L] at exhaustion in response to 0, 5, 10, and 15 g of L-Aspartic 
Acid (A) supplementation. 
 
Subject 0g  0g  5g  10g  15g  
a 258 235 227 170 139 
b 207 237 212 143 218 
c 231 204 175 137 146 
d 249 259  250  
      
Mean 236.3 233.8 204.7 175.0 167.7 
SEM 11.3 11.3 15.5 26.0 25.2 
SD 22.5 22.6 26.8 52.0 43.7 
Minimum 207 204 175 137 139 
Maximum 258 259 227 250 218 
SEM – standard error of measurement; SD – standard deviation from the mean. 
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APPENDIX E.  RAW DATA AND ANALYSES FOR EXPERIMENT 1 
 
 
Table E.1. Staff instructions for distributing placebo (P) or L-Aspartic Acid (A) packets  
to subjects for experiment 1 (reliability). 
 
  
1) Subjects report to staff for receiving powder packets at least 24 hours 
prior to each exercise session 
2) Staff hands out 2 packets to each subject 
3)  Staff instructs subject to mix one packet in 8 oz water 24 hours prior to 
testing, and drink, and likewise the second packet 1 one hour prior to 
testing. 
4)   Staff crosses out the A x 2, or P x 2 on the master sheet below, as 
packets are distributed: 
 
 
  
Subject 
 
Session 1 
 
Session 2 
 
Session 3 
 
Session 4 
 
Session 5 
 
 
 
A x 2 
 
P x 2 
 
A x 2 
 
P x 2 
 
P x 2 
 
 
 
P x 2 
 
A x 2 
 
P x 2 
 
A x 2 
 
P x 2 
 
 
 
P x 2 
 
P x 2 
 
A x 2 
 
P x 2 
 
A x 2 
 
 
 
A x 2 
 
P x 2 
 
A x 2 
 
P x 2 
 
P x 2 
 
 
 
P x 2 
 
A x 2 
 
P x 2 
 
A x 2 
 
P x 2 
 
 
 
P x 2 
 
P x 2 
 
A x 2 
 
P x 2 
 
  A x 2 
 
 
 
A x 2 
 
P x 2 
 
A x 2 
 
P x 2 
 
P x 2 
 
 
 
P x 2 
 
A x 2 
 
P x 2 
 
A x 2 
 
P x 2 
 
 
 
P x 2 
 
P x 2 
 
A x 2 
 
P x 2 
 
A x 2 
 
 
 
A x 2 
 
P x 2 
 
A x 2 
 
P x 2 
 
P x 2 
 
 
 
P x 2 
 
A x 2 
 
P x 2 
 
A x 2 
 
P x 2 
 
 
 
P x 2 
 
P x 2 
 
A x 2 
 
P x 2 
 
A x 2 
 
 
 
A x 2 
 
P x 2 
 
A x 2 
 
P x 2 
 
 P x 2 
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Table E.2. Individual blood NH3 [µM/L] responses across three sessions of placebo (P1, P2, 
P3).  Blood was drawn 3 minutes post-exercise. 
 
Subject P1 [µM/L] P2 [µM/L] P3 [µM/L] 
1 179 211 199 
2 182 230 235 
3 151 139 138 
4 190 183 194 
5 91 107 88 
6 146 131 143 
7 134 150 163 
8 120 132 116 
9 256 293 237 
10 168 158 166 
11 207 219 189 
12 247 232 257 
13 259 276 230 
14 171 193 183 
15 193 200 225 
     
Mean 179.6 190.3 184.2 
SEM 12.6 14.1 12.6 
SD 48.8 54.6 48.8 
Minimum 91 107 88 
Maximum 259 293 257 
SEM – standard error of measurement; SD – standard deviation from the mean 
 
 144 
  
 
Table E.3. Individual blood NH3 [µM/L] responses across two sessions of L-Aspartic 
Acid supplementation (A1, A2).  Blood was drawn 3 minutes post-exercise. 
 
Subject A1 [µM/L] A2 [µM/L] 
1 167 201 
2 162 151 
3 177 168 
4 124 137 
5 124 139 
6 98 85 
7 221 246 
8 158 150 
9 239 162 
10 177 187 
   
Mean 164.7 162.6 
SEM 13.7 13.6 
SD 43.2 42.9 
Minimum 98 85 
Maximum 239 246 
SEM – standard error of measurement; SD – standard deviation from the mean 
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Table E.4.  Reliability analyses of blood NH3 [µM/L] across placebo sessions (P1, P2, and 
P3). 
_______________________________________________________________________ 
 
RELIABILITY ANALYSIS  
 
          Mean          Std Dev        Cases 
P1 NH3           179.6000         48.8186         15.0 
P2 NH3           190.4667         55.0271         15.0 
P3 NH3           184.2000         48.7621         15.0 
 
Inter-item Intraclass Correlation Coefficient Matrix 
 
                 P1 NH3         P2 NH3        P3 NH3  
 
P1 NH3          1.0000 
 
P2 NH3          . 9109       1.0000 
 
P3 NH3           . 9009        . 8874       1.0000 
 
Intraclass Correlation Coefficient (P1 NH3 vs. P2 NH3 vs. P3 NH3) 
 
One-way random effect model: People Effect Random 
 Single Measure Intraclass Correlation =    .8998 
    95.00% C.I.:            Lower =    .7850          Upper =    .9617 
 F = 27.9417   DF = (14, 30.0)   Sig. = 0.0000  (Test Value = 0.0000 ) 
  
Intraclass Correlation Coefficient (P1 NH  vs. P2 NH ) 3 3
 
One-way random effect model: People Effect Random 
 Single Measure Intraclass Correlation =    .9109 
    95.00% C.I.: Lower =    .7624         Upper =    .9689 
 F = 21.4481   DF = (14, 15.0) Sig. = 0.0000  (Test Value = 0.0000 ) 
 
Intraclass Correlation Coefficient (P1 NH3 vs. P3 NH3) 
 
One-way random effect model: People Effect Random 
 Single Measure Intraclass Correlation =    .9009 
    95.00% C.I.: Lower =    .7381          Upper =    .9653 
 F = 19.1875   DF = (14, 15.0) Sig. = 0.0000  (Test Value = 0.0000 ) 
 
Intraclass Correlation Coefficient (P2 NH  vs. P3 NH ) 3 3
 
One-way random effect model: People Effect Random 
 Single Measure Intraclass Correlation =    .8874 
    95.00% C.I.: Lower =    .7057          Upper =    .9603 
F = 16.7563   DF = (14, 15.0) Sig. = 0.0000  (Test Value = 0.0000 ) 
__________________________________________________________________ 
 146 
  
 
Table E.5.  Reliability analysis of blood NH3 [µM/L] across L-Aspartic Acid 
supplementation sessions (A1, A2). 
_______________________________________________________________________ 
 
RELIABILITY ANALYSIS  
 
Intraclass Correlation Coefficient Matrix 
 
                 A1 NH3        A2 NH3  
 
A1 NH3            1.0000 
 
A2 NH3            .7426       1.0000 
 
N of Cases = 10.0 
 
 
Intraclass Correlation Coefficient 
 
One-way random effect model: People Effect Random 
 Single Measure Intraclass Correlation =    .7643 
    95.00% C.I.:            Lower =    .3290          Upper =    .9348 
 F = 7.4847   DF = (9, 10.0)   Sig. = .0021  (Test Value = .0000 ) 
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Table E.6. Group comparisons of blood NH3 [µM/L] across three sessions of placebo 
(P1, P2, P3) and two of L-Aspartic Acid supplementation (A1, A2). 
______________________________________________________________________ 
 
MEAN  P1 NH3 [µM/L]  =   179.6 
VAR.  P1 NH3 [µM/L]  =   695.1 
 
MEAN  P2 NH3 [µM/L]  =   190.5 
VAR.  P2 NH3 [µM/L]  =   883.1 
 
MEAN  P3 NH3 [µM/L]  =  184.2 
VAR.  P3 NH3 [µM/L]  =   693.5 
 
MEAN  A1 NH3 [µM/L]  =   164.7 
VAR.  A1 NH3 [µM/L]  =   350.3 
 
MEAN  A2 NH3 [µM/L]  =   162.6 
VAR.  A2 NH3 [µM/L]  =   345.5 
 
 
ANOVA SUMMARY TABLE 
 
SOURCE            SUM SQRES      DF      MEAN SQRES   F-RATIO             P 
  
BETWEEN GRPS      29215.9     4       7303.0      25.7    < 0.0001 
    
WITHIN SUBJ      87806.2      48      1829.3  
    
ERROR              54633.0      192     284.6 
    
TOTAL              171656.2    244 
 
   
TUKEY’S PROTECTED T-TESTS 
 
                   P1 NH3        P2 NH3         P3 NH3        A1 NH3   A2 NH3 
     
P1 NH3       0              -1.8       -.748         2.2*  2.5 
        
P2 NH3     -1.8       0              1.089        3.7**  4.0** 
        
P3 NH3      -.7         1.08       0             2.8**  3.1** 
        
A1 NH3       2.2*      3.78**     2.88**     0  .  .3 
        
A2 NH3      2.5*       4.08**      3.18**     .3    0 
 
        ** p < 0.01    * p < 0.05 
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APPENDIX F.  RAW DATA AND ANALYSES FOR EXPERIMENT 2 
 
 
Table F.1. Staff instructions for distributing placebo (P) or L-Aspartic Acid (A) 
supplementation packets to subjects for experiment 2 (performance) in intercollegiate water 
polo players (WP) and moderately-trained males (MOD). 
 
 
1) Subject report to staff for receiving powder packets at least 24 hours prior to 
each exercise session 
2) Staff hands out 2 packets to each subject 
3)  Staff instructs subject to mix one packet in 8 oz water 24 hours prior to 
testing, and drink, and likewise the second packet 1 one hour prior to 
testing. 
4)   Staff crosses out the A x 2, or P x 2 on the master sheet below, as packets 
are distributed: 
 
 
Subject Session 1 Session 2 
 
 
 
A x 2 
 
P x 2 
 
 
 
P x 2 
 
A x 2 
 
 
 
A x 2 
 
P x 2 
 
 
 
P x 2 
 
A x 2 
 
 
 
A x 2 
 
P x 2 
 
 
 
P x 2 
 
A x 2 
 
 
 
A x 2 
 
P x 2 
 
 
 
P x 2 
 
A x 2 
 
 
 
A x 2 
 
P x 2 
 
 
 
P x 2 
 
A x 2 
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Table F.2. Individual blood NH3 [µM/L] in response to placebo (P) or L-Aspartic Acid 
(A) supplementation in intercollegiate water polo players (WP).  Blood was drawn 3 
minutes post-exercise. 
 
Subject P [µM/L] A [µM/L] 
1 273 269 
2 195 163 
3 307 233 
4 277 202 
5 302 287 
6 268 212 
7 170 113 
8 207 213 
9 170 113 
   
Mean 241.0 200.6 
SEM 18.4 20.5 
SD 55.3 61.5 
Minimum 170 113 
Maximum 307 287 
SEM – standard error of measurement; SD – standard deviation from the mean 
 
 
 
 
Table F.3. Individual blood NH3 [µM/L] in response to placebo (P) or L-Aspartic Acid 
(A) supplementation in moderately-trained college males (MOD).  Blood was drawn 3 
minutes post-exercise. 
 
Subject P [µM/L] A [µM/L] 
1 230 193 
2 150 90 
3 231 166 
4 172 156 
5 243 222 
6 133 120 
7 233 128 
8 243 227 
9 342 368 
   
Mean 219.7 185.6 
SEM 20.8 27.5 
SD 62.4 82.5 
Minimum 133 90 
Maximum 342 368 
SEM – standard error of measurement; SD – standard deviation from the mean 
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Table F.4. Individual performance power (W·min-1) in response to placebo (P) or L-
Aspartic Acid (A) supplementation in intercollegiate water polo players (WP). 
 
Subject P (W·min-1) A (W·min-1) 
1 255 278 
2 319 248 
3 254 210 
4 185 343 
5 208 249 
6 194 201 
7 228 365 
8 214 316 
9 191 222 
   
Mean 227.6 270.2 
SEM 14.3 19.8 
SD 42.8 59.3 
Minimum 185 201 
Maximum 319 365 
SEM – standard error of measurement; SD – standard deviation from the mean 
 
 
 
 
 
Table F.5. Individual performance power (W·min-1) r response to placebo (P) or L-
Aspartic Acid (A) supplementation in moderately-trained college males (MOD). 
 
Subject P (W·min-1) A (W·min-1) 
1 253 209 
2 176 241 
3 205 188 
4 211 259 
5 188 200 
6 192 182 
7 209 231 
8 177 249 
9 229 222 
   
Mean 204.4 220.1 
SEM 8.4 9.1 
SD 25.0 27.3 
Minimum 176 182 
Maximum 253 259 
SEM – standard error of measurement; SD – standard deviation from the mean 
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Table F.6. Group comparisons of blood NH3 [µM/L] in response to placebo (P) or L-
Aspartic Acid supplementation (A) in intercollegiate water polo players (WP) and 
moderately-trained males (MOD).   
 
 
MEAN NH3   [µM/L] WP P  =   241.0 
 VAR. NH3   [µM/L] WP P  =    720.0 
 
MEAN NH3   [µM/L] WP A  =   200.6 
 VAR. NH3   [µM/L] WP A  =   889.4 
 
MEAN NH3   [µM/L] MOD P  =   219.7 
 VAR. NH3   [µM/L] MOD P  =  914.8 
 
MEAN NH3   [µM/L] MOD A  =   185.6 
 VAR. NH3  [µM/L] MOD A  =   1599.5 
 
 
 
ANOVA SUMMARY TABLE 
 
   SOURCE            SUM SQRES        DF   MEAN SQRES  F-RATIO       P 
 
   BETWEEN GRPS    60539.08951      3      20179.6965      23.19     < 0.0001 
 
   WITHIN SUBJ      51460.88889      34    1513.55556  
 
   ERROR              88747.55556     102   870.07407  
 
   TOTAL             200747.53395    139  
 
 
 
TUKEY’S PROTECTED T-TESTS 
 
                 WP P        WP A        MOD P       MOD A 
 
    WP P      0               2.90862**      1.53422         3.98737** 
 
    WP A      2.90862**      0               -1.3744          1.07875  
 
    MOD P     1.53422        -1.3744          0               2.45315* 
 
    MOD A     3.98737**       1.07875         2.45315*        0  
 
            ** p < 0.01    * p < 0.05 
______________________________________________________________________ 
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Table F.7. Group comparisons of performance power (W·min-1) in response to placebo 
(P) or L-Aspartic Acid (A) supplementation in intercollegiate water polo players (WP) 
and moderately-trained males (MOD). 
 
                          
MEAN  W·min-1    WP P  =   227.5 
  VAR.  W·min-1    WP P  =   428.1 
 
MEAN  W·min-1    WP A  =   270.3 
   VAR  W·min-1    WP A  =   827.6 
 
MEAN  W·min-1  MOD P  =   204.4 
   VAR. W·min-1   MOD P =   148.4 
 
MEAN  W·min-1   MOD A =  220.2 
  VAR.  W·min-1   MOD A =   175.5 
 
 
 
ANOVA SUMMARY TABLE 
 
   SOURCE            SUM SQRES       DF      MEAN SQRES     F RATIO    P 
 
   BETWEEN GRPS     83426.83287      3       27808.94429     76.09     < 0.0001 
 
   WITHIN SUBJ      16435.435        34      483.39515  
 
   ERROR             37275.59833      102     365.44704  
 
   TOTAL              137137.8662      139  
 
 
 
TUKEY’S PROTECTED T-TESTS 
           
                   WP P          WP A        MOD P        MOD A 
 
       WP P      0               -4.75062**   2.56704*      .81376  
 
       WP A    -4.75062**      0               7.31766**  5.56438** 
 
       MOD P    2.56704*        7.31766**      0            -1.75328  
 
       MOD A    .81376          5.56438**     -1.75328        0  
 
            ** p < 0.01    * p < 0.05 
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APPENDIX G.  RAW DATA AND ANALYSES FOR EXPERIMENT 3  
 
 
Table G.1. Staff instructions for distributing placebo (P) and L-Aspartic Acid (A) packets 
packet(s) to subjects for experiment 3 (performance) in recreationally-trained females 
(FEM). 
 
 
1)  Subject report to staff for receiving powder packets at least 24 hours prior to 
each exercise session 
2) Staff hands out 2 packets to each subject 
3)  Staff instructs subject to mix one packet in 8 oz water 24 hours prior to 
testing, and drink, and likewise the second packet 1 one hour prior to 
testing. 
4)   Staff crosses out the A x 2, or P x 2 on the master sheet below, as packets 
are distributed: 
 
 
Subject Session 1 Session 2 
 
 
 
A x 2 
 
P x 2 
 
 
 
P x 2 
 
A x 2 
 
 
 
A x 2 
 
P x 2 
 
 
 
P x 2 
 
A x 2 
 
 
 
A x 2 
 
P x 2 
 
 
 
P x 2 
 
A x 2 
 
 
 
A x 2 
 
P x 2 
 
 
 
P x 2 
 
A x 2 
 
 
 
A x 2 
 
P x 2 
 
 
 
P x 2 
 
A x 2 
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Table G.2.  Individual blood NH3 [µM/L] in response to placebo (P) or L-Aspartic 
Acid (A) supplementation in recreationally-trained female subjects (FEM). Blood was 
drawn 3 minutes post-exercise. 
 
Subject P [µM/L]    A [µM/L] 
1 207 245 
2 257 283 
3 230 191 
4 161 140 
5 226 166 
6 222 138 
7 300 306 
8 249 321 
9 257 218 
10 198 203 
11 183 140 
12 150 211 
13 193 186 
14 185 213 
15 238 252 
16 257 273 
17 150 131 
18 142 102 
   
Mean 215.5 212.8 
SEM 10.3 14.6 
SD 42.4 60.2 
Minimum 150 131 
Maximum 300 321 
SEM – standard error of measurement; SD – standard deviation from the mean 
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Table G.3. Individual performance power (W·min-1) in response to placebo (P) or L-
Aspartic Acid (A) supplementation in recreationally-trained female subjects (FEM). 
 
Subject P (W·min-1) A (W·min-1) 
1 195 174 
2 199 209 
3 182 212 
4 171 124 
5 168 175 
6 138 154 
7 144 148 
8 140 196 
9 132 111 
10 272 168 
11 156 120 
12 135 170 
13 204 193 
14 146 164 
15 122 137 
16 171 167 
17 180 193 
18 194 277 
   
Mean 167.9 165.6 
SEM 8.9 7.4 
SD 36.7 30.3 
Minimum 122 111 
Maximum 272 212 
SEM – standard error of measurement; SD – standard deviation from the mean 
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Table G.4. Group comparisons of blood NH3 [µM/L] in response to placebo (P) or L-
Aspartic Acid supplementation  (A) in recreationally-trained female subjects (FEM).   
_______________________________________________________________________ 
 
MEAN  NH3 [µM/L] FEM P =    211.6 
VAR.   NH3 [µM/L] FEM P =    1981.5 
 
MEAN  NH3 [µM/L] FEM A =    206.6 
VAR.   NH3 [µM/L] FEM A =    4088.4 
 
 
ANOVA SUMMARY TABLE 
                             
SOURCE            SUM SQRES      DF     MEAN SQRES    F-RATIO      P 
 
BETWEEN GRPS     225                  1         225             . 2554      .6197  
 
WITHIN SUBJ      88217.55556        17      5189 
 
ERROR              14971            17      880.64706  
 
TOTAL              103413.55556    35 
 
 
 
 
Table G.5. Group comparisons of performance power (W·min-1) in response to placebo (P) 
or L-Aspartic Acid supplementation  (A) in recreationally-trained female subjects (FEM).  
_______________________________________________________________________ 
            
MEAN  FEM  W·min-1 P =   172.4 
 VAR. FEM  W·min-1 P =   1235.1 
 
MEAN  FEM  W·min-1 A =   179.1 
  VAR.  FEM  W·min-1 A =   1177.9 
 
 
ANOVA SUMMARY TABLE 
 
   SOURCE            SUM SQRES       DF     MEAN SQRES     F-RATIO   P 
 
   BETWEEN GRPS    404.68028       1       404.68028       .54354    .471  
 
   WITHIN SUBJ      28364.41472     17      1668.49498  
 
   ERROR              12657.01472    17     744.53028  
 
   TOTAL              41426.10972    35 
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